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Abstract  
Background: Interferon-gamma release assays (IGRAs) are blood tests recommended for 
diagnosis of tuberculosis (TB) infection.  There is currently uncertainty in the role and 
clinical utility of IGRAs in the diagnostic work up of suspected active TB in routine NHS 
clinical practice. 
 
Objectives: To compare the diagnostic accuracy and cost-effectiveness of T-SPOT.TB and 
QuantiFERON GOLD In-Tube (QFT-GIT) for diagnosis of suspected active TB; and to 
estimate the diagnostic accuracy of next generation IGRAs. 
 
Design: Prospective within-patient comparative diagnostic accuracy study. 
 
Setting: Secondary care. 
 
Participants: Adults (≥16 years old) presenting as inpatients or outpatients at 12 NHS 
hospital trusts in London, Slough, Oxford, Leicester and Birmingham with suspected active 
TB. 
 
Interventions: The index tests—T-SPOT.TB, QFT-GIT, and new enzyme-linked 
immunospot assays utilising novel Mycobacterium tuberculosis antigens (Rv3615c, Rv2654, 
Rv3879c and Rv3873)—were verified against a composite reference standard applied by a 
panel of clinical experts blinded to IGRA results. 
 
Main outcome measures: Sensitivity, specificity, predictive values and likelihood ratios 
were calculated to determine diagnostic accuracy. A decision tree model was developed to 
calculate the incremental costs and incremental health utilities (quality-adjusted life-years 
[QALYs]) of changing from current practice to using an IGRA as an initial rule out test. 
 
Results: 363 patients had active TB (culture confirmed and highly probable TB cases), 439 
had no active TB and 43 had an indeterminate final diagnosis. Comparing T-SPOT.TB and 
QFT-GIT, the sensitivities (95% CI) were 82.3% (77.7%–85.9%) and 67.3% (62.1%–72.2%) 
while specificities (95% CI) were 82.6% (78.6%–86.1%) and 80.4% (76.1%–84.1%), 
respectively. T-SPOT.TB was more sensitive than QFT-GIT [relative sensitivity (95% CI): 
ii 
 
1.22 (1.14–1.31); P <0.001] but the specificities were similar [relative specificity (95% CI): 
1.02 (0.97–1.08); P = 0.3]. Amongst HIV positive patients, the sensitivities of both IGRAs 
were lower while specificities were higher than those of HIV negative patients.  
 
The most promising novel antigen was RV3615c. The added value of Rv3615c to 
T- SPOT.TB was a 9% (5% to 12%) relative increase in sensitivity at the expense of 
specificity with a relative decrease of 7% (4% to 10%). 
 
The use of current IGRA tests for ruling out active TB is unlikely to be considered cost-
effective if a QALY was valued at £20,000 or £30,000. For T-SPOT.TB, the probability of 
being cost-effective for a willingness-to-pay of £20,000/QALY was 26% and 21% when 
patients with indeterminate test results were excluded or included, respectively. In 
comparison, the QFT-GIT probabilities were 8% and 6%. While the use of IGRAs is cost-
saving, the health detriment is large due to delay in diagnosing active TB leading to 
prolonged illness. There was substantial between-patient variation in the tests used in the 
diagnostic pathway. 
 
Limitations: Recruitment target for the HIV co-infected population was not achieved. 
 
Conclusions: Although T-SPOT.TB was more sensitive than QFT-GIT for diagnosis of 
active TB, the tests are insufficiently sensitive for ruling out active TB in routine clinical 
practice in the UK. Novel assays offer some promise. 
 
Future work: The novel assays require evaluation in distinct clinical settings and in 
immunosuppressed patient groups. 
 
Funding: National Institute for Health Research Health Technology Assessment programme 
and the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College 
London. 
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Plain English summary 
Tuberculosis (TB) is one of the world’s most important infectious diseases. In 2014, 1.5 
million deaths were caused by the disease—about one death every 25 seconds. Traditional 
diagnosis of TB is based partly on the tuberculin skin test. Blood tests such as QuantiFERON 
GOLD In-Tube (QFT-GIT) and T-SPOT.TB are now available. However, these two tests are 
not used as part of current NHS practice due to lack of evidence about how well the tests 
perform when diagnosing symptomatic (active) TB in routine clinical practice.  
 
The purpose of our study was to compare the ability of QFT-GIT and T-SPOT.TB to detect 
people with active TB from those without active TB in a population suspected of the disease. 
We also assessed new blood tests that are currently being developed for diagnosis of active 
TB. 
 
We recruited 1,074 patients with suspected TB from 14 NHS hospitals in London, Slough, 
Oxford, Leicester and Birmingham into our study. We found that T-SPOT.TB correctly 
detected more people with active TB than QFT-GIT; T.SPOT.TB would miss about 18 
people while QFT-GIT would miss about 33 people out of every 100 with active TB.  
 
As such both tests are not good enough for routine clinical use because the number of people 
with active TB who are incorrectly diagnosed as not having active TB is unacceptably high. 
Also, both tests do not produce value for money. However, we did find that some of the 
newer blood tests performed better than T-SPOT.TB and their usefulness should be further 
investigated.   
 
Word count: 250 
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Scientific summary  
 
Background 
Interferon-gamma release assays (IGRAs) are blood tests recommended for diagnosis of 
tuberculosis (TB) infection.  The two types of commercially available IGRAs are 
QuantiFERON GOLD In-Tube, (QFT-GIT) a whole-blood enzyme-linked immunosorbent 
assay (ELISA), and T-SPOT.TB, an enzyme-linked immunospot assay (ELISpot). There is 
currently uncertainty in the role and clinical utility of IGRAs in the diagnostic work up of 
suspected active TB in routine NHS clinical practice. 
 
Aim 
To evaluate and compare the diagnostic accuracy and cost-effectiveness of IGRAs for 
diagnosis of active TB. 
 
Objectives 
Primary objectives 
• To compare the diagnostic performance (sensitivity, specificity, positive and negative 
predictive values) of T-SPOT.TB and QFT-GIT for the diagnosis of active pulmonary 
and extra pulmonary TB in routine clinical practice; 
• To develop an evidence-based optimal testing algorithm that defines the role of 
IGRAs in the diagnostic work-up of suspected active TB; 
• To deliver the objectives above for a key subgroup: HIV co-infected patients (the 
highest risk subgroup of TB); and 
• To quantify and compare the cost-effectiveness of a range of possible testing 
strategies against the present testing regime. 
 
Secondary objectives 
• To quantify the sensitivity, specificity, and positive and negative predictive values of 
T-SPOT.TB and QFT-GIT in a number of key patient subgroups such as patients with 
pre-existing diabetes, end-stage renal failure and iatrogenic immunosuppression; and 
• To quantify the use of next generation IGRAs compared to existing commercially-
available assays. 
xvi 
 
 
Methods 
We used a within-patient (paired) design to compare test accuracy by applying all IGRAs to 
blood samples from each patient. The final diagnosis of participants was verified using a 
composite reference standard (based on the Dosanjh criteria) applied by a panel of clinicians 
blinded to local (routine) and study IGRA results. The diagnostic accuracy of ESAT-6 and 
CFP-10 (both antigens comprise T-SPOT.TB), and four new ELISpot-based assays utilising 
novel Mycobacterium tuberculosis antigens (Rv3615c, Rv2654, Rv3879c and Rv3873)—
were also evaluated individually and in test combinations. The test combinations were 
compared with T-SPOT.TB. 
 
Statistical analysis 
The main clinical utility of IGRAs in the assessment of suspected active TB is likely to be in 
their negative predictive value (NPV), which enables clinicians to reliably rule out TB from 
the differential diagnoses. This depends on the sensitivity of the test and the prevalence of 
active TB in the tested population. To detect a 10% difference in sensitivity between T-
SPOT.TB and QFT-GIT (assuming a sensitivity of 85% for T-SPOT.TB and 75% for QFT-
GIT) at the 5% significance level with 90% power, 855 participants were required assuming a 
40% prevalence of active TB. To allow for missing data, indeterminate index test and 
reference standard results, withdrawal of consent and possible logistical errors, we aimed to 
recruit 1,012 patients. For the HIV positive subgroup, we computed sample size based on 
sensitivities of 85% and 65% for T.SPOT.TB and QFT-GIT, respectively. We assumed a 
20% prevalence of active TB and so required 390 participants to detect a 20% difference with 
80% power. 
 
We estimated sensitivity, specificity, positive and negative predictive values and likelihood 
ratios for each test and combinations of tests. For test comparisons, relative test performance 
was assessed by comparing the sensitivity and specificity of one test relative to those of 
another test. The comparisons between different IGRAs were done using generalized 
estimating equation models to exploit the paired nature of the data. Variation in the relative 
performance of T SPOT.TB and QFT-GIT with HIV status and other clinical characteristics 
was investigated by including one covariate at a time in the models.  
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Economic evaluation 
The economic analyses were based on the main study cohort. The diagnostic tests performed, 
their costs, and time taken between decision points involving each test were considered in the 
economic analyses. The analysis was undertaken from an NHS perspective. No discounting 
was required since the diagnostic process occurs over a relatively short time period. For 
preference estimates we followed the NICE reference case, using quality-of-life weights 
obtained from literature. A decision tree model was developed to calculate the incremental 
costs and incremental health utilities (quality-adjusted life-years [QALY]) of changing from 
current practice to using an IGRA as an initial rule out test. The model was parameterised 
using the IDEA study clinical patient records and relevant current literature. 
 
Results 
Between 25th November 2011 and 31st August 2013, the IDEA study recruited 1,074 adults 
(≥16 years old) presenting as inpatients or outpatients at 10 NHS hospital trusts in London, 
Slough, Oxford, Leicester and Birmingham with suspected active TB. We refer to this group 
as the main study cohort. Due to low recruitment of HIV positive patients, the study was 
extended to 31st December 2014 to recruit only this group of patients. Two additional hospital 
trusts were added. A total of 263 HIV positive patients, were recruited from 12 NHS trusts 
between 25th November 2011 and 19th December 2014. This is the HIV positive sub study 
cohort.  
 
In the main cohort, the median (range) age of the 845 patients included in the analyses was 38 
(16–86) years, most (59.3%) were male, approximately half (48.2%) were of Indian ethnicity, 
and 135 (16.0%) were HIV positive. There were 88 (10.4%) patients with pre-existing 
diabetes, 12 (1.4%) with chronic/end stage renal failure and five (0.6%) were on 
immunosuppressive therapy. In the HIV positive sub study cohort, the median (range) age of 
the 201 patients included in the analyses was 43 (18–79) years, the majority (67.7%) were 
male, and a substantial number were of black (45.3%) or white (37.8%) ethnicity. 
 
Principal findings of diagnostic accuracy in main study cohort 
363 (43.0%) patients had a diagnosis of active TB (culture confirmed and highly probable TB 
cases) while active TB was excluded in 439 (52.0%) patients. The remaining 43 (5.1%) 
patients had an indeterminate final diagnosis and were excluded from all analyses. The rate of 
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indeterminate IGRA results was higher for QFT-IT (8.9%) compared to T-SPOT.TB (6.7%). 
Indeterminate IGRA results were excluded from the main analyses. Comparing the two 
IGRAs, sensitivities (95% CI) were 82.3% (77.7%–85.9%) and 67.3% (62.1%–72.2%) while 
specificities (95% CI) were 82.6% (78.6%–86.1%) and 80.4% (76.1%–84.1%) for 
T-SPOT.TB and QFT-GIT respectively. The sensitivity of T-SPOT.TB was superior to that 
of QFT-GIT [relative sensitivity (95% CI): 1.22 (1.14–1.31); P <0.001] but there was no 
statistical evidence of a difference in specificity [relative specificity (95% CI): 1.02 (0.97–
1.08); P = 0.3].  In sensitivity analyses with indeterminates included as test positives (because 
only a negative result can rule out TB), conclusions about differences in the sensitivities and 
specificities of T-SPOT.TB and QFT-GIT were unchanged. 
 
The sensitivities of T-SPOT.TB and QFT-GIT were lower in those with HIV co-infection 
relative to the HIV negative subgroup. Similarly, the two IGRAs had lower sensitivities in 
those with diabetes compared to those without. Specificity was higher in HIV positive 
patients compared to HIV negative patients but was lower in those with diabetes compared to 
those without diabetes. Although, there appeared to be differences in test performance 
between subgroups, there was no statistical evidence of an effect of HIV status or diabetes on 
relative test performance. The findings from these analyses should be taken with caution as 
the number of test results in some subgroups was small. Due to limited data, subgroup 
analyses were not possible for the other two key subgroups—those with end stage renal 
failure and those on immune suppressants. 
 
The most promising novel antigen was RV3615c, with a sensitivity that was higher than that 
of the other antigens. Test combinations including Rv3615c showed higher sensitivity 
compared to T-SPOT.TB. The added value of Rv3615c to T SPOT.TB was a 9% (95% CI 
5%–12%) relative increase in sensitivity at the expense of specificity with a relative decrease 
of 7% (4%–10%). The combination of CFP-10 with Rv3615c (i.e. akin to replacing ESAT-6 
in T-SPOT.TB) showed a relative increase of 7% (3%–11%) in sensitivity and a relative 
decrease of 5% (2%–8%) in specificity. 
 
Principal findings of diagnostic accuracy in HIV positive sub study cohort 
Thirty two (15.9%) patients had a diagnosis of active TB (culture confirmed and highly 
probable TB cases) while active TB was excluded in 165 (82.1%) patients. The remaining 
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four (2.0%) patients had an indeterminate final diagnosis and were excluded from all 
analyses. The indeterminate rate was 19.5% for QFT-GIT and 23.1% for T-SPOT.TB. The 
difference (95% CI) of 3.6% (-4.5%–11.6%) was not significant (P = 0.4). Excluding 
indeterminate IGRA results, the sensitivities (95% CI) for T-SPOT.TB and QFT-GIT were 
62.8% (44.1% –78.3%) and 56.1% (38.3%–72.4%) and the specificities were 83.4% (75.7%–
88.9%) and 91.7% (85.4%–95.4%). The sensitivity of T-SPOT.TB was higher than that of 
QFT-GIT with a relative sensitivity (95% CI) of 1.12 (0.87–1.44). There was no statistical 
evidence of a difference (P = 0.4). In contrast, the specificity of T-SPOT.TB was significantly 
lower (P = 0.02) than that of QFT IT with a relative specificity (95% CI) of 0.91 (0.84–0.99).  
 
When indeterminate IGRA results were included in a sensitivity analysis, there was a small 
increase in the sensitivity of QFT-GIT but a large increase in the sensitivity of T-SPOT.TB 
due to the higher indeterminate rate for T-SPOT.TB (18.2%) amongst active TB cases 
compared to that of QFT-GIT (5.9%). Nevertheless, there was no statistical evidence of a 
difference in sensitivity (P = 0.1) nor specificity (P = 0.1).  
 
Main findings of economic evaluation 
TB diagnosis rarely followed the idealised diagnostic pathways and there was considerable 
individual-level variability. This implies that costs and time delays until diagnosis may be 
very different from typical assumptions made in economic analyses. The number and order of 
diagnostic tests that were performed varied between patients as well as between final 
diagnosis categories. For instance, nearly all active TB patients were given a culture test and 
sputum spear microscopy, while approximately 20% and 25% of non-active TB patients were 
given a culture test and sputum spear microscopy, respectively. The median cost of diagnosis 
was highest for unconfirmed diagnosis patients (£502), followed by the non-culture 
confirmed active TB patients (£476). 
 
The use of current IGRA tests for ruling out active TB would be unlikely to be considered 
cost-effective if a QALY were to be valued at £20,000 or £30,000. T-SPOT.TB performed 
better than QFT-GIT in the cost-effectiveness analysis. The probability of being cost-
effective for a willingness-to-pay of £20,000/QALY was 26% and 21% for T-SPOT.TB when 
patients with indeterminate test results were excluded or included, respectively. In 
comparison, the QFT-GIT probabilities were 8% and 6%. 
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For the study cohort, the cost saving in these scenarios ranged from £65120 to £86850, but 
the health detriment in QALYs was between -6.50 and -3.58. 
 
Stratifying the main study cohort by HIV status, the HIV negative group of patients had 
similar results to those from the analyses of the entire cohort. However, cost-effectiveness 
results were worse for the HIV positive group with the probability of being cost-effective for 
a willingness-to-pay of £20,000/QALY of approximately 12% and 9% for T-SPOT.TB and 
QFT-GIT when patients with indeterminate IGRA results were excluded. When patients with 
indeterminate IGRA results were included, the probability was 4% for both IGRAs. The HIV 
positive group had ranges of cost savings and health detriment of £42110 to £106090 and -
7.86 to -5.91, respectively. 
 
While IGRAs are cost-saving, the health detriment is large due to delay in diagnosing active 
TB leading to prolonged illness. Whether there is a net health detriment or gain for the patient 
cohort as a whole depends on the prevalence of active TB, the performance characteristics of 
the rule out test, and the length of delay introduced by adding the initial rule out test. 
 
Conclusions 
 
Implications for health care 
Despite the significantly higher sensitivity of T-SPOT.TB over QFT-GIT, neither IGRA can 
be used routinely as a reliable rule out test for suspected active TB in this patient population 
in secondary care. Both IGRAs were also not cost-effective in this setting.  However, in 
patients where there is a suspicion of TB but the pre-test probability is low, the negative 
predictive value of a negative T-SPOT.TB result would be correspondingly higher. Hence, it 
would not be unreasonable to use a negative T-SPOT.TB result to weigh the odds in favour 
of excluding TB from the differential diagnosis as long as the test result is interpreted with an 
awareness of the limited sensitivity as shown by this study.  
 
The incorporation of novel antigens into T-SPOT.TB, in particular Rv3615c, provided high 
diagnostic sensitivity values coupled with a modest reduction in specificity. Notably, 
replacing ESAT-6 with Rv3615c also conferred higher sensitivity than T-SPOT.TB. This 
observation is relevant for TB control internationally because one of the leading TB vaccine 
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candidates currently in clinical trials, H56/IC31, incorporates ESAT-6. The vaccine is 
protective in the nonhuman primate model and is likely to be licensed if it proves to be 
protective in humans. If rolled-out, vaccinated individuals are likely to develop T cell 
responses to ESAT-6 which would lead to false positive IGRA results, akin to the current 
scenario with Bacille Calmette-Guérin (BCG) vaccination inducing false positive tuberculin 
skin test results. Replacing ESAT-6 with Rv3615c may be a potential solution because a 
CFP-10 and Rv3615c-based IGRA would have significantly higher sensitivity than existing 
IGRAs and specificity would not be compromised in H56/IC31-vaccinated individuals. 
 
Recommendations for research 
The next generation IGRAs evaluated in the IDEA study do not need to be re-evaluated in a 
UK routine practice setting because this study provided an equally rigorous evaluation of 
these novel assays as it did for conventional IGRAs. However, the novel assays require 
evaluation in distinct clinical settings with much lower or much higher prevalence of active 
TB and in immunosuppressed subgroups. A new generation of QFT-GIT, QuantiFERON-TB 
Gold Plus (QFT-Plus), was recently launched. Although higher sensitivity than QFT-GIT has 
been reported, there is very little published evidence about the performance of the test in 
routine practice. A comparative accuracy study of the novel assays and QFT-Plus may be 
needed. 
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Chapter 1 Introduction  
Background  
In 2014, globally, an estimated 9.6 million cases of tuberculosis (TB) and 1.5 million deaths 
caused by the disease were reported to the World Health Organisation.1 Co-infection of TB 
cases with HIV makes up a significant proportion of cases globally (12%) and together these 
infections are the biggest infectious causes of death. Health inequalities are exacerbated by 
the burden TB places on the most vulnerable and poor around the world. Over the past 20 
years, worldwide TB incidence and mortality has declined. However, despite this, the 
prevalence of TB still remains unacceptably high. Furthermore, there is not yet evidence of a 
reduction in number of cases in England, particularly in major cities such as London and 
Birmingham.  
 
In England, 6,520 cases of TB were reported in 2014 with an incidence rate of 12.0 per 
100,000.2 Of these, 2,572 cases were from London, where the incidence rate was 30.1 per 
100,000.2 Other urban high incidence areas include Leicester, Birmingham, Luton, 
Manchester and Coventry. In 2014, the rate of TB was 139 cases per year with an incidence 
of 41.2 per 100,000 populations in Leicester Local authority and 319 cases of TB with an 
incidence of 28.9 per 100,000 in Birmingham local authority.3 The majority of cases in 
England (72%) occurred in new entrants who were born outside the UK.2  
 
TB is caused by active infection with Mycobacterium tuberculosis (Mtb).  Upon initial 
infection with Mtb, a state of asymptomatic dormancy typically occurs. In most infected 
individuals this results in a prolonged and perhaps lifelong latent TB infection (LTBI). In 
others, however, a breakdown of immune control and activation of infection results in 
symptomatic disease, which can be fatal without treatment. Co-infection with HIV 
dramatically increases the likelihood of progression from latent to active disease. 
 
Active TB can manifest with pulmonary or extra pulmonary phenotypes. In its active 
pulmonary form, TB is highly contagious. Diagnosis of active TB is central to preventing 
spread of disease and thus controlling the TB epidemic.4 However, the slow speed and poor 
sensitivity of existing diagnostic tools often delays diagnosis and treatment of the disease.5  
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Diagnosis of TB 
Conventional methods of diagnosing active TB rely primarily on the identification of Mtb 
bacilli, as well as imaging affected areas. Smear microscopy is quick and inexpensive, but 
typically lacks sensitivity. Whilst cell culture is considered ‘gold standard’ for diagnosis of  
active TB due to its higher sensitivity, it is often slow, taking up to six or eight weeks to give 
a result. Polymerase chain reaction (PCR) tests for Mtb, such as the new GeneXpert 
Mtb/RIF®, can be quick and sensitive, but they are typically expensive and require a high 
standard of infrastructure. Imaging techniques such as chest X-ray and computed tomography 
(CT) scanning are quick and usually sensitive, but are not specific. Furthermore, they can be 
expensive, and again require a high standard of infrastructure (for example in the case of CT 
scans). All of these tests tend to be less accurate in cases of active TB with HIV co-infection, 
and also in cases of extra pulmonary TB. 
 
Currently available tests for latent TB infection (LTBI) include the tuberculin skin test (TST) 
and interferon-gamma release assays (IGRAs). TST measures the in vivo delayed-type 
hypersensitivity response to intradermal inoculation of a crude mixture of Mycobacterial 
antigens. Because this mixture contains antigens also present in Bacille Calmette-Guérin 
(BCG), the test can be confounded by prior BCG vaccination. IGRAs, on the other hand, 
detect ex vivo interferon-gamma (IFN-γ) release from T cells (lymphocytes that play a key 
role in cell-mediated immunity) in response to Mtb-specific antigens, ESAT-6 and CFP-10. 
These antigens are absent from the BCG vaccine and most environmental mycobacteria, and 
thus IGRAs tend to be more specific than the TST.6  The two types of commercially available 
IGRAs are QuantiFERON GOLD In-Tube (QFT-GIT, Cellestis, Carnegie, Australia), a 
whole-blood enzyme-linked immunosorbent assay (ELISA), and T-SPOT.TB (Oxford 
Immunotec, Abingdon, United Kingdom), an enzyme-linked immunospot assay (ELISpot); 
both IGRAs utilise peripheral blood mononuclear cells (PBMCs). These tests have been 
recommended by UK, European and North American guidelines for diagnosis of LTBI.7 
 
Although typically used in the diagnosis of LTBI, TST and IGRAs actually detect Mtb 
infection in its entirety (i.e. active or latent). The role of the tests within published guidelines 
for diagnostic evaluation of suspected active TB to date has been limited due to their low 
specificity for the disease; they could never confirm a diagnosis of active TB because they 
cannot differentiate latent and active infection. However, because Mtb infection is a pre-
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requisite for TB disease, reliable determination of infection status could accelerate 
diagnostic assessment by enabling rapid exclusion of TB (within 24 hours) where the 
result is negative.   
 
In order for the IGRA or TST to reliably rule out a diagnosis of Mtb infection and thus TB 
disease, the sensitivity of the test must be very high (>95%). The sensitivity and specificity of 
IGRAs compared to TST in active TB have been compared in a number of studies, ranging in 
size and quality.8  IGRAs are typically more specific than TST for diagnosing Mtb infection, 
and T-SPOT.TB is more sensitive than TST for diagnosing TB. However, the diagnostic 
accuracy of T-SPOT.TB and QFT-GIT has not been compared directly ‘head-to-head’ in 
suspected active TB in the UK, nor comprehensively assessed in immunosuppressed patients. 
There is therefore uncertainty in the role and clinical utility of IGRAs in the diagnostic work 
up of suspected TB, as well as their cost-effectiveness in UK NHS practice.   
  
Aim and study objectives 
 
Aim 
To evaluate and compare the diagnostic accuracy and cost-effectiveness of IGRAs against 
conventional testing for diagnosis of active TB. Specifically, the study aimed to determine 
the sensitivity, specificity, positive and negative predictive values, and likelihood ratios of 
T-SPOT.TB and QFT-GIT for diagnosis of active TB in routine NHS clinical practice. Next 
generation IGRAs were also evaluated.  
 
Study objectives 
Primary Objectives 
1. To compare the diagnostic accuracy of T-SPOT.TB and QFT-GIT for the diagnosis of 
active pulmonary and extra pulmonary TB in routine clinical practice; 
2. To develop an evidence-based optimal testing algorithm that defines the role of 
IGRAs in the diagnostic work-up of suspected active TB; 
3. To deliver the objectives above for a key subgroup: HIV co-infected patients (the 
highest risk subgroup of TB); and 
4. To quantify and compare the cost-effectiveness of a range of possible testing 
strategies against the present testing regime. 
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Secondary Objectives: 
1. To quantify the sensitivity, specificity, and positive and negative predictive values of 
T-SPOT.TB and QFT-GIT in a number of key patient subgroups such as patients with 
pre-existing diabetes, end-stage renal failure and iatrogenic immunosuppression; and 
2. To quantify the use of next generation IGRAs compared to existing commercially-
available assays. 
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Chapter 2 Methods  
This chapter describes the study design and methods for the evaluation of the diagnostic 
accuracy of IGRAs in active TB. Our report adheres to the Standards for the Reporting of 
Diagnostic Accuracy Studies (STARD) guideline9 as shown in Appendix 1 (Table 51). 
Methods for the health economic evaluation are described separately in Chapter 6. 
 
Overview of the study design 
This prospective multi-centre study comparing the accuracy of IGRAs was conducted in 
routine clinical practice in the UK. Adults presenting with suspected active TB at NHS out-
patient or in-patient services within participating hospitals in London, Slough, Oxford, 
Leicester and Birmingham were recruited. We used a within-patient design to compare test 
accuracy by performing all IGRAs on blood samples from each patient with the presence or 
absence of active TB verified using the reference standard. This design minimises between-
patient variability while also allowing estimation of the accuracy of combinations of IGRAs. 
Blood samples for IGRA testing were collected from patients at baseline and follow up (two 
and six months). If necessary and where available, TST results were used as part of the 
composite reference standard for verifying the final diagnosis of patients. TST results were 
obtained from routine clinical care and so the availability of TST results reflects local 
practice in participating hospitals. 
 
Participants 
Inclusion criteria 
Adults (≥16 years old) presenting with suspected (pulmonary or extra pulmonary) active TB 
at NHS outpatient or inpatient services were included. To replicate clinical practice, patients 
with a previous diagnosis of TB and/or history of TB treatment were recruited. However, 
they were excluded from the analyses on the basis that when evaluating patients with 
suspected active TB, the clinician should not perform an IGRA because any immunological 
biomarker would remain positive and thus affect test accuracy. The study population was 
expected to be representative of the national TB burden in terms of ethnic mix and range of 
co-morbidities. A key subgroup was HIV positive patients.  
 
Exclusion criteria 
Participants less than 16 years or those unable to give informed consent were excluded. 
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Setting 
Patients were recruited at the point of diagnostic work-up from 14 hospitals in 10 NHS trusts 
in the UK.  
 
Recruitment process 
An overview of the recruitment process is shown in Figure 1. Potential participants 
presenting at participating NHS centres were referred to a TB Research Nurse by the 
attending clinician. The nurse then screened participants to ensure they were eligible for the 
study according to the inclusion/exclusion criteria stated above. Each potential participant 
was provided with an information sheet and a verbal description of the study. Participants 
were included in the study if they were willing and informed consent was obtained.  
 
 
Figure 1 Overview of recruitment process 
 
Data collection and management 
Follow up 
Participants were seen by research nurses for follow up visits at two and six months after 
recruitment. Follow up visits were scheduled to be carried out at the same time as the 
 
No 
No 
(<16 years old) 
Consecutive series of participants suspected of active TB 
Inclusion criteria met? 
Informed consent given? 
Exclude from study 
Include in study 
Screening process 
Yes 
Yes 
(≥16 years old) 
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patient’s routine clinic appointments. At these visits blood was collected for IGRA testing 
and data on patient diagnosis were obtained. If patients were no longer being seen as part of 
their routine NHS care, they were not required to attend study follow up visits. In such cases, 
information about a patient’s diagnosis was obtained from their medical notes. In addition to 
following up patients at two and six months, a review of patient records was performed up to 
one year post recruitment if required in order to obtain a final diagnosis.  
 
Data management 
A case report form (CRF) was used to collect patient data at each recruiting hospital after a 
patient consented to participate in the IDEA study. Following receipt of the CRFs, data were 
entered into an electronic password protected database. The results of study IGRAs and all 
other study laboratory tests were entered into a separate secure database. This laboratory 
database was only accessible to specific laboratory staff. Thus, the Study Management Group 
(SMG) responsible for day-to-day management of IDEA, were blinded to the IGRA results. 
Furthermore, NHS clinicians responsible for routine care and diagnosis of patients involved 
in the study were also blinded to study IGRA results. To enable preparation of study reports 
for meetings of the independent oversight committee (Study Steering Committee [SSC]), the 
study statistician was granted access to the clinical database and excerpts of the laboratory 
database at specific periods during the study. 
 
Sample collection 
Blood samples 
Blood sampling was done at three time points—baseline, and follow up at two and six 
months. Only blood samples collected at baseline were used in the assessment of the index 
tests and for the reference standard. Samples taken at follow up were used for further IGRA 
testing (but not analysed as part of the IDEA study) and also stored for future research as 
consented by patients. Blood taking (venepuncture) procedures were carried out in 
accordance with local trust venepuncture guidelines. The baseline sample was obtained no 
later than 14 days after the start of treatment for TB or within seven days of consent, 
whichever was earlier, depending on the patient’s diagnosis. For patients with a diagnosis of 
active TB, sarcoidosis or other non TB diagnosis, follow up study blood samples were taken 
at two and six months after the start of treatment. For patients with a diagnosis of latent TB, 
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where possible and if the patient returned to the same clinical team, blood samples were taken 
at three and six months post onset of treatment (if treatment was indicated and given). 
  
A 35ml blood sample was taken at each time point. Blood was collected into heparinised 
collection tubes and QFT-GIT collection tubes for T-SPOT.TB and QFT-GIT assays, 
respectively. Further heparinised blood was collected for performance of next generation 
IGRAs and to store plasma and PBMCs for future research. In addition, blood was collected 
into uncoated collection tubes in order to store serum for future research. 
 
Blood samples were transported on the same day as sample collection either by a member of 
the research team or by courier in appropriate UN-type approved packaging to the TB 
Research Centre for testing. All samples were processed within six hours of blood collection 
for London based sites and within eight hours for Outer London sites. IGRAs were performed 
the same day as samples were received. Excess PBMCs were stored in a liquid nitrogen tank, 
and serum and plasma were stored in a -80°C freezer at the TB Research Centre (led by 
Professor Ajit Lalvani) at Imperial College London (St. Mary’s Hospital).  
 
Diagnostic bronchoscopy samples 
In patients with sputum smear negative pulmonary TB, diagnostic bronchoscopies were 
performed and bronchoalveolar lavage (BAL) was obtained as part of routine clinical care. 
When surplus BAL samples were available and not required for diagnostic procedures, 
aliquots were cryopreserved and stored in the research bio-repository for subsequent testing 
by IGRA. The bronchoscopic procedure, along with collection of surplus BAL samples were 
only applicable for patients recruited at St. Mary’s Hospital, Imperial College Healthcare 
NHS Trust, in accordance with set clinical practice guidelines. The BAL sample consent was 
covered under the consent form, as “tissue samples”. However, patients were informed if a 
surplus BAL sample was kept for the IDEA study. 
 
Index tests  
Interferon-gamma release assays   
Two types of commercially available IGRAs, QFT-GIT and T-SPOT.TB, were evaluated. In 
addition, a new ELISpot-based assay utilising novel antigens (Rv3615c, Rv2654, Rv3879c 
and Rv3873) was evaluated. The performance of each antigen was evaluated individually and 
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in combinations which included either or both ESAT-6 and CFP-10, the two antigens which 
comprise T-SPOT.TB. IGRA testing is not common practice for HIV negative patients 
suspected of TB in the hospitals of our consortium and is not currently recommended for HIV 
positive patients suspected of TB. However, if IGRAs were used locally at participating 
hospitals as part of the routine diagnostic work-up of patients, we recorded the tests done but 
we did not analyse the test results as study results for IDEA. Thus, only IGRA results 
obtained from samples taken specifically for this study were recorded and assessed. 
Laboratory staff performing the IGRAs and recording the test results were blinded to clinical 
information and reference standard results. 
 
Analysis of T-SPOT.TB and novel antigens 
PBMCs were isolated from heparinised whole blood using the Ficoll Paque density 
centrifugation method, as described in Whitworth et al.7 In brief, whole blood was diluted in 
RPMI 1640 medium and layered onto Ficoll-Plaque Plus at a ratio of two to one in 50ml 
falcon tubes. The tubes were centrifuged for 20 minutes at 18 to 25°C, and the cloudy PBMC 
layer was aspirated into fresh RPMI medium. Cells were washed with fresh RPMI medium 
and counted using Trypan blue exclusion dye. T-SPOT.TB was carried out on the freshly 
isolated PBMCs as per the manufacturer’s instructions10 and as described in Whitworth et al.7 
 
Cells were re-suspended in AIM-V (serum-free) at a concentration of 2.5 million cells/ml and 
250,000 cells per well were incubated overnight (18 hours) at 37°C with Mtb-specific 
antigens (ESAT-6, CFP-10, Rv3615c, Rv2654, Rv3879c, Rv3873) individually, and positive 
(phytohemagglutinin (PHA)) and nil (RPMI medium) controls in a 96-well plate, pre-coated 
with IFN-γ specific monoclonal capture antibodies. Thus, a total of eight wells were used per 
patient and samples from 12 patients were included on a plate. Overnight incubation of the 
cells with antigens allows for IFN-γ secretion from activated Mtb-specific effector T cells 
present in the culture. Secreted IFN-γ binds to the pre-coated IFN-γ-specific monoclonal 
capture antibodies on the membrane of each well. After incubation, wells were washed with 
phosphate-buffered saline (PBS) and an alkaline phosphatase-conjugated secondary IFN-γ 
specific monoclonal antibody was added to bind to any captured IFN-γ. For a visible 
representation of the spots on the membrane, an alkaline-phosphatase chromogen substrate 
was added.  
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Each spot formed on the membrane signifies IFN-γ release by a single activated Mtb antigen 
specific T cell. Spot forming cells (SFCs) are expected to be detected in positive control wells 
and absent in nil control wells. SFCs in TB antigen stimulated wells indicate infection. 
SFCs were counted using an automated ELISpot plate reader (AID Elispot read system 
ELRIFL04 with saturation level set at 60%). For individual antigens, test results were 
classified as negative, positive, borderline (equivocal) or indeterminate (invalid) by 
subtracting the spot count in the nil control well from the spot count in each Panel, according 
to the algorithm illustrated in Figure 2 (based on the package insert for T-SPOT.TB).10 Panels 
A, B, C, D, E and F correspond to ESAT-6, CFP-10, Rv3615c, Rv2654, Rv3879c and 
Rv3873, respectively.  
 
For T-SPOT.TB as well as other antigen combinations, if the positive control spot count was 
<20 the result was deemed indeterminate, unless the response to one of the Mtb antigens was 
positive (or borderline) in which case the test result for the combination was deemed positive 
(or borderline).  Thus we applied an “OR” rule (at least one antigen spot count deemed 
positive) for antigen combinations. For example, for T-SPOT.TB, a result was positive if the 
nil control spot count was ≤ 10 and either ‘Panel A minus nil control’ or ‘Panel B minus nil 
control’ was ≥8 spots. This implies the T-SPOT.TB result was negative if both ‘Panel A 
minus nil control’ and ‘Panel B minus nil control’ were negative (≤ 4 spots).  In the IDEA 
study, borderline test results (5 to 7 spots) were considered as positives. 
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Figure 2 Algorithm for defining test positivity of antigens 
TNTC, too numerous to count. 
Panel X indicates one of the six Panels A to F which correspond to the antigens ESAT-6, 
CFP-10, Rv3615c, Rv2654, Rv3879c and Rv3873, respectively. 
 
Analysis of QuantiFERON GOLD In-Tube 
The QFT-GIT assay was performed in two stages as per the manufacturer’s instructions11 and 
as described in Whitworth et al.7 First, whole blood was collected from each participant into 
three QFT-GIT tubes containing nil control, mitogen positive control and Mtb antigens 
(ESAT-6, CFP-10 and TB7.7 combined), as provided by the manufacturer.11 The tubes were 
incubated at 37°C for 16 to 24 hours to allow IFN-γ secretion from antigen-specific effector 
T cells into the extracellular fluid (plasma). After incubation, tubes were centrifuged and 150 
µl plasma was collected and stored in a 96-well plate for up to four weeks at 2°C to 8°C 
(-20°C for extended periods) prior to performing the remainder of the assay.  
 
To perform the ELISA step, 50ul plasma from each of the QFT tubes (i.e. containing mitogen 
control, nil control and Mtb antigens) was transferred to wells of another 96-well plate pre-
coated with IFN-γ specific monoclonal capture antibodies and incubated with a conjugate (an 
IFN-γ specific antibody conjugated to horse-radish peroxidase(HRP)) for two hours at room 
               
 
  
Nil Control spot count 
≤10 spots >10 spots 
INDETERMINATE  Positive Control spot count 
≥ 20 spots or 
saturation (TNTC) 
<20 spots 
Panel X – Nil 
Control spot count 
≥ 8 spots 
 
Panel X – Nil 
Control spot count 
is 5, 6 or7 spots 
Borderline test 
Panel X – Nil 
Control spot count 
≤ 4 spots 
POSITIVE 
BORDERLINE 
NEGATIVE 
Panel X – Nil 
Control spot count 
≥ 8 spots 
 
Panel X – Nil 
Control spot count 
is 5, 6 or7 spots 
Borderline test 
Panel X – Nil 
Control spot count 
≤ 4 spots 
POSITIVE 
BORDERLINE 
INDETERMINATE 
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temperature (22°C). Plasma sample in each well was mixed thoroughly using a microplate 
shaker for one minute to ensure that any IFN-γ was evenly distributed throughout the sample. 
Secreted IFN-γ in the plasma will be sandwiched between the two antibodies.  
 
After incubation and thorough washing with detergent, a photosensitive chromogen substrate 
solution (3, 3’, 5, 5’-tetramethylbenzidine (TMB)) was added which converted the sample to 
a detectable form (blue colour signal). The reaction was stopped with a substrate stopping 
solution (H2SO4). The intensity of the colour is directly proportional to the levels of IFN-γ 
present in the plasma after activation of TB-specific T cells by Mtb antigens. Colour should 
develop in the positive control well and not in the nil control well. Colour in the TB antigen 
well indicates infection. 
 
The optical density of each well was measured using a microplate reader with a 450 nm filter 
and a 620-650 nm reference filter. The concentration (IU/ml) of IFN-γ for the plasma sample 
from each of the three tubes (nil, mitogen, Mtb antigen) was determined against a series of 
standard concentrations (the standard curve). The test result (negative, positive or 
indeterminate) was calculated from the concentration values using an FDA approved 
algorithm (see Figure 3) run on QFT-GIT software according to the manufacturer’s 
instructions.11 
 
 
Figure 3 Determination of test results for QuantiFERON GOLD In-Tube 
Reprinted from Methods, Vol 61, HS Whitworth, M Scott, DW Connell, B Dongés and A 
Lalvani, IGRAs - The gateway to T cell based TB diagnosis, Pages 52-62, Copyright (2013), 
with permission from Elsevier. 
Nil ≤ 8.0 IU/ml
AND
Mitogen ≥ 0.5 IU/ml
TB Antigen - Nil ≥ 0.35 IU/ml
AND
TB Antigen - Nil ≥ 25% of Nil
Nil ≤ 8.0 IU/ml
AND
Any Mitogen
AND AND AND
POSITIVE NEGATIVE INDETERMINATE
TB Antigen - Nil ≤ 0.35 IU/ml
AND
TB Antigen - Nil < 25% of Nil
Nil ≤ 8.0 IU/ml
AND
Mitogen < 0.5 IU/ml
Nil > 8.0 IU/ml
AND
Any Mitogen
AND
Any TB Antigen - Nil
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Tuberculin skin test 
TST was performed as part of routine clinical care. Each recruiting centre has its own policy 
for TST use based on NICE guidance.12 Patients eligible for TST, as defined by local or 
NICE guidance, received a single intradermal injection of two tuberculin units or 0.1 ml of 
unlicensed tuberculin Mantoux test. The test was administered by trained specialist TB nurses 
who were entitled to administer medicines within the Trust under a Patient Group Directive. 
The degree of skin induration was measured 48 to 96 hours later. Test results were obtained 
from centres and we determined test positivity using three thresholds— ≥5mm, ≥10mm4, 13 
and a stratified threshold based on BCG vaccination status (≥6mm for unvaccinated and 
≥15mm for vaccinated participants).12 Patients were considered BCG vaccinated if they 
reported they had been vaccinated and/or had a BCG scar. 
 
Reference standard 
Participating hospitals followed the minimum set of tests defined within the NICE guideline 
[CG117, 2011]12 for diagnosing active TB and in accordance with local routine practice. 
However, the final diagnosis of participants was verified using the composite reference 
standard defined in Appendix 2 (Table 52). The reference standard was applied by a panel of 
clinicians blinded to local (routine) and study IGRA results. The role of the clinical panel was 
to assess anonymised patient clinical data without knowledge of the IGRA results in order to 
confirm the diagnostic category of all study participants. The composition of the panel and 
the assessment process is described below. 
 
Composition of the clinical panel 
Clinical panel members were appointed from among the PIs and co-investigators by the chief 
investigators. The panel included 
• An independent chair 
• A chest physician 
• An HIV physician with knowledge of HIV/TB infection 
• An infectious disease physician 
All physicians had extensive TB expertise. 
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Structure of case panel meetings 
Meetings were arranged and minutes were recorded by the study coordinator or a designated 
member of the study team. The panel meetings were held quarterly and the schedule was 
decided by the SMG depending on the quantity of data available for review. At each meeting 
priority was given to assessment of indeterminate (category 3) cases. Additional meetings 
were arranged to ensure all patients in categories 2 and 3, and some in category 4 were 
reviewed (see below). All panel members had to attend the meeting in person. 
 
Assessment of final diagnosis 
Diagnosis data (based on the Dosanjh categorisation4 outlined in Appendix 2) received from 
recruiting centres were reviewed as follows: 
• Category 1: all culture confirmed cases were not reviewed but were signed off at the 
end of the clinical panel meeting by the chief or co-investigators. 
• Category 2: all probable cases were reviewed. 
• Category 3: all indeterminate cases were reviewed. 
• Category 4:  non-active TB cases with a confirmed alternative diagnosis were not 
reviewed by the panel. Complicated category 4 patients were reviewed by the panel. 
 
Reviewing cases in this way ensured consistent final diagnosis categorisation. 
 
Data available to the panel 
For each patient that was reviewed, the following information was presented to the panel: 
• Patient demographics; 
• TB symptoms, previous TB information, TB exposure history, current medication, 
patient medical history, follow up data, HIV status and relevant clinical information 
and travel data; 
• Relevant clinical correspondence and test results during diagnosis and follow up 
(excluding results of routine and study IGRAs) such as culture, smear, PCR, TST, 
bronchoscopy, biopsy and/or radiological reports. 
 
Documentation 
Each panel member reviewed a patient’s documents and completed a form with the following 
information: 
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1. Diagnosis category (based on the Dosanjh criteria). 
2. Body site of disease (only if final diagnosis was active TB). 
3. Method of diagnosis: included culture, PCR, imaging, smear microscopy, histology, 
clinical features, response to treatment, multiple and other. For multiple and other, 
details were to be specified. 
 
Confirmation of diagnosis 
Final diagnosis decisions were made by a majority vote, with the chair having a casting vote 
if necessary. Final diagnoses were recorded by the study coordinator. If necessary, where a 
panel member had treated a patient being reviewed, the member was asked to provide 
information (without disclosing local or study IGRA results) and the member was excluded 
from final decision making (their vote was replaced with a vote from the chair) for the 
patient.  
 
Outcomes 
Sensitivity, specificity, positive and negative predictive values and likelihood ratios for each 
test and combinations of tests, were calculated to determine their diagnostic accuracy and 
clinical utility. The likely primary clinical utility of immune-based testing is to exclude TB. 
Thus, when interpreting the analyses and drawing conclusions, focus was primarily on the 
sensitivities and negative predictive values (NPVs). For test comparisons, relative test 
performance was assessed by comparing the sensitivity and specificity of one test with those 
of another test. These results were presented as relative sensitivities and relative specificities. 
 
Statistical analyses 
Sample size calculation 
As stated above, the primary clinical utility of IGRA results in the assessment of suspected 
active TB is likely to be in their NPV, which may enable clinicians to reliably rule out TB 
from the differential diagnoses. This in turn depends on the sensitivity of the test and the 
prevalence of active TB in the tested population. In a meta-analysis, the average sensitivity 
(95% CI) of T-SPOT.TB and QFT-GIT was 90% (86% to 93%) and 70% (63% to 78%) 
respectively.8 However, the estimates were mainly based on small studies and most studies 
included only patients without HIV infection. Furthermore, the estimates were not based on 
head-to-head comparative accuracy studies. Two large studies (n=194 active TB cases 
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diagnosed from n=389 TB suspects;4 n=216 active TB cases diagnosed from n=413 TB 
suspects14) gave more robust estimates of 85.1% (79.2% to 89.9%) and 85.2% (76.1% to 
91.9%) for T.SPOT.TB. The latter study compared T-SPOT.TB and QFT-GIT, and gave an 
estimate of 78.1% (70.7% to 84.3%) for QFT-GIT.14 
 
Given the available evidence, we powered the IDEA study to detect a conservatively 
estimated 10% difference in sensitivity between T-SPOT.TB and QFT-GIT, assuming a 
sensitivity of 85% for T-SPOT.TB and 75% for QFT-GIT. To detect this difference at the 5% 
significance level (two-tailed) with 90% power, 855 patients were required (each receiving 
both tests), assuming a 40% prevalence of active TB in the study population. This calculation 
was done using a method which accounts for the paired nature of the data (based on 
McNemar’s test).15 The method requires knowledge of the probability of positive T-
SPOT.TB and positive QFT-GIT results amongst cases of active TB (concordance 
probability). A positive correlation, such as may be expected between both blood tests, would 
give a lower sample size compared to assuming independence or a negative correlation of test 
errors. However, as no pilot data was available to inform the choice of the concordance 
probability, we chose to be conservative and so assumed independence. To allow for missing 
data, indeterminate index test and reference standard results, withdrawal of consent and 
possible logistical errors, we aimed to recruit 1,012 participants.  
 
According to published evidence, the sensitivity of QFT-GIT decreases in HIV positive 
subgroups while that of T-SPOT.TB is unaffected in some studies and decreased in others.16 
Therefore, we computed sample size for the HIV positive subgroup based on sensitivities of 
85% and 65% for T.SPOT.TB and QFT-GIT, respectively. Assuming a 50% prevalence of 
active TB among these participants, we thus required 156 patients to detect a 20% difference 
between the IGRAs at the 5% significance level with 80% power. We aimed to recruit 200 
patients for similar reasons to those outlined above. 
 
Revision of sample size calculation and study extension for recruitment of HIV positive 
participants  
During the study recruitment period, the proportion of HIV positive patients with a final 
diagnosis of active TB was found to be substantially lower (20% rather than 50%) than 
originally anticipated when the study was designed. This was attributed to a decrease in TB 
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incidence in this population in recent years.17 In order to answer a key objective regarding the 
utility of IGRAs in HIV positive patients, the SSC supported an extension of recruitment of 
HIV positive participants to ensure the study was adequately powered.  
 
The sample size calculation was revised to take into account the reduced prevalence of active 
TB in this population. Given a prevalence of 20%, 390 HIV positive participants will be 
required to detect a 20% difference between the sensitivity of T-SPOT.TB and QFT-GIT with 
80% power at the 5% significance level. Thus the sample size was increased from 156 to 390. 
Ethical approval was sought and an extension of 12 months was granted on 5th November 
2014 to recruit and follow up only HIV positive participants. Given the purposive recruitment 
of additional HIV positive participants, results are presented separately for the main cohort 
(including HIV positive participants recruited during the first phase of IDEA prior to the 
extension period) in Chapters 3 and 4, and for the entire HIV positive cohort in Chapter 5. 
 
Data analysis 
Sensitivity, specificity, positive predictive value (PPV), NPV and likelihood ratios for each 
test and combination of tests, were calculated to determine their diagnostic accuracy and 
clinical utility in the main cohort and within the key subgroups outlined in the study 
objectives. For all proportions, 95% confidence intervals (CIs) were calculated using the 
Wilson method.18, 19 Confidence intervals for positive and negative likelihood ratios were 
calculated using the method by Simel et al.20 Separate analyses of the complete cohort of HIV 
positive participants were also performed.  
 
Patients classified as having culture confirmed (category 1) or highly probable (category 2) 
active TB, and those without active TB (category 4), were included in the analyses (see 
definition of categories in Appendix 2, Table 52. However, the proportion of patients 
classified as clinically indeterminate (category 3) was reported. For the primary analyses, 
patients with indeterminate IGRA results were excluded from the analyses. In clinical 
practice, if an IGRA was used as a rule out test for active TB, then an indeterminate result 
would have the same implications as a positive result, i.e., it could not rule out a diagnosis of 
the disease (and thus TB would remain a differential diagnosis). The impact of including 
indeterminate IGRA results as test positives (i.e. true positives and false positives depending 
on final diagnosis of active TB or no active TB) was assessed in sensitivity analyses. 
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Sensitivity analyses were also conducted to investigate the impact of including category 2 
patients on the sensitivity of IGRAs. 
 
Comparisons between different IGRAs were done using generalized estimating equation 
(GEE) models to exploit the paired nature of the data. Our analysis was based on all available 
data (i.e. included patients who did not have a complete set of index test results). Separate 
GEE models were fitted for those with active TB (Dosanjh categories 1 and 2) and those with 
no active TB (category 4) to determine differences in sensitivity and specificity respectively. 
The outcome variable in the GEE model was IGRA result (positive versus negative) and the 
explanatory variable was type of IGRA, for example, T-SPOT-TB versus QFT-GIT. The 
natural outputs from these models are odds ratios. For example, comparing the sensitivity of 
T-SPOT.TB to that of QFT-GIT, the odds ratio is the odds of a positive T-SPOT.TB result 
compared to the odds of a positive QFT-GIT result in patients with active TB. For the 
comparison of specificities, the odds ratio is the odds of a negative T-SPOT.TB result 
compared to the odds of a negative QFT-GIT result in non TB patients. Since odds ratios do 
not have an intuitive interpretation, we computed ratios of sensitivities (relative sensitivity) 
and ratios of specificities (relative specificity) using a function (nlcom) that computes point 
estimates and confidence intervals for nonlinear combinations of parameter estimates post 
estimation of the models. The confidence intervals are computed using the delta method.  
 
Variation in the relative performance of T-SPOT.TB and QFT-GIT with HIV status and other 
clinical characteristics was investigated by including one covariate at a time in the GEE 
models.21 To assess the effect of a covariate on relative test performance, an interaction term 
for test type and the covariate was included in the model. In addition to these characteristics 
pre-specified in the protocol, we investigated the effect of smoking because this has been 
associated with a two fold increase in the risk of developing active TB.22 We included both 
inpatients and outpatients in all our analyses of diagnostic accuracy to allow for 
generalisability of these tests as an initial test in any case of possible active TB. However, 
because disease severity and spectrum can influence the diagnostic performance of a test, we 
also investigated the effect of clinical setting (inpatients versus outpatients) to determine if 
our approach was tenable. We were interested in exploring the effect of Vitamin D as it is an 
important co-factor for the intracellular killing of TB. It is associated with an increased 
resistance to TB infection, and with the phenotype of active TB. The value of vitamin D 
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supplementation in active TB to improve disease outcome is unclear. However, we were 
unable to evaluate the effect of vitamin D status on IGRA performance due to variation 
between centres in the definition of vitamin D status. 
 
In the subset of patients presenting with a TST result as part of their clinical diagnostic work-
up, the performance of TST used in sequence with IGRAs was evaluated. The performance of 
this combination was assessed using logistic regression models constructed in the same form 
as Bayesian updating (post-test odds = pre-test odds x likelihood ratio) by including the log 
of the pre-test odds of prevalence (a constant term of known value) as an offset in the model. 
A linear predictor was then used to estimate log likelihood ratios, rather than log odds ratios, 
and bootstrap methods were used to obtain valid confidence intervals (CIs).23 Model 
parameterisations from Knottnerus24 were used to compute likelihood ratios for the additional 
diagnostic value of each test in a testing sequence. Non-parametric, bias-adjusted CIs for 
parameter estimates from 1,000 bootstrap samples were computed. 
 
We performed all analyses using Stata, version 13.0 (Stata, College Station, Texas). 
 
Patient and public involvement 
Ms Nisha Karnani was our patient representative for the duration of the study. She was 
consulted at key points during the study, and was invited to SSC meetings and the IDEA 
presentation at the end of the study. 
  
Study oversight and management arrangements 
Study Management Group 
The SMG included the chief investigators, study coordinator, lead research nurse and a post-
doctoral research associate. The day-to-day management of the study was carried out by the 
study coordinator, with close support provided by the chief investigators and other members 
of the SMG. The SMG met monthly to discuss study progress and oversight. 
 
Data Management Group  
The DMG consisted of members of the statistical team and members of the SMG. The group 
met regularly to review data on recruitment, and the prevalence of TB and HIV in the study 
cohort. The DMG reported to the SSC (see below).  
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Study Steering Committee 
Independent oversight was provided by the SSC. The committee included an independent 
chair (Professor Khalid Khan), three other independent members (Dr Stephen Gordon, Dr 
James Gray and Dr Johannes B Reitsma) and a Patient and Public Involvement (PPI) 
representative (Nisha Karnani).  
 
Ethical arrangements and regulatory approvals 
Ethics approval for this study 
This study received ethical approval from the North West London REC1 Ethics Committee 
(REC ref: 11/H0722/8). The research study was submitted for Site Specific Assessment 
(SSA) at each participating NHS Trust. The chief investigators required a copy of the 
Research and Development (R&D) approval letter before accepting participants into the 
study. The study was conducted in accordance with the recommendations for physicians 
involved in research on human subjects adopted by the 18th World Medical Assembly, 
Declaration of Helsinki (1964) and later revisions. 
 
Consent and study withdrawal 
Consent to enter the study was sought from each participant only after a full explanation had 
been given, an information sheet offered and time allowed for consideration. Signed 
participant consent was then obtained. The right of the participant to refuse to participate 
without giving reasons was respected. After a participant was entered into the study, the 
clinician remained free to give any treatment that he or she considered necessary, or to refer 
onto an appropriate healthcare professional, at any stage if it was judged to be in the best 
interest of the participant. Reasons for such decisions were recorded. In such cases, 
participants remained in the study for the purposes of follow up and data analysis. All 
participants were free to withdraw at any time from the study without giving reasons. 
Assurance was provided by the person taking consent that withdrawal will not affect the 
patient’s care. In accordance with Good Clinical Practice guidance, participants who 
withdrew were not required to give a reason for withdrawal. Data were collected on 
participant’s final diagnosis unless consent was withdrawn for any data to be used. 
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Confidentiality 
The chief investigator and all members of the research team abided by the Data Protection 
Act and preserved the confidentiality of participants involved in the study. Participants were 
allocated a unique identifying code (anonymised) on recruitment, with no personal identifiers 
recorded on any sample or data. 
 
Indemnity 
Imperial College, London as sponsor of this study holds negligent and non-negligent harm 
insurance policies which applied to this study. These were arranged through the Joint 
Research Office. 
 
Protocol amendments  
Between April 2011 and February 2015, the protocol underwent seven amendments as 
detailed in Appendix 3, Table 53. Six of the seven amendments were deemed substantial 
amendments which required ethical approval while one was a minor amendment.
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Chapter 3 Participant characteristics  
The results presented in this chapter are based on all participants recruited prior to the study 
extension, including those with HIV infection. Thus, the chapter excludes HIV positive 
patients recruited during the study extension period. 
 
Recruitment of participants into main study cohort 
A total of 1,074 participants, including 177 (16.5%) who were HIV positive, were recruited 
from 10 NHS trusts into the main study between 25th November 2011 and 31st August 2013. 
The number of patients recruited at each centre is shown in Table 1. Over half of the study 
participants were recruited from two Trusts—Imperial College Healthcare NHS Trust 
(26.4%) and Northwest London Hospitals NHS Trust (27.8%). 
 
Table 1 Recruitment by centre 
Hospital Trust Number of 
patients 
recruited 
Imperial College Healthcare NHS Trust 283 (26.4) 
Heart of England NHS Foundation Trust  106 (9.9) 
Chelsea and Westminster Hospital NHS Foundation Trust  52 (4.8) 
Royal Free Hampstead NHS Trust  59 (5.5) 
St George's Healthcare NHS Trust  61 (5.7) 
Heatherwood and Wexham Park Hospitals NHS Foundation Trust 44 (4.1) 
University of Leicester Hospitals NHS Trust  116 (10.8) 
Northwest London Hospitals NHS Trust  299 (27.8) 
Oxford University Hospitals NHS Trust  4 (0.4) 
Sandwell and West Birmingham Hospitals NHS Trust  50 (4.7) 
Total 1074 (100)  
 
The flow of patients through the study is shown in Figure 4. Of the 1,074 patients recruited, 
845 were included in the analyses. Reasons for exclusion are shown in Figure 4. Forty 
patients from Heatherwood and Wexham Park Hospitals NHS Trust were excluded because 
patients with a high pre-test probability of active TB were selectively recruited. The decision 
to exclude these patients was approved by the SSC following an SSC meeting during which 
the diagnosis of patients recruited at each centre was reviewed.  
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Figure 4 Study flow diagram of patients with suspected active TB 
QFT-GIT, QuantiFERON GOLD In-Tube; TST, tuberculin skin test. 
aOriginally considered eligible but later judged by the clinical panel to be ineligible  
bNot eligible for inclusion in the analyses because the patient was HIV negative and 
recruitment into the main study had closed. 
cPatients recruited at this Trust were excluded because patients with a high pre-test 
probability of active TB were selectively recruited. 
The final four boxes show the number of patients with available IGRA results. 
  
 
Patients with suspected TB 
n=1074 
Eligible for analyses 
n=984 
Consent withdrawn/invalid (n=64) 
• Lost to follow up = 39 
• Withdrawn = 8 
• Dead = 3  
• Invalid consent form = 13 
• Otherb = 1 
 
Patients recruited from 
10 Trusts 
n=885 
Patients recruited at 
Heatherwood and Wexham Park 
Hospitals NHS Foundation Trustc 
n=40 
Ineligiblea 
n=26 
Previous diagnosis of active TB 
n=99 
Patients from 9 Trusts included in analyses 
n=845 
Culture 
confirmed TB 
n=261 
Highly 
probable TB 
n=102 
Clinically 
indeterminate 
n=43 
Active TB 
excluded 
n=439 
T-SPOT.TB: n=246 
QFT-GIT: n=252 
T-SPOT.TB: n=99 
QFT-GIT: n=101 
T-SPOT.TB: n=41 
QFT-GIT: n=42 
T-SPOT.TB: n=423 
QFT-GIT: n=425 
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Table 2 shows the number of patients assigned to each diagnostic category. There were 43 
(5.1%) patients with a clinically indeterminate (category 3) diagnosis. Of the remaining 802 
patients, there were 363 (45.3%) cases of active TB (based on those with culture confirmed 
[category 1] and highly probable [category 2] TB) and 439 (54.7%) where active TB was 
excluded (categories 4A to 4D). Of the 439 non-active TB cases, 117 (26.7%) were category 
4D. 
 
Table 2 Reference standard results according to Dosanjh categories 
Diagnostic category Criteria Patients 
1: Culture confirmed TB Microbiological culture of M. tuberculosis, AND 
suggestive clinical and radiological findings. 
261 
2: Highly probable TB Clinical and radiological features highly 
suggestive of TB unlikely to be caused by other 
disease, AND a decision to treat made by a 
clinician, AND appropriate response to therapy, 
AND histology supportive if available. 
102 
3: Clinically indeterminate Final diagnosis of TB neither highly probable, nor 
reliably excluded. 
43 
4: Active TB excluded   
Subclassification   
     4A: Inactive TB Stable CXR changes, AND TST positivea (if 
done), AND bacteriologically negative (if done), 
AND no clinical evidence of active disease. 
7 
     4B:  One or more risk factors for 
TB exposureb, TST positivea 
TST positivea, AND bacteriologically negative (if 
done) AND no clinical evidence of active disease. 
48 
     4C: One or more risk factors for 
TB exposureb, TST negative 
History of TB exposure, AND TST negative (if 
done). 
267 
     4D: No risk factors for TB 
exposureb, TST negative 
No history of TB exposure, AND TST negative (if 
done) 
117 
Total  845 
CXR, chest radiograph; TB, tuberculosis; TST, tuberculin skin test. 
aTST using Mantoux test with  threshold ≥15mm considered positive  
bRisk factors for TB exposure: recent exposure to active TB patient, born in country of high 
prevalence or belonging to an ethnic group with a high prevalence of TB (Incidence 
>100/100,00025). 
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Diagnostic categories adapted from Dosanjh et al.4 
 
Baseline characteristics of participants 
The main demographic characteristics of the 845 patients are given in Table 3. Most patients 
(64.4%) were recruited from an outpatient setting while the remaining were from an inpatient 
setting. The median (range) age of patients was 38 (16 to 86) years and most (59.3%) of the 
patients were male. Almost half (48.2%) of the study population were of Indian origin. 
Altogether, 75 countries of birth were represented in the study; 16 of the countries had at 
least 10 participants with India (26.7%) and the UK (22.8%) accounting for almost half of the 
study population. The complete list of countries is given in Appendix 4, Table 54.  
 
Table 3 Demographics 
Characteristic Dosanjh category Total 
Culture 
confirmed TB 
Highly 
probable TB 
Clinically 
indeterminate 
Active TB 
excluded 
Clinical setting, n (%)      
Inpatient 90 (34.5) 30 (29.4) 11 (25.6) 170 (38.7) 301 (35.6) 
Outpatient  171 (65.5) 72 (70.6) 32 (74.4) 269 (61.3) 544 (64.4) 
Median age (range), years 32 (16–81) 36 (18–76) 38 (16–79) 44 (17–86) 38 (16–86) 
Male, n (%) 177 (67.8) 53 (52.0) 21 (48.8) 250 (56.9) 501 (59.3) 
Ethnic origin, n (%)      
Asian 16 (6.1) 6 (5.9) 5 (11.6) 14 (3.2) 41 (4.9) 
Black 50 (19.2) 22 (21.6) 10 (23.3) 102 (23.2) 184 (21.8) 
Hispanic 1 (0.4) 0 0 7 (1.6) 8 (0.9) 
Indian subcontinent 167 (64.0) 61 (59.8) 16 (37.2) 168 (38.3) 412 (48.8) 
Middle Eastern 4 (1.5) 0 0 12 (2.7) 16 (1.9) 
Mixed 1 (0.4) 4 (3.9) 0 8 (1.8) 13 (1.5) 
White 22 (8.4) 9 (8.8) 12 (27.9) 126 (28.7) 169 (20.0) 
Unknown 0 0 0 2 (0.5) 2 (0.2) 
Median years in UK (range) 4.9 (0.1–52.9) 6.1 (0.3–59.7) 10.5 (0.4–56.9) 13.2 (0.0–60.3) 8.3 (0.0–60.3) 
Profession, n (%)a      
Paid employment 130 (49.8) 52 (51.0) 21 (48.8) 214 (48.7) 417 (49.4) 
Unpaid employment 62 (23.8) 24 (23.5) 16 (37.2) 164 (37.4) 266 (31.5) 
Student 50 (19.2) 13 (12.8) 3 (7.0) 26 (5.9) 92 (10.9) 
Healthcare/laboratory 
worker 16 (6.1) 9 (8.8) 2 (4.7) 24 (5.5) 51 (6.0) 
Social/prison worker 1 (0.4) 1 (1.0) 0 2 (0.5) 4 (0.5) 
Sex worker 0 1 (1.0) 0 2 (0.5) 3 (0.4) 
Unknown 2 (0.8) 2 (2.0) 1 (2.3) 7 (1.6) 12 (1.4) 
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aSome patients had more than one profession. 
The percentages are column percentages for each characteristic. 
 
Table 4 shows the clinical characteristics of the patients. Of the 845 patients, 135 (16.0%) 
were HIV positive. Out of the 135 patients, there were two (1.5%) patients with a clinically 
indeterminate diagnosis. Of the remaining 133 patients, 25 (18.8%) were active TB cases 
while 108 (81.2%) were non-active TB cases.  
 
Of the 845 patients, over half had other co-morbidities; 300 (35.5%) patients had a single co-
morbidity, 127 (15.0%) had multiple and the remaining 418 (49.5%) had none. There were 88 
(10.4%) patients with pre-existing diabetes, 12 (1.4%) with chronic/end stage renal failure 
and five (0.6%) patients were on immunosuppressive therapy (Table 5). These were the three 
key subgroups that we had planned to investigate in subgroup analyses. Due to the limited 
data, subgroup analyses will be presented in Chapter 4 for only those with diabetes. The 
thresholds used to categorise vitamin D status varied between hospital trusts as detailed in 
Appendix 5, Table 55. Although vitamin D measurements were missing for a large 
proportion of patients (49.1%), where results were available, many patients were categorised 
as either vitamin D deficient (26.5%) or insufficient (16.9%) with few (7.5%) having normal 
results (Table 4).  
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Table 4 Clinical characteristics 
Characteristic Dosanjh category Total 
Culture 
confirmed 
TB 
Highly 
probable 
TB 
Clinically 
indeterminate 
Active TB 
excluded 
Median height (range), m 1.7 (1.4–2.0) 1.7 (1.5–1.9) 1.6 (1.5–1.8) 1.7 (1.3–2.0) 1.7 (1.3–2.0) 
Median weight (range), kg 63 (35–127) 64 (40–116) 71 (37–110) 68 (38–157) 65 (35–157) 
Median BMI (range) 22 (14–48) 22 (16–42) 24 (13–45) 24 (15–47) 23 (13–48) 
BCG vaccinated, n (%) 194 (74.3) 79 (77.5) 36 (83.7) 340 (77.4) 649 (76.8) 
BCG scar visible, n (%)      
Yes 172 (65.9) 72 (70.6) 29 (67.4) 283 (64.5) 556 (65.8) 
No  12 (4.6) 3 (2.9)  3 (7.0)  19 (4.3)  37 (4.4)  
Unsure  16 (6.1) 8 (7.8)  6 (14.0)  44 (10.0)  74 (8.8)  
Missing  61 (23.4) 19 (18.6)  5 (11.6)  93 (21.2)  178 (21.1)  
Recent known TB contact, n 
(%) 
70 (26.8) 25 (24.5) 12 (27.9) 83 (18.9) 190 (22.5) 
HIV positive, n (%) 13 (5.0) 12 (11.8) 2 (4.7) 108 (24.6) 135 (16.0) 
Other pre-existing 
conditions/co-morbidities, n 
(%)a 
     
None 169 (64.8) 61 (59.8) 19 (44.2) 169 (38.5) 418 (49.5) 
Diabetes 22 (8.4) 5 (4.9) 8 (18.6) 53 (12.1) 88 (10.4) 
Hepatitis B 5 (1.9) 1 (1.0) 0 5 (1.1) 11 (1.3) 
Hepatitis C 1 (0.4) 1 (1.0) 0 10 (2.3) 12 (1.4) 
Chronic/end stage renal 
failure 
5 (1.9) 1 (1.0) 2 (4.7) 4 (0.9) 12 (1.4) 
Cancer 1 (0.4) 1 (1.0) 0 12 (2.7) 14 (1.7) 
Organ transplantation 0 0 0 2 (0.5) 2 (0.2) 
Asthma 12 (4.6) 5 (4.9) 4 (9.3) 50 (11.4) 71 (8.4) 
Sarcoidosis 1 (0.4) 0 0 0 1 (0.1) 
Other 74 (28.4) 37 (36.3) 20 (46.5) 228 (51.9) 359 (42.5) 
Vitamin D deficiency b, n (%)      
Deficient 106 (40.6) 35 (34.3) 12 (27.9) 59 (13.4)  212 (25.1)  
Insufficient 49 (18.8)  14 (13.7)  7 (16.3)  65 (14.8)  135 (16.0)  
Normal 13 (5.0) 8 (7.8)  5 (11.6)  34 (7.7)  60 (7.1)   
Not Known 93 (35.6) 45 (44.1)  19 (44.2)  281 (64.0)  438 (51.8) 
aSome patients had multiple co-morbidities and so the numbers do not add up to 845. The 
same applies to medication.  
bFor definition of the thresholds used for categorising vitamin D status, see Appendix 5. 
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Percentages presented are column percentages for the characteristic.  
 
Table 5 Medication history  
Medication, n (%)a  Dosanjh category Total 
Culture 
confirmed 
TB 
Highly 
probable 
TB 
Clinically 
indeterminate 
Active TB 
excluded 
None 63 (24.1) 35 (34.3) 13 (30.2) 203 (46.2) 314 (37.2) 
Chemotherapy 0 0 0 1 (0.2) 1 (0.1) 
Corticosteroids >15 mg/day 20 (7.7) 5 (4.9) 5 (11.6) 20 (4.6) 50 (5.9) 
Corticosteroids <15 mg/day 13 (5.0) 7 (6.9) 1 (2.3) 19 (4.3) 40 (4.7) 
Corticosteroids unknown 1 (0.4) 1 (1.0) 0 0 2 (0.2) 
Cyclosporine; tacralimus; 
everolimus 
0 0 0 1 (0.2)  1 (0.1) 
Immune suppressants 0 0 0 5 (1.1) 5 (0.6) 
Methotrexate 1 (0.4) 0 0 5 (1.1) 6 (0.7) 
Other 191 (73.2) 64 (62.7) 30 (69.8) 233 (53.1) 518 (61.3) 
Unknown 1 (0.4) 0 0 1 (0.2) 2 (0.2) 
Percentages presented are column percentages for the characteristic.  
 
The social history of participants is outlined in Table 6. Smoking history was missing for two 
patients; about two-thirds of the patients had never smoked while the remaining were ex or 
current smokers. Most (58.6%) patients also had no history of alcohol use. Almost all patients 
(97.6%) had no history of homelessness and a few patients (27/845, 3.2%) had a history of 
imprisonment.  
 
Table 7 summarises the frequency of presenting symptoms for 580 patients. The main 
symptoms recorded were cough, fever, night sweats, weight loss, haemoptysis and lethargy. 
Patients generally presented with multiple symptoms but cough was often present (423/580, 
72.9%). The median (range) number of symptoms was 7 (6 to11). One patient had no 
symptoms but was recruited on the basis of chest X-ray findings.   
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Table 6 Social history 
Characteristic Dosanjh category Total 
Culture 
confirmed 
TB 
Highly 
probable 
TB 
Clinically 
indeterminate 
Active TB 
excluded 
Smoking history, n (%)      
Never smoked 181 (69.3) 81 (79.4) 26 (60.5) 248 (56.5) 536 (63.4) 
Ex-smoker 31 (11.9) 8 (7.8) 6 (14.0) 93 (21.2) 138 (16.3) 
Current smoker 49 (18.8) 13 (12.7) 11 (25.6) 96 (21.9) 169 (20.0) 
Unknown 0 0 0 2 (0.5) 2 (0.2) 
Pack years if current smoker, n (%)      
≤10 11 (22.4) 6 (46.2) 4 (36.4) 27 (28.1) 48 (28.4) 
11-20 1 (2.0) 2 (15.4) 1 (9.1) 6 (6.3) 10 (5.9) 
21-50 1 (2.0) 1 (7.7) 0  7 (7.3) 9 (5.3) 
>51 1 (2.0) 0 0 1 (1.0) 2 (1.2) 
Unknown 35 (71.4) 4 (30.8) 6 (54.5) 55 (57.3) 100 (59.2) 
History of alcohol use, n (%)      
Non-drinker  163 (62.5) 80 (78.4) 27 (62.8) 225 (51.3) 495 (58.6) 
Ex-drinker 10 (3.8) 2 (2.0) 1 (2.3) 35 (8.0) 48 (5.7) 
Current drinker 88 (33.7) 20 (19.6) 15 (34.9) 175 (39.9) 298 (35.3) 
Unknown 0 0 0 4 (0.9) 4 (0.5) 
Median units/week if current 
drinker (range) 4 (0–250) 5 (1–35) 2 (0–140) 5 (0–210) 4 (0–250) 
History of alcohol misuse, n (%) 9 (3.4) 0 1 (2.3) 20 (4.6) 30 (3.6) 
History of recreational drug use, n 
(%)   
     
Non-user 21 (8.0) 10  (9.8) 1 (2.3) 18 (4.1) 50 (5.9) 
Ex-user  2 (0.8) 0 1 (2.3) 5 (1.1) 8 (0.9) 
Current user 5 (1.9) 3 (2.9) 1 (2.3) 13 (3.0) 22 (2.6) 
Unknown 233 (89.3) 89 (87.3) 40 (93.0) 403 (91.8) 765 (90.5) 
History of homelessness, n (%)      
None 256 (98.1) 101 (99.0) 43 (100.0) 425 (96.8) 825 (97.6) 
Previously homeless 2 (0.8) 1 (1.0) 0 11 (2.5) 14 (1.7) 
Currently homeless 3 (1.1) 0 0 3 (0.7) 6 (0.7) 
Median years homeless if currently 
or previously homeless (range) 4 (0–6) 12 – 6 (0–24) 6 (0–24) 
History of imprisonment, n (%) 4 (1.5) 2 (2.0) 0 21 (4.8) 27 (3.2) 
The percentages are column percentages for each characteristic. 
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Table 7 Symptoms at presentation 
Symptom Dosanjh category Total 
Culture 
confirmed TB 
Highly 
probable TB 
Clinically 
indeterminate 
Active 
TB 
excluded 
Cough, n (%) 112 (70.9) 46 (59.7) 20 (55.6) 245 (79.3) 423 (72.9) 
Fever, n (%) 83 (52.5) 39 (50.6) 12 (33.3) 143 (46.3) 277 (47.8) 
Night sweats, n (%) 84 (53.2) 43 (55.8) 18 (50.0) 156 (50.5) 301 (51.9) 
Weight loss, n (%) 96 (60.8) 45 (58.4) 18 (50.0) 153 (49.5) 312 (53.8) 
Haemoptysis, n (%) 17 (10.8) 7 (9.1) 2 (5.6) 48 (15.5) 74 (12.8) 
Lethargy, n (%) 82 (51.9) 44 (57.1) 20 (55.6) 157 (50.8) 303 (52.2) 
Other, n (%) 86 (54.4) 45 (58.4) 20 (55.6) 142 (46.0) 293 (50.5) 
No symptoms, n (%)a 1 (0.6) 0 0 0 1 (0.2) 
Median number of 
symptoms (range) 7 (6–11) 7 (6–10) 7 (6–10)  6 (6–10) 7 (6–11) 
aOne patient without symptoms was recruited on the basis of chest X-ray findings. 
Symptom data were available for 580 patients. The percentages are column percentages for 
each symptom. 
 
Final diagnosis  
Table 8 shows the diagnostic tests performed during the diagnostic work up of patients. Chest 
X-rays and culture were often performed (in 89.4% and 86.2% of patients respectively) but 
cerebrospinal fluid testing and MRI were uncommon (in 3.6% and 12.0% respectively). The 
number of T-SPOT.TB, QFT-GIT and TST tests performed as part of routine care at each 
centre is shown in Appendix 6, Table 56. However, for the purpose of the IDEA study, 
IGRAs were not used in determining the final diagnosis of patients. TST was only performed 
in 336 patients across the nine centres and results were available for 322 patients. Most of 
these 336 patients were recruited at Northwest London Hospitals NHS Trust (57%) and 
Imperial College Healthcare NHS Trust (26%). 
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Table 8 Diagnostic tests performed during diagnostic work up  
Test, n (%) Dosanjh category Total 
Culture 
confirmed TB 
Highly 
probable TB 
Clinically 
indeterminate 
Active TB 
excluded 
BAL investigation 51 (19.5) 20 (19.6) 7 (16.3) 108 (24.6) 186 (22.0) 
Chest X-ray 231 (88.5) 95 (93.1) 38 (88.4) 391 (89.1) 755 (89.3) 
CSF investigation 7 (2.7) 6 (5.9) 3 (7.0) 14 (3.2)  30 (3.6) 
CT 142 (54.4) 69 (67.6) 26 (60.5) 273 (62.2) 510 (60.4) 
Culture 261 (100) 87 (85.3) 29 (67.4) 351 (80.0) 728 (86.2) 
Histology or biopsy 72 (27.6) 42 (41.2) 15 (34.9) 101 (23.0) 230 (27.2) 
MRI 29 (11.1) 17 (16.7) 8 (18.6) 47 (10.7) 101 (12.0) 
PCR 85 (32.6) 20 (19.6) 6 (14.0) 66 (15.0) 177 (20.9) 
Smear test 232 (88.9) 75 (73.5) 24 (55.8) 335 (76.3) 666 (78.8) 
BAL, bronchoalveolar lavage; CSF, cerebrospinal fluid; CT, computed tomography; MRI, 
magnetic resonance imaging; PCR, polymerase chain reaction .  
 
The final diagnosis of active TB patients is detailed in Table 9. Of the 363 with active TB, 
234 (64.5%) had smear negative TB. Forty four (12.1%) active TB cases had both pulmonary 
and extra pulmonary TB. Approximately half (189/363, 52.1%) had only extra pulmonary 
TB. This occurred more often amongst those diagnosed as highly probable TB (75/102, 
73.5%) relative to culture confirmed cases (114/261, 43.7%). In 130 (35.8%) active TB cases, 
patients had only pulmonary TB. In contrast to extra pulmonary TB, pulmonary TB was more 
common amongst culture confirmed cases (111/261, 42.5%) compared to highly probable TB 
cases (19/102, 18.6%).  The most common sites of TB infection were the lungs (174/363, 
47.9%) and lymph nodes (154/363, 42.4%). The drug sensitivity profile shows that 238 
(65.6%) were fully sensitive and the level of resistance was unknown for 94 (25.9%) or 
missing for nine (2.5%). The 22 (6.1%) with drug resistance were all culture confirmed cases. 
  
Table 10 shows the final diagnosis of non-active TB patients. A patient may have multiple 
conditions. Of the seven conditions listed in the table, pneumonia was the most frequent 
diagnosis with 104 of 439 (23.7%) patients having the condition. A higher proportion of 
inpatients were diagnosed with cancer (14.1%) or pneumonia (38.8%) compared to 
outpatients (4.5% and 14.1% respectively). In contrast, a higher proportion of outpatients 
were diagnosed with chest infections, latent TB infection and sarcoidosis. 
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Table 9 Final diagnosis of patients with active TB  
N (%) Category 1 TB Category 2 TB Total 
All TB  261 (71.9) 102 (28.1) 363 (100) 
Smear positive TB  66 (25.3) 3 (2.9) 69 (19.0) 
Smear negative TB  163 (62.5) 71 (69.6) 234 (64.5) 
Pulmonary TB  111 (42.5) 19 (18.6) 130 (35.8) 
Extra pulmonary TB  114 (43.7) 75 (73.5) 189 (52.1) 
Pulmonary and extra pulmonary TB 36 (13.8) 8 (7.8) 44 (12.1) 
Site of infectiona    
Abdomen 6 (2.3) 3 (2.9) 9 (2.5) 
Bones 5 (1.9) 0 5 (1.4) 
Brain 2 (0.8) 4 (3.9) 6 (1.7) 
Chest 1 (0.4) 1 (1.0) 2 (0.6) 
Lungs 147 (56.3) 27 (26.5) 174 (47.9) 
Lymph node 105 (40.2) 49 (48.0) 154 (42.4) 
Miliary TB (disseminated) 11 (4.2) 0 11 (3.0) 
Pericardium 4 (1.5) 2 (2.0) 6 (1.7) 
Pleura 15 (5.7) 11 (10.8) 26 (7.2) 
Spine 10 (3.8) 6 (5.9) 16 (4.4) 
Other 15 (5.7) 16 (15.7) 31 (8.5) 
Drug sensitivity profile    
Fully sensitive 233 (89.3) 5 (4.9) 238 (65.6) 
Drug resistant 21 (8.1) 0 21 (5.8) 
MDR 1 (0.4) 0 1 (0.3) 
Level of resistance unknown  0 94 (92.2) 94 (25.9) 
Missing 6 (2.3) 3 (2.9) 9 (2.5) 
MDR, multidrug resistant. 
aSome patients had TB at multiple sites and so percentages do not add up to 100%. 
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Table 10 Final diagnosis of patients without active TB 
Diagnosis Inpatients (%) 
n =170 
Outpatients (%) 
n = 269 
Total (%) 
n = 439 
Cancer 24 (14.1) 12 (4.5) 36 (8.2) 
Chest Infection 1 (0.6) 15 (5.6) 16 (3.6) 
Lower respiratory tract infection  10 (5.9) 13 (4.8) 23 (5.2) 
Latent TB infection: treatment indicated 1 (0.6) 19 (7.1) 20 (4.6) 
Pneumonia 66 (38.8) 38 (14.1) 104 (23.7) 
Sarcoidosis 5 (2.9) 33 (12.3) 38 (8.7) 
Upper respiratory tract infection 0 8 (3.0) 8 (1.8) 
Other  70 (41.2) 153 (56.9) 223 (50.8)  
Some patients had multiple diagnoses and so percentages represent the number of patients 
with that particular diagnosis out of the total number. 
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Chapter 4 Diagnostic accuracy results 
Overview 
Estimates of the accuracy of IGRAs presented in this chapter are for the main cohort of 
patients (including HIV positive patients recruited prior to the extension period). Estimates of 
the accuracy of T-SPOT.TB and QFT-GIT are presented individually, followed by 
comparisons of test accuracy (T-SPOT.TB versus QFT-GIT). The results of subgroup 
analyses are then presented for T-SPOT.TB and QFT-GIT. Lastly, test accuracy estimates are 
provided for ESAT-6, CFP-10 and next generation IGRAs (Rv3615c, Rv2654, Rv3879c, 
Rv3873) individually and in combinations; the diagnostic accuracy of the test combinations 
were then compared with that of T-SPOT.TB. For completeness, we also briefly address the 
accuracy of TST. 
 
Completeness of IGRA results 
Of the 845 patients, T-SPOT.TB and QFT-GIT results were available for 809 (96%) and 820 
patients, respectively. All 809 patients with T-SPOT.TB results also had results for the next 
generation IGRAs (Rv3615c, Rv2654, Rv3879c and Rv3873). Table 11 shows the results for 
T-SPOT.TB and QFT-GIT against diagnostic category. For 805 patients, results were 
available for both IGRAs; reasons for missing T-SPOT.TB and QFT-GIT results are shown 
in Table 12.The cross classified results of the two tests are given in Appendix 7 (Table 57) 
for the 805 patients.  
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Table 11 T-SPOT.TB and QFT-GIT results by diagnostic category 
Index test result Dosanjh category Total 
1 2 3 4A 4B 4C 4D 4A-D  
T-SPOT.TB          
Positive 201 69 15 0 19 41 7 67 352 
Negative 33 25 23 6 26 200 87 319 400 
Indeterminate 12 5 3 1 1 18 17 37 57 
Missing 15 3 2 0 2 8 6 16 36 
Total 261 102 43 7 48 267 117 439 845 
Median SFCs 
ESAT-6 (range) 
13 (0–387) 13 (0–492) 0 (0–325) 0 (0–1) 2 (0–274) 0 (0–210) 0 (0–147) 0 (0–274) 1 (0–492) 
Median SFCs 
CFP-10 (range) 
17 (0–465) 13 (0–437) 1 (0–315) 0 (0–3) 1 (0–160) 0 (0–166) 0 (0–148) 0 (0–166) 1 (0–465) 
QFT-GIT          
Positive 163 57 14 0 19 49 6 74 308 
Negative 68 39 22 7 25 187 85 304 433 
Indeterminate 21 5 6 0 2 26 19 47 79 
Missing 9 1 1 0 2 5 7 14 25 
Total 261 102 43 7 48 267 117 439 845 
Median IFN-γ 
levels (range) 
0.69 (0–10) 0.64 (0–10) 0.15 (0–6.69) 0.02 (0–0.34) 0.15 (0–10) 0.03 (0–10) 0.01 (0–7.58) 0.03 (0–10) 0.12 (0–10) 
SFCs, spot forming cells.
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Table 12  Reasons for missing IGRA results 
Reason QFT-GIT T-SPOT.TB 
No sample could be taken 1 0 
Sample destroyed for laboratory reasons 2 11 
Sample unsuitable for testing 6 8 
Unable to obtain sample from patient 16 17 
Total 25 36 
The same reason applied to both test results for 20 participants. 
 
Diagnostic accuracy of T-SPOT.TB and QFT-GIT  
Table 13 shows the cross tabulation of T-SPOT.TB and QFT-GIT results against active TB 
status (i.e. active TB or not). The proportion of indeterminate test results was 6.7% (54/809) 
for T-SPOT.TB and 8.9% (73/820) for QFT-GIT. The difference between the two 
proportions was 2.2% (-0.4% to 4.8%; P = 0.09). Based on all culture confirmed and highly 
probable active TB cases and excluding indeterminate IGRA results, sensitivity (95% CI) 
was 82.3% (77.8% to 86.1%) for T-SPOT.TB and 67.3% (62.0% to 72.1%) for QFT-GIT. 
Amongst those in whom active TB was excluded, specificity (95% CI) was 82.6% (78.6% to 
86.1%) for T-SPOT.TB and 80.4% (76.1% to 84.1%) for QFT-GIT (Table 14). The PPVs for 
T-SPOT.TB and QFT-GIT were 80.1% (75.5% to 84.0%) and 74.8% (69.6% to 79.5%), and 
the NPVs were 84.6% (80.6% to 87.9%) and 74.0% (69.5% to 78.0%). 
 
Using only culture confirmed active TB cases, the sensitivities of T-SPOT.TB and QFT-GIT 
increased slightly to 85.9% (80.9% to 89.8%) and 70.6% (64.4% to 76.1%), respectively. The 
sensitivity of T-SPOT.TB was 6.8% lower in patients diagnosed with pulmonary TB 
compared to those with extra pulmonary TB [77.2% (68.7% to 83.9%) versus 84.0% (77.9% 
to 88.7%)]. In contrast, although the difference was small (2.6%), the sensitivity of QFT-GIT 
was higher in patients who had pulmonary TB [68.7% (59.7% to 76.5%)] compared to those 
with extra pulmonary TB [66.1% (58.7% to 72.8%)]. Using only category 4D patients 
without active TB gave much higher specificities than using all patients without active TB 
(see Table 14). 
 
In sensitivity analyses with indeterminate test results included as test positives, the sensitivity 
(95% CI) of T-SPOT.TB was 83.2% (78.9% to 86.8%) and 69.7% (64.7% to 74.2%) for 
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QFT-GIT. The specificity (95% CI) of T-SPOT.TB was 75.4% (71.1% to 79.3%) and 71.5% 
(67.1% to 75.6%) for QFT-GIT. Full results are provided in Appendix 7, Table 58. 
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Table 13 Cross-tabulation of T-SPOT.TB and QFT-GIT against final diagnosis 
Active TB positive (categories 1 and 2) Active TB negative (category 4) 
N 
T-SPOT.TB 
N 
T-SPOT .TB 
Positive Negative Indeterminate Missing Total Positive Negative Indeterminate Missing Total 
QFT-
GIT 
Positive 193 13 9 5 220 
QFT-
GIT 
Positive 40 30 3 1 74 
Negative 57 41 7 2 107 Negative 24 250 26 4 304 
Indeterminate 19 4 1 2 26 Indeterminate 3 36 8 0 47 
Missing 1 0 0 9 10 Missing 0 3 0 11 14 
Total 270 58 17 18 363 Total 67 319 37 16 439 
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Table 14 Diagnostic accuracy of T-SPOT.TB and QFT-GIT for diagnosis of active TB  
Test performance T-SPOT.TB QFT-GIT 
n/N Estimate  
(95% CI) 
n/N Estimate  
(95% CI) 
Sensitivity for a diagnosis of active TB     
All TB 270/328 82.3 (77.8–86.1) 220/327 67.3 (62.0–72.1) 
Culture positive TB 201/234 85.9 (80.9–89.8) 163/231 70.6 (64.4–76.1) 
Culture negative TB 57/80 71.3 (60.5–80.0) 46/81 56.8 (45.9–67.0) 
Smear positive TB 49/59 83.1 (71.5–90.5) 41/55 74.6 (61.7–84.2) 
   Smear negative TB 179/216 82.9 (77.3–87.3) 148/221 67.0 (60.5–72.8) 
Pulmonary TB 88/114 77.2 (68.7–83.9) 79/115 68.7 (59.7–76.5) 
Extra pulmonary TB 147/175 84.0 (77.9–88.7) 113/171 66.1 (58.7–72.8) 
Specificity for a diagnosis of active TB     
Active TB excluded  319/386 82.6 (78.6–86.1) 304/378 80.4 (76.1–84.1) 
Active TB excluded, TST negative, no 
risk factors for LTBI 
87/94 92.3 (85.4–96.4) 85/91 93.4 (86.4–96.9) 
Predictive values     
Positive predictive value 270/337 80.1 (75.5–84.0) 220/294 74.8 (69.6–79.5) 
Negative predictive value 319/377 84.6 (80.6–87.9) 304/411 74.0 (69.5–78.0) 
Likelihood ratios     
Positive likelihood ratio  4.74 (3.79–5.93)  3.44 (2.76–4.27) 
Negative likelihood ratio  0.21 (0.17–0.27)  0.41 (0.35–0.48) 
LTBI, latent tuberculosis infection; TST, tuberculin skin test. 
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate 
IGRA results were excluded from these analyses. See Appendix 5 for sensitivity analyses 
with indeterminates included as test positives. 
 
Comparison of diagnostic accuracy of T-SPOT.TB and QFT-GIT 
Excluding indeterminate IGRA results, there were 714 T-SPOT.TB results and 705 QFT-GIT 
results. Based on analyses using GEE models, the sensitivity of T-SPOT.TB was superior to 
that of QFT-GIT [relative sensitivity (95% CI): 1.22 (1.14 to 1.31); P <0.001] but there was 
no statistical evidence of a difference in specificity [relative specificity (95% CI): 1.02 (0.97 
to 1.08); P = 0.3] (Table 15). When indeterminate IGRA results were included as test 
positives in a sensitivity analysis, the analysis included 768 T-SPOT.TB results and 778 
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QFT-GIT results. Similar to the primary analysis, there was statistical evidence of a 
difference in sensitivity [relative sensitivity (95% CI): 1.19 (1.12 to 1.28); P <0.001] and no 
evidence of a difference in specificity [relative specificity (95% CI): 1.05 (0.98 to 1.13); P = 
0.1] (Appendix 7, Table 59). 
 
Table 15 Comparison of diagnostic accuracy of T-SPOT.TB and QFT-GIT 
Test Na Sensitivity (95% CI) Nb Specificity (95% CI) 
T-SPOT.TB  328 82.2 (77.7–85.9) 386 83.0 (78.9–86.4) 
QFT-GIT  327 67.3 (62.1–72.2) 378 81.0 (76.8–84.6) 
Ratioc (95% CI); P value  1.22 (1.14–1.31); <0.001  1.02 (0.97–1.08);  0.3 
aNumber of test results amongst those with active TB. 
bNumber of test results amongst those without active TB. 
cRatio of the sensitivity (or specificity) of T-SPOT.TB to that of QFT-GIT. The natural 
outputs from generalized estimating equation models are odds ratios. Ratios of sensitivities 
(relative sensitivity) and ratios of specificities (relative specificity) were computed post 
estimation of the models. Confidence intervals were obtained using the delta method. 
Sensitivities and specificities are presented as percentages. 
 
Subgroup analyses for T-SPOT.TB and QFT-GIT 
HIV positive and HIV negative patients 
HIV co-infected patients are the highest risk subgroup for TB. In this section we briefly 
present results for the 135 HIV positive patients in the main cohort and address the primary 
objectives related to this subgroup in Chapter 5 using all HIV positive patients recruited into 
the IDEA study. Appendix 8 (Table 60) shows the results for T-SPOT.TB and QFT-GIT 
against active TB status.  Appendix 8 (Table 61) shows the cross tabulation of T-SPOT.TB 
and QFT-GIT results in HIV positive patients. For 134 patients, results were available for 
both T-SPOT.TB and QFT-GIT. 
 
The number of test results for active TB and non-active TB patients that was available for the 
analyses of test performance in HIV positive patients was small (Appendix 8, Table 60). 
Using culture confirmed and highly probable active TB cases and excluding indeterminate 
IGRA results, sensitivity (95% CI) was 63.2% (41.0% to 80.9%) for T-SPOT.TB and 56.5% 
(36.8% to 74.4%) for QFT-GIT. Amongst all non-active TB patients, specificity (95% CI) 
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was 89.9% (81.3% to 94.8%) for T-SPOT.TB and 92.0% (84.3% to 96.1%) for QFT-GIT 
(Table 16). For T-SPOT.TB and QFT-GIT, the PPVs were 60.0% (38.7% to 78.1%) and 
65.0% (43.3% to 81.9%), and the NPVs were 91.0% (82.6% to 95.6%) and 88.9% (80.7% to 
93.9%).  
 
For HIV negative patients (Table 17) results were generally similar to those of the entire 
cohort which included both HIV negative and positive patients (see Table 14). For both 
subgroups, inclusion of indeterminate IGRA results in sensitivity analyses led to higher 
sensitivities, lower specificities and no change in negative predictive values as expected due 
to inclusion of indeterminates as test positives (see Appendix 8, Table 62and Table 63).  
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Table 16 Diagnostic accuracy of T-SPOT.TB and QFT-GIT in HIV positive patients 
Test performance T-SPOT.TB QFT-GIT 
n/N Estimate  
(95% CI) 
n/N Estimate  
(95% CI) 
Sensitivity for a diagnosis of active TB     
All TB 12/19 63.2 (41.0–80.9) 13/23 56.5 (36.8–74.4) 
Culture positive TB 7/11 63.6 (35.4–84.8) 8/13 61.5 (35.5–82.3) 
Culture negative TB 5/8 62.5 (30.6–86.3) 5/9 55.6 (26.7–81.1) 
Smear positive TB 1/4 25.0 (4.6–69.9) 3/5 60.0 (23.1–88.2) 
   Smear negative TB 7/11 63.6 (35.4–84.8) 7/13 53.8 (29.1–76.8) 
Pulmonary TB 3/5 60.0 (23.1–88.2) 5/8 62.5 (30.6–86.3) 
Extra pulmonary TB 7/10 70.0 (39.7–89.2) 6/12 50.0 (25.4–74.6) 
Specificity for a diagnosis of active TB     
Active TB excluded  71/79 89.9 (81.3–94.8) 80/87 92.0 (84.3–96.1) 
Active TB excluded, TST negative, 
no risk factors for LTBI 
28/29 96.6 (82.8–99.4) 36/38 94.7 (82.7–98.5) 
Predictive values     
Positive predictive value 12/20 60.0 (38.7–78.1) 13/20 65.0 (43.3–81.9) 
Negative predictive value 71/78 91.0 (82.6–95.6) 80/90 88.9 (80.7–93.9) 
Likelihood ratios     
Positive likelihood ratio  6.24 (2.97–13.1)  7.03 (3.17–15.6) 
Negative likelihood ratio  0.41 (0.22–0.74)  0.47 (0.30–0.76) 
LTBI, latent tuberculosis infection; TST, tuberculin skin test. 
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate 
IGRA results were excluded from these analyses. See Appendix 8 (Table 62) for sensitivity 
analyses with indeterminates included as test positives. 
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Table 17 Diagnostic accuracy of T-SPOT.TB and QFT-GIT in HIV negative patients 
Test performance T-SPOT.TB QFT-GIT 
n/N Estimate 
(95% CI) 
n/N Estimate  
(95% CI) 
Sensitivity for a diagnosis of active TB     
All TB 258/309 83.5 (79.0–87.2) 207/304 68.1 (62.7–73.1) 
Culture positive TB 194/223 87.0 (81.9-90.8) 155/218 71.1 (64.8-76.7) 
Culture negative TB 52/72 72.2 (61.0-81.2) 41/72 56.9 (45.4-67.7) 
Smear positive TB 48/55 87.3 (76.0-93.7) 38/50 76.0 (62.6-85.7) 
   Smear negative TB 172/205 83.9 (78.3-88.3) 141/208 67.8 (61.2-73.8) 
Pulmonary TB 85/109 78.0 (69.3-84.7) 74/107 69.2 (59.9-77.1) 
Extra pulmonary TB 140/165 84.8 (78.6-89.5) 107/159 67.3 (59.7-74.1) 
Specificity for a diagnosis of active TB     
Active TB excluded  248/307 80.8 (76.0–84.8) 224/291 77.0 (71.8–81.4) 
Active TB excluded, TST negative, no 
risk factors for LTBI 
59/65 90.8 (81.3-95.7) 49/53 92.5 (82.1-97.0) 
Predictive values     
Positive predictive value 258/317 81.4 (76.7–85.3) 207/274 75.6 (70.1–80.3) 
Negative predictive value 248/299 82.9 (78.3–86.8) 224/321 69.8 (64.6–74.6) 
Likelihood ratios     
Positive likelihood ratio  4.35 (3.44–5.49)  2.96 (2.37–3.70) 
Negative likelihood ratio  0.20 (0.16–0.26)  0.42 (0.35–0.49) 
LTBI, latent tuberculosis infection; TST, tuberculin skin test. 
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate 
IGRA results were excluded from these analyses. See Appendix 8 (Table 63) for sensitivity 
analyses with indeterminates included as test positives. 
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Other key patient subgroups 
For our secondary objective of quantifying test accuracy in three key patient subgroups 
(patients with pre-existing diabetes, end-stage renal failure and iatrogenic 
immunosuppression), subgroup analyses were only performed for those with diabetes due to 
few patients in the other two subgroups (see Table 4). The results for T-SPOT.TB and 
QFT-GIT against active TB status are shown in Appendix 9, Table 64. Due to limited data for 
TST, only the performance of T-SPOT.TB and QFT-GIT are presented below.  Table 65 in 
Appendix 9 shows the cross tabulation of T-SPOT.TB and QFT-GIT results in the 88 patients 
with diabetes. For 86 patients, results were available for both T-SPOT.TB and QFT-GIT. 
 
Excluding indeterminate IGRA results, sensitivity (95% CI) was 68.0% (48.4% to 82.8%) for 
T-SPOT.TB and 55.6% (37.3% to 72.4%) for QFT-GIT amongst patients with culture 
confirmed and highly probable active TB. Based on all non-active TB patients, specificity 
(95% CI) was 77.6% (64.1% to 87.0%) for T-SPOT.TB and 78.7% (65.1% to 88.0%) for 
QFT-GIT (Table 18). The PPVs were 60.7% (42.4% to 76.4%) and 60.0% (40.7% to 76.6%), 
and the NPVs were 82.6% (69.3% to 90.9%) and 75.5% (61.9% to 85.4%) for T-SPOT.TB 
and QFT-GIT. These analyses were based on limited data and so should be interpreted with 
caution. Appendix 9 (Table 66) shows the performance of both tests when indeterminate 
IGRA results were included as test positives in sensitivity analyses.  
 
  
45 
 
Table 18 Diagnostic accuracy of T-SPOT.TB and QFT-GIT in patients with diabetes 
Test performance T-SPOT.TB QFT-GIT 
n/N Estimate  
(95% CI) 
n/N Estimate  
(95% CI) 
Sensitivity for a diagnosis of active TB     
All TB 17/25 68.0 (48.4–82.8) 15/27 55.6 (37.3–72.4) 
Culture positive TB 14/21 66.7 (45.4–82.8) 12/22 54.5 (34.7–73.1) 
Culture negative TB 3/4 75.0 (30.1–95.4) 3/5 60.0 (23.1–88.2) 
Smear positive TB 6/8 75.0 (40.9–92.9) 5/8 62.5 (30.6–86.3) 
   Smear negative TB 9/14 64.3 (38.8–83.7) 7/16 43.8 (23.1–66.8) 
Pulmonary TB 4/8 50.0 (21.5–78.5) 5/9 55.6 (26.7–81.1) 
Extra pulmonary TB 10/13 76.9 (49.7–91.8) 8/14 57.1 (32.6–78.6) 
Specificity for a diagnosis of active TB     
Active TB excluded  38/49 77.6 (64.1–87.0) 37/47 78.7 (65.1–88.0) 
Active TB excluded, TST negative, 
no risk factors for LTBI 
6/7 85.7 (48.7–97.4) 4/5 80.0 (37.6–96.4) 
Predictive values     
Positive predictive value 17/28 60.7 (42.4–76.4) 15/25 60.0 (40.7–76.6) 
Negative predictive value 38/46 82.6 (69.3–90.9) 37/49 75.5 (61.9–85.4) 
Likelihood ratios     
Positive likelihood ratio  3.03 (1.69–5.44)  2.61 (1.37–4.98) 
Negative likelihood ratio  0.41 (0.23–0.75)  0.57 (0.36–0.88) 
LTBI, latent tuberculosis infection; TST, tuberculin skin test. 
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate 
IGRA results were excluded from these analyses. See Appendix 9, Table 66 for sensitivity 
analyses with indeterminates included as test positives. 
 
Variation in relative performance of T-SPOT.TB and QFT-GIT 
We explored the effect of HIV co-infection, diabetes, smoking and clinical setting on the 
relative test performance of T-SPOT.TB and QFT-GIT. Each covariate was investigated in a 
separate regression model. The sensitivities of both tests were superior in HIV negative 
patients compared to HIV positive patients. However, there was no statistical evidence of an 
effect of HIV status on relative sensitivity (P = 0.2). In contrast, specificities were superior in 
HIV positive patients compared to HIV negative patients but there was no statistical evidence 
of an effect of HIV status on relative specificity (P = 0.2).  
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Although, the sensitivities and specificities of both tests were higher in those without diabetes 
compared to those with diabetes, there was no statistical evidence of an effect on relative test 
performance (Table 19). Although the P value from the Wald test of the interaction between 
test type and smoking gave a P value of 0.01 for the difference in relative sensitivity between 
the group that had never smoked and the group of previous smokers, the global test of 
whether relative test performance varied across smoking subgroups was not statistically 
significant for sensitivity (P = 0.7) or for specificity (P = 0.4). The sensitivities of 
T-SPOT.TB and QFT-GIT were lower in inpatients compared to outpatients; the converse 
was the case for their specificities. 
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Table 19 Effect of co-morbidities, smoking, and clinical setting on relative test performance of T-SPOT.TB and QFT-GIT 
Covariate NTD NQD Sensitivity (95% CI) P value NTND NQND Specificity (95% CI) P value 
   T-SPOT.TB QFT-GIT   T-SPOT.TB QFT-GIT 
None 328 327 82.2 (77.7–85.9) 67.3 (62.1–72.2) N/A 386 378 83.0 ( 78.9–86.4) 81.0 (76.8–84.6) N/A 
HIV status           
Negative 309 304 83.5 (79.0–87.3) 68.2 (62.8–73.2)  307 291 80.8 (76.0–84.8) 77.5 (72.4–81.9)  
Positive 19 23 60.1 (38.0–78.7) 56.1 (36.1–74.35 0.2 79 87 90.0 (81.2–94.7) 92.3 (84.7–96.3)  0.2 
Diabetes           
No 303 300 83.3 (78.7–87.1) 68.3 (62.9–73.3)  337 331 83.8 (79.6–87.3) 81.2 (76.7–85.0)  
Yes 25 27 67.8 (47.8–82.9) 55.6 (36.9–72.8) 0.5 49 47 76.9 (63.2–86.6) 79.8 (66.0–88.8) 0.4 
Smoking statusa           
Never 238 239 83.8 (78.6–87.9) 65.3 (59.1–71.1)  220 216 83.0 (77.5–87.3) 78.0 (72.1–83.0)  
Previous 34 29 77.0 (60.2–88.1) 82.2 (64.5–92.2) 0.01 82 77 81.0 (71.1–88.0) 80.4 (70.2–87.8) 0.4 
Current  56 59 78.5 (66.0–87.3)  68.3 (55.6–78.8) 0.2 82 83 84.3 (75.0–90.6) 88.8 (80.2–94.0) 0.06 
Clinical setting           
Inpatient 104 96 77.7 (69.0–84.6) 64.3 (54.5–73.1)  140 132 86.8 (80.2–91.5) 90.0 (83.6–94.1)  
Outpatient 224 231 84.2 (78.8–88.4) 68.7 (62.4–74.3) 0.4 246 246 80.6 (75.2–85.0) 76.0 (70.3–80.9) 0.09 
aThe global effect of smoking status on the relative performance of TSPOT.TB and QFT-GIT was not significant for sensitivity (P = 0.7)  or for 
specificity (P = 0.4).  
N/A, not applicable; NTD, number of T-SPOT.TB results in active TB cases; NTND, number of T-SPOT.TB results in non-active TB patients; 
NQD, number of QFT-GIT results in active TB cases; NQND, number of QFT-GIT results in non-active TB patients. Sensitivity and specificity are 
presented as percentages. The P values are from the Wald tests of the interaction between test type and the covariate. 
48 
 
 
Diagnostic accuracy of next generation IGRAs 
The diagnostic accuracy of ESAT-6, CFP-10, and four next generation IGRAs—Rv3615c, 
Rv2654, Rv3879c and Rv3873—are presented in the following sections as individual tests 
and as test combinations. The accuracy of different test combinations was compared with that 
of T-SPOT.TB. 
 
Individual antigens 
The results of the six antigens cross tabulated against active TB status are shown in Table 20 
and their diagnostic accuracy in Table 21. Based on all culture confirmed and highly probable 
active TB cases and excluding indeterminate IGRA results, the three antigens with the 
highest sensitivities were Rv3615c, ESAT-6 and CFP-10. The sensitivities were 78.0% 
(73.1% to 82.1%), 69.4% (64.1% to 74.1%) and 71.6% (66.5% to 76.2%), and the 
specificities were 82.7% (78.7% to 86.1%), 87.8% (84.2% to 90.7%) and 86.3% (82.5% to 
89.4%) for Rv3615c, ESAT-6 and CFP-10. The performance of the remaining three antigens 
was very poor with sensitivities of 34.2% (29.2% to 39.5%), 37.4% (33.3% to 42.9%) and 
38.2% (33.1% to 43.7%) for Rv3873, Rv2654 and Rv3879c, respectively. However, their 
specificities were high—95.1% (92.4% to 96.8%), 91.7% (88.5% to 94.0%) and 93.3% 
(90.3% to 95.4%) for Rv3873, Rv2654 and Rv3879c. Table 21 also shows the performance 
of the tests in different clinical groups. For each antigen, sensitivity was higher in those with 
culture confirmed active TB compared to those with culture negative active TB. 
 
Results of the sensitivity analyses in which indeterminate test results were included as test 
positives are given in Appendix 10, Table 67. The results show slight increases in sensitivity 
with reductions in specificities.
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Table 20 Results of next generation IGRAs by diagnostic category 
IGRA result Dosanjh category Total 
1 2 3 4A 4B 4C 4D 4A-D 
Rv3615c          
Positive 192 59 14 0 18 41 8 67 332 
Negative 38 33 24 6 28 200 86 320 415 
Indeterminate 16 7 3 1 0 18 17 36 62 
Missing 15 3 2 0 2 8 6 16 36 
Total 261 102 43 7 48 267 117 439 845 
Median SFCs (range) 25 (0–642) 19 (0–450)  1 (0–102) 0 (0–4) 1 (0–134) 0 (0–493) 0 (0–406) 0 (0–493) 2 (0–642) 
Rv3873          
Positive 81 28 3 0 2 14 3 38 70 
Negative 146 64 34 6 43 225 92 366 610 
Indeterminate 19 7 4 1 1 20 16 38 68 
Missing 15 3 2 0 2 8 6 16 36 
Total 261 102 43 7 48 267 117 439 845 
Median SFCs (range) 2 (0–178) 1 (0–181) 0 (0–145) 0 (0–0) 0 (0–30) 0 (0–64) 0 (0–71) 0 (0–71) 0 (0–181) 
Rv2654          
Positive 88 31 8 0 9 17 6 32 159 
Negative 138 61 29 6 36 222 88 352 580 
Indeterminate 20 7 4 1 1 20 17 39 70 
Missing 15 3 2 0 2 8 6 16 36 
Total 261 102 43 7 48 267 117 439 845 
Median SFCs (range) 2 (0–260) 1 (0–395) 1 (0–55) 0 (0–1) 1 (0–44) 0 (0–370) 0 (0–57) 0 (0–370) 0 (0–395) 
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IGRA result Dosanjh category Total 
1 2 3 4A 4B 4C 4D 4A-D 
Rv3879c          
Positive 89 33 5 0 4 17 5 26 153 
Negative 138 59 32 6 41 222 90 359 588 
Indeterminate 19 7 4 1 1 20 16 38 68 
Missing 15 3 2 0 2 8 6 16 36 
Total 261 102 43 7 48 267 117 439 845 
Median SFCs (range) 2 (0–241) 1 (0–225) 0 (0–154) 0 (0–3) 0 (0–42) 0 (0–83) 0 (0–58) 0 (0–83) 0 (0–241) 
ESAT-6          
Positive 167 57 10 0 16 24 7 47 281 
Negative 63 36 27 6 29 217 87 339 465 
Indeterminate 16 6 4 1 1 18 17 37 63 
Missing 15 3 2 0 2 8 6 16 36 
Total 261 102 43 7 48 267 117 439 845 
Median SFCs (range) 14 (0–642) 13 (0–492) 0 (0–325) 0 (0–1) 2 (0–274) 0 (0–210) 0 (0–147) 0 (0–274) 1 (0–642) 
CFP-10          
Positive 174 58 12 0 2 8 6 16 34 
Negative 57 35 26 6 29 208 90 333 451 
Indeterminate 15 6 3 1 1 18 17 37 61 
Missing 15 3 2 0 2 8 6 16 36 
Total 261 102 43 7 48 267 117 439 845 
Median SFCs (range) 18 (0–642) 13 (0–437) 1 (0–315) 0 (0–3) 1 (0–160) 0 (0–166) 0 (0–148) 0 (0–166) 1 (0–642) 
SFCs, spot forming cells.  
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Table 21 Diagnostic accuracy of individual next generation IGRAs, ESAT-6 and CFP-10 
Test performance Rv3615c Rv3879c Rv3873 Rv2654 
n/N Estimate (95% CI) n/N Estimate (95% CI) n/N Estimate (95% CI) n/N Estimate (95% CI) 
Sensitivity for a diagnosis of active TB         
All TB 251/322 78.0 (73.1–82.1) 122/319 38.2 (33.1–43.7) 109/319 34.2 (29.2–39.5) 119/318 37.4 (33.3–42.9) 
Culture positive TB 192/230 83.5 (78.1–87.7) 89/227 39.2 (33.1–45.7) 146/227 64.3 (57.9–70.3) 138/226 61.1 (54.6–67.2) 
Culture negative TB 50/79 63.3 (52.3–73.1) 27/79 34.2 (24.7–45.2) 24/79 30.4 (21.3–41.2) 26/79 32.9 (23.6–43.9) 
Smear positive TB 47/57  82.5 (70.6–90.2) 22/56 39.3 (27.6–52.4) 20/57 35.1 (24.0–48.1) 15/63 23.8 (15.0–35.6) 
   Smear negative TB 162/212 76.4 (70.3–81.6) 86/212 40.6 (34.2–47.3) 70/211 33.2 (27.2–39.8) 85/211 40.3 (33.9–47.0) 
Pulmonary TB 85/112 75.9 (67.2–82.9) 35/112 31.3 (23.4–40.3) 28/112 25.0 (17.9–33.8) 41/112 36.6 (28.3–45.8) 
Extra pulmonary TB 133/172 77.3 (70.5–83.0) 71/170 41.8 (34.6–49.3) 63/169 37.3 (30.3–44.8) 62/169 36.7 (29.8–44.2) 
Specificity for a diagnosis of active 
TB 
        
Active TB excluded  320/387 82.7 (78.7–86.1) 359/385 93.3 (90.3–95.4) 366/385 95.1 (92.4–96.8) 352/384 91.7 (88.5–94.0) 
Active TB excluded, TST negative, 
no risk factors for LTBI 
86/94 91.5 (84.1–95.6) 90/95 94.7 (88.3–97.7) 92/95 96.8 (91.1–98.9) 88/94 93.6 (86.8–97.0) 
Predictive values         
Positive predictive value 251/318 78.9 (74.1–83.1) 122/148 82.4 (75.5–87.7) 109/128 85.2 (78.0–90.3) 119/151 78.8 (71.6–84.6) 
Negative predictive value 320/391 81.8 (77.7–85.4) 359/556 64.6 (60.5–68.4) 366/576 63.5 (59.5–67.4) 352/551 63.9 (59.8–67.8) 
Likelihood ratios         
Positive likelihood ratio  4.50 (3.59–5.64)  5.66 (3.81–8.42)  6.92 (4.35–11.01)  4.49 (3.13–6.44) 
Negative likelihood ratio  0.27 (0.22–0.33)  0.66 (0.61–0.73)  0.69 (0.64–0.75)  0.68 (0.62–0.75) 
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Table 21 continued 
Test performance ESAT-6 CFP-10 
n/N Estimate (95% CI) n/N Estimate (95% CI) 
Sensitivity for a diagnosis of active TB     
All TB 224/323 69.4 (64.1–74.1) 232/324 71.6 (66.5–76.2) 
Culture positive TB 167/230 72.6 (66.5–78.0) 174/231 75.3 (69.4–80.4) 
Culture negative TB 46/80 57.5 (46.6–67.7) 48/79 60.8 (49.7–70.8) 
Smear positive TB 38/57 66.7 (53.7–77.5) 42/58 72.4 (59.8–82.2) 
   Smear negative TB 151/213 70.9 (64.5–76.6) 155/215 72.1 (65.7–77.7) 
Pulmonary TB 72/112 64.3 (55.1–72.6) 76/114 66.7 (57.6–74.7) 
Extra pulmonary TB 124/173 71.7 (64.5–77.9) 127/172 73.8 (66.8–79.8) 
Specificity for a diagnosis of active 
TB 
    
Active TB excluded  339/386 87.8 (84.2–90.7) 333/386 86.3 (82.5–89.4) 
Active TB excluded, TST negative, 
no risk factors for LTBI 
87/94 92.6 (85.4–96.3) 90/94 95.7 (89.6–98.3) 
Predictive values     
Positive predictive value 224/271 82.7 (77.7–86.7) 232/285 82.4 (77.3–86.8) 
Negative predictive value 339/492 77.4 (73.3–81.1) 333/425 78.4 (74.2–82.0) 
Likelihood ratios     
Positive likelihood ratio  5.70 (4.32–7.52)  5.22 (4.02–6.76) 
Negative likelihood ratio  0.35 (0.30–0.41)   0.33 (0.28–0.39) 
LTBI, latent tuberculosis infection; TST, tuberculin skin test. 
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Sensitivity, specificity and predictive values are presented as percentages. Indeterminate IGRA results were excluded from these analyses. See 
Appendix 10 (Table 67) for sensitivity analyses with indeterminates included as test positives. 
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Combinations of antigens 
Various combinations of the antigens are shown cross tabulated against diagnostic category 
in Table 22. Table 23 shows the diagnostic accuracy of the combinations. The sensitivity of 
the four-antigen (CFP-10, ESAT-6, Rv3615c and Rv3879c) and three-antigen (CFP-10, 
ESAT-6 and Rv3615c) combinations containing both CFP-10 and ESAT-6 were identical 
irrespective of whether all active TB cases or different subgroups were analysed as shown in 
Table 23. For this three-antigen combination, the sensitivity (95% CI) was 89.9% (86.2% to 
92.7%) amongst all active TB cases and the specificity (95% CI) was 76.5% (72.0% to 
80.4%) in all non-active TB patients. Another three-antigen combination—CFP-10, 
Rv3615c and Rv3879c— gave similar sensitivity and specificity of 89.0% (85.1% to 91.9%) 
and 76.3% (71.8% to 80.3%). Reducing this combination to a two-antigen combination of 
CFP-10 and Rv3615c gave a sensitivity of 88.4% (84.5% to 91.4%) and specificity of 78.0% 
(73.7%–81.9%). For results of the sensitivity analyses including indeterminate test results, 
see Appendix 10,Table 68. 
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Table 22 Results of combinations of IGRAs against diagnostic category 
IGRA 
combination 
result 
Dosanjh category Total 
1 2 3 4A 4B 4C 4D 4A-D 
CFP-10 + Rv3615c      
Positive 219 70 16 0 24 53 8 85 390 
Negative 15 23 23 6 22 188 86 302 363 
Indeterminate 12 6 2 1 0 18 17 36 56 
Missing 15 3 2 0 2 8 6 16 36 
Total 261 102 43 7 48 267 117 439 845 
CFP-10 + Rv3615c + Rv3879c      
Positive 220 71 16 0 24 57 11 92 399 
Negative 14 22 23 6 22 184 84 296 355 
Indeterminate 12 6 2 1 0 18 16 35 55 
Missing 15 3 2 0 2 8 6 16 36 
Total 261 102 43 7 48 267 117 439 845 
ESAT-6 + CFP-10 + Rv3615c        
Positive 221 74 17 0 24 57 10 91 403 
Negative 13 20 22 6 22 184 84 296 351 
Indeterminate 12 5 2 1 0 18 17 36 55 
Missing 15 3 2 0 2 8 6 16 36 
Total 261 102 43 7 48 267 117 439 845 
          
ESAT-6 + CFP-10 + Rv3615c + Rv3879c 
Positive 221 74 17 0 24 61 13 98 410 
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IGRA 
combination 
result 
Dosanjh category Total 
1 2 3 4A 4B 4C 4D 4A-D 
Negative 13 20 22 6 22 180 82 290 345 
Indeterminate 12 5 2 1 0 18 16 35 54 
Missing 15 3 2 0 2 8 6 16 36 
Total 261 102 43 7 48 267 117 439 845 
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Table 23 Diagnostic accuracy of combinations of next generation IGRAs 
Test performance ESAT-6 + CFP-10 + 
Rv3615c + Rv3879c 
ESAT-6 + CFP-10 + 
Rv3615c 
CFP-10  + Rv3615c + 
Rv3879c 
CFP-10 + Rv3615c 
n/N Estimate (95% CI) n/N Estimate (95% CI) n/N Estimate (95% CI) n/N Estimate (95% CI) 
Sensitivity for a diagnosis of active TB         
All TB 295/328 89.9 (86.2–92.7) 295/328 89.9 (86.2–92.7) 291/327 89.0 (85.1–91.9) 289/327 88.4 (84.5–91.4) 
Culture positive TB 221/234 94.4 (90.7–96.7) 221/234 94.4 (90.7–96.7) 220/234 94.0 (90.2–96.4) 219/234 93.6 (89.7–96.1) 
Culture negative TB 61/80 76.3 (65.9–84.2) 61/80 76.3 (65.9–84.2) 59/79 74.7 (64.1–83.0) 58/79 73.4 (62.8–81.9) 
Smear positive TB 56/59  94.9 (86.1–98.3) 56/59 94.9 (86.1–98.3) 56/59 94.9 (86.1–98.3) 56/59 94.9 (86.1–98.3) 
   Smear negative TB 192/216 88.9 (84.0–92.4) 192/216 88.9 (84.0–92.4) 189/215 87.9 (82.9–91.6) 187/215 87.0 (81.8–90.8) 
Pulmonary TB 102/114 89.5 (82.5–93.9) 102/114 89.5 (82.5–93.9) 102/114 89.5 (82.5–93.9) 101/114 88.6 (81.5–93.2) 
Extra pulmonary TB 156/175 89.1 (83.7–92.9) 156/175 89.1 (83.7–92.9) 152/174 87.4 (81.6–91.5) 151/174 86.8 (80.9–91) 
Specificity for a diagnosis of active TB         
Active TB excluded  290/388 74.7 (70.2–78.8) 296/387 76.5 (72.0–80.4) 296/388 76.3 (71.8–80.3) 302/387 78.0 (73.7–81.9) 
Active TB excluded, TST negative, 
no risk factors for LTBI 
82/95 86.3 (78.0–91.8) 84/94 89.4 (81.5–94.1) 84/95 88.4 (80.4–93.4) 86/94 91.5 (84.1–95.6) 
Predictive values         
Positive predictive value 295/393 75.1 (70.6–79.1) 295/386 76.4 (71.9–80.4) 291/383 76.0 (71.5–80.0) 289/374 77.3 (72.8–81.2) 
Negative predictive value 290/323 89.8 (86.0–92.6) 296/329 90.0 (86.3–92.8) 296/332 89.2 (85.4–92.1) 302/340 88.8 (85.0–91.8) 
Likelihood ratios         
Positive likelihood ratio  3.56 (2.99–4.24)  3.83 (3.18–4.59)  3.75 (3.13–4.51)  4.02 (3.32–4.88) 
Negative likelihood ratio  0.14 (0.10–0.19)  0.13 (0.10–0.18)  0.14 (0.11–0.20)  0.15 (0.11–0.20) 
LTBI, latent tuberculosis infection; TST, tuberculin skin test. 
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Sensitivity, specificity and predictive values are presented as percentages. Indeterminate IGRA results were excluded from these analyses. See 
Appendix 10, Table 68 for sensitivity analyses with indeterminates included as test positives. 
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Comparison of novel antigen combinations with T-SPOT.TB 
Results of individual antigens classified against those of T-SPOT.TB show few discordant 
results between Rv3615c and T-SPOT.TB unlike those of the other three novel antigens 
(Rv3873, Rv2654 and Rv3879c) that are not components of T-SPOT.TB (Table 24).  
 
Table 25 and Table 26 show comparisons of the sensitivity and specificity of different test 
combinations versus those of T-SPOT.TB. Indeterminate test results were excluded from 
these analyses (see Appendix 10, Table 69 and Table 70 for results of sensitivity analyses 
with indeterminates included).The sensitivity of T-SPOT.TB was lower than those of any of 
the four test combinations (Table 25) but had higher specificity (Table 26). The sensitivity of 
the two-antigen combination of CFP-10 and Rv3615c was 7% higher than that of T-
SPOT.TB with a relative sensitivity (95% CI) of 1.07 (1.03 to 1.11). However, the specificity 
of the combined CFP-10 and Rv3615c was 5% lower than that of T-SPOT.TB with a relative 
specificity (95% CI) of 0.95 (0.92 to 0.98).
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Table 24 Cross-tabulation of individual IGRA results against T-SPOT.TB results 
IGRA result T-SPOT.TB.TB 
Positive Negative Indeterminate Missing Total 
Rv3615c      
Positive 281 49 2 0 332 
Negative 64 351 0 0 415 
Indeterminate 7 0 55 0 62 
Missing 0 0 0 36 36 
Total 352 400 57 36 845 
Rv3873      
Positive 123 7 1 0 131 
Negative 217 393 0 0 610 
Indeterminate 12 0 56 0 68 
Missing 0 0 0 36 36 
Total 352 400 57 36 845 
Rv2654      
Positive 143 16 0 0 159 
Negative 196 384 0 0 580 
Indeterminate 13 0 57 0 70 
Missing 0 0 0 36 36 
Total 352 400 57 36 845 
Rv3879c      
Positive 142 10 1 0 153 
Negative 198 390 0 0 588 
Indeterminate 12 0 56 0 68 
Missing 0 0 0 36 36 
Total 352 400 57 36 845 
ESAT-6      
Positive 281 0 0 0 281 
Negative 65 400 0 0 465 
Indeterminate 6 0 57 0 63 
Missing 0 0 0 36 36 
Total 352 400 57 36 845 
CFP-10      
Positive 297 0 0 0 297 
Negative 51 400 0 0 451 
Indeterminate 4 0 57 0 61 
Missing 0 0 0 36 36 
Total 352 400 57 36 845 
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Table 25 Comparison of sensitivity of IGRA combinations and T-SPOT.TB 
Test   Na Sensitivity 
(95% CI) 
Relative sensitivityb  
(95% CI) 
P value 
T-SPOT.TB (ESAT-6 + CFP-10) 328 82.3 (77.7–86.1) – – 
CFP-10 + Rv3615c 327 88.4 (84.5–91.5) 1.07 (1.03–1.12) <0.001 
CFP-10 + Rv3615c + Rv3879c 327 89.0 (85.1–92.0) 1.08 (1.04–1.12) <0.001 
ESAT-6 + CFP-10 + Rv3615c 328 89.9 (86.2–92.8) 1.09 (1.06–1.13) <0.001 
ESAT-6 + CFP-10 + Rv3615c + Rv3879c 328 89.9 (86.2–92.8) 1.09 (1.06–1.13) <0.001 
a Number of test results. 
bSensitivity of combination test divided by sensitivity of T-SPOT.TB. 
Indeterminate test results were excluded in these analyses. See Appendix 13 for results of 
sensitivity analyses with indeterminates included as test positives. 
 
Table 26 Comparison of specificity of IGRA combinations and T-SPOT.TB 
Test Na  Specificity  
(95% CI) 
Relative specificityb 
(95% CI) 
P value 
T-SPOT.TB (ESAT-6 + CFP-10) 386 82.5 (78.4–86.0) – – 
CFP-10 + Rv3615c 387 78.0 (73.6–81.9) 0.95 (0.91–0.98) 0.001 
CFP-10 + Rv3615c + Rv3879c 388 76.3 (71.8–80.3) 0.93 (0.89–0.96) <0.001 
ESAT-6 + CFP-10 + Rv3615c 387 76.5 (72.0–80.5) 0.93 (0.90–0.96) <0.001 
ESAT-6 + CFP-10 + Rv3615c + Rv3879c 388 74.7 (70.2–78.8) 0.91 (0.88–0.94) <0.001 
aNumber of test results. 
bSpecificity of combination test divided by specificity of T-SPOT.TB. 
Indeterminate test results were excluded in these analyses. See Appendix 13 for results of 
sensitivity analyses with indeterminates included as test positives. 
 
Evaluation of TST 
TST was not performed as part of the IDEA study. We did not aim to evaluate the accuracy 
of TST and so we did not impose a standard protocol for the conduct of TST; each centre 
followed local Trust policy. Five of the nine hospital Trusts included in the analyses 
performed TST but only on a subset of patients, ranging between 20% and 74% of those 
recruited. We do not know why certain patients were selected for TST and others were not 
but the reasons may involve a mix of patient-specific and clinician-specific factors. 
Altogether, TST results were available for only 38% of the study population. TST was mainly 
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performed at two centres (Northwest London Hospitals NHS Trust and Imperial College 
Healthcare NHS Trust) and both centres accounted for 83% (266/322) of the available TST 
results. Furthermore, practice varied across the centres in the IDEA study.  
Nonetheless, for completeness we estimated the diagnostic accuracy of TST alone. In 
addition, because one of our primary objectives was to develop an evidence-based optimal 
testing algorithm that defines the role of IGRAs in the diagnostic work-up of suspected active 
TB, we considered combinations with T-SPOT.TB or QFT-GIT. The results are presented in 
Appendix 11. 
 
The sensitivity of TST was evaluated at each of the three pre-specified thresholds (≥5mm, 
≥10mm and the stratified threshold). The findings presented in Appendix 11 should be 
interpreted cautiously given the limited data and variation in practice between centres. 
Moreover, the findings may be subject to bias. The final diagnosis of patients was verified 
using a composite reference standard applied by a panel of clinicians to anonymised patient 
clinical data. The panel were blinded to routine and study IGRA results. However, if TST 
was performed, then the results were available thus creating a potential for incorporation bias 
in the evaluation of the diagnostic accuracy of TST.  
 
Discussion 
This large prospective study of the diagnostic accuracy of T-SPOT.TB, QFT-GIT, TST and 
next generation IGRAs was conducted in secondary care in a population representative of 
clinical practice. The differences observed between inpatients and outpatients reflect the case 
mix of acute admissions where for instance pneumonia-like illnesses and advanced 
malignancy presentations are commoner. However, the final TB diagnosis in these two 
groups was broadly similar and allows for generalisability of our findings.  Figure 5 
summarises the sensitivities of T-SPOT.TB, QFT-GIT, TST, and combinations of TST and 
IGRAs. The figure also shows the sensitivities of combinations of novel antigens. 
T-SPOT.TB showed higher sensitivity in comparison to QFT-GIT, a relative increase of 22% 
(14% to 31%), thus indicating greater utility as a rule out test.  
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Figure 5 Summary of sensitivities of IGRAs 
The sensitivities of the six tests are sorted on the plot in increasing order.  
 
Literature searches in PubMed were regularly conducted during the IDEA study to update the 
SSC on developments in the field. Appendix 12, Table 73 gives a summary of 31 IGRA 
studies and one systematic review published between 1st January 2013 and 16th March 2016. 
To the authors’ knowledge, the IDEA study is the largest prospective and most recent 
comparative evaluation of the accuracy of T-SPOT.TB and QFT-GIT for diagnosis of active 
TB. None of the studies in Appendix 12 compared T-SPOT.TB and QFT-GIT either 
prospectively or retrospectively.  QFT-GIT was compared with TST in 14 (45.2%) studies 
and T-SPOT.TB was compared with TST in four (12.9%) studies; the remaining 13 (41.9%) 
studies evaluated only T-SPOT.TB or QFT-GIT. According to the systematic review of 
pleural TB published in 2015, there was only one good quality study out of the 21 studies and 
two small studies compared QFT-GIT and T-SPOT.TB. The authors of the review pooled 
results across all QuantiFERON and T-SPOT.TB assays and so results are not comparable 
with the findings of the IDEA study. 
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The rate of indeterminate IGRA results was higher for QFT-GIT (8.9%) compared to 
T-SPOT.TB (6.7%). For both IGRAs, most of the indeterminate results were amongst 
patients without active TB, with 59% (47/79) and 65% (37/57) occurring for QFT-GIT and 
T-SPOT.TB. Appendix 13 (Table 74) summarises some key characteristics of patients with 
indeterminate IGRA results. Indeterminates were excluded from the main analyses and the 
impact on findings was investigated in sensitivity analyses by including indeterminate IGRA 
results as test positives, i.e., as true positives for those with culture confirmed or highly 
probable active TB and as false positives for those without active TB. Based on this rule, an 
increase in sensitivities, a decrease in specificities and no change in negative predictive 
values was expected. Generally, small increases were seen in sensitivity accompanied by 
decreases in specificity.  
 
HIV positive patients were a key subgroup in which analyses of T-SPOT.TB and QFT-GIT 
were planned. However, the number of patients (n = 135) recruited in the main cohort was 
small. The IDEA study was extended to facilitate recruitment of additional patients. The 
results for the entire HIV cohort (i.e. including patients recruited during the extension period) 
are presented in the next chapter. For the main study cohort, the sensitivities of T-SPOT.TB 
and QFT-GIT were lower in those with HIV co-infection relative to the HIV negative 
subgroup. Similarly, the two IGRAs had lower sensitivities in those with diabetes compared 
to those without. Specificity was higher in HIV positive patients compared to HIV negative 
patients but was lower in those with diabetes compared to those without diabetes. Although, 
there appeared to be differences in test performance between subgroups, there was no 
statistical evidence of an effect of HIV status or diabetes on relative test performance. The 
findings from these analyses should be taken with caution as the number of test results in 
some subgroups was small. Subgroup analyses were not possible for the other two key 
subgroups—those with end stage renal failure and those on immune suppressants. 
 
The most promising novel antigen was RV3615c, with a sensitivity that was higher than that 
of the other five antigens, including CFP-10 and ESAT-6, the two antigens that comprise 
T-SPOT.TB. Test combinations including Rv3615c showed higher sensitivity compared to T-
SPOT.TB, with limited gains in sensitivity when more antigens were added to a combination. 
Thus the two-antigen combination of CFP-10 and Rv3615c or the three-antigen combination 
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of ESAT-6, CFP-10 and Rv3615c seem promising. The latter combination had a sensitivity 
and specificity of 90.5% (86.9% to 93.2%) and 70.0% (65.4% to 74.2%), compared to 83.2% 
(78.9% to 86.8%) and 75.4% (71.1% to 79.3%) for T-SPOT.TB. The added value of 
Rv3615c to T-SPOT.TB was a 9% (5% to 12%) relative increase in sensitivity at the expense 
of specificity with a relative decrease of 7% (4% to 10%). The incremental gain in sensitivity 
to 90% is likely to be clinically useful and warrants further investigation. 
 
 66 
 
Chapter 5 Sub study of HIV positive participants 
 
Recruitment of HIV positive patients 
Following the closure of the main study to recruitment, two additional NHS trusts (King’s 
College Healthcare NHS Trust and Bart’s Healthcare NHS Trust) were invited to participate 
in the study to facilitate recruitment of HIV positive patients. A total of 263 patients were 
recruited from 12 NHS trusts between 25th November 2011 and 19th December 2014. The 
number of patients recruited at each centre is shown in Table 27. Over half of the patients 
were recruited from two Trusts—Royal Free Hampstead NHS Trust (29.3%) and Imperial 
College Healthcare NHS Trust (25.9%). 
 
Table 27 Recruitment of HIV positive patients by centre 
Hospital Trust Number of 
patients 
recruited 
Imperial College Healthcare NHS Trust 68 (25.9) 
Heart of England NHS Foundation Trust  7 (2.7) 
Chelsea and Westminster Hospital NHS Foundation Trust  49 (18.6) 
Royal Free Hampstead NHS Trust  77 (29.3) 
St George's Healthcare NHS Trust  6 (2.3) 
Heatherwood and Wexham Park Hospitals NHS Foundation Trust 2 (0.8) 
University of Leicester Hospitals NHS Trust  28 (10.7) 
Northwest London Hospitals NHS Trust  8 (3) 
Oxford University Hospitals NHS Trust  6 (2.3) 
Sandwell and West Birmingham Hospitals NHS Trust  1 (0.4) 
King’s College Healthcare NHS Trust 3 (1.1) 
Bart’s Healthcare NHS Trust 8 (3) 
Total 263 (100)  
 
The flow of patients through the study is shown in Figure 6. Of the 263 HIV positive patients 
recruited, 201 were included in the analyses. Reasons for exclusion are shown in Figure 6. 
Two patients from Heatherwood and Wexham Park Hospitals NHS Trust were excluded as 
mentioned earlier in Chapter 3. 
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Figure 6 Study flow diagram of HIV positive patients with suspected active TB 
QFT-GIT, QuantiFERON GOLD In-Tube; TST, tuberculin skin test. 
aOriginally considered eligible but later judged by the clinical panel to be ineligible 
bThe two patients recruited at this Trust were excluded because patients with a high pre-test 
probability of active TB were selectively recruited. 
The final four boxes show the number of patients with results available for each IGRA. 
 
The final diagnosis of four (2.0%) patients was clinically indeterminate (Figure 6 and Table 
28). Of the remaining 197 patients, there were 32 (16.2%) cases of active TB and 165 
(83.8%) non-active TB cases. Of the 165 non-active TB cases, 68 (41.2%) were category 4D.  
 
 
HIV positive patients with suspected TB 
n=263  
Eligible for analyses 
n=245 
Consent withdrawn/invalid (n=16) 
• Lost to follow up = 8 
• Withdrawn = 3 
• Invalid consent form = 5 
 
Patients recruited from 
12 Trusts 
n=203 
Patients recruited at 
Heatherwood and Wexham Park 
Hospitals NHS Foundation Trustb 
n=2 
Ineligiblea 
n=2 
Previous diagnosis of active TB 
n=42 
Patients from 11 Trusts included in analyses 
n=201 
Culture 
confirmed TB 
n=18 
Highly 
probable TB 
n=14 
Clinically 
indeterminate 
n=4 
Active TB 
excluded 
n=165 
T-SPOT.TB: n=18 
QFT-GIT: n=18 
T-SPOT.TB: n=13 
QFT-GIT: n=14 
T-SPOT.TB: n=4 
QFT-GIT: n=4 
T-SPOT.TB: n=160 
QFT-GIT: n=164 
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Table 28 Reference standard categories for HIV positive patients 
Diagnostic category Patients 
1: Culture confirmed TB 18 (9.0) 
2: Highly probable TB 14 (7.0) 
3: Clinically indeterminate 4 (2.0) 
4: Active TB excluded  
Subclassification  
     4A 2 (1.0) 
     4B 2 (1.0) 
     4C 93 (46.3) 
     4D 68 (33.8) 
Total 201 (100) 
 
Baseline characteristics of HIV positive cohort 
The demographic characteristics of the 201 patients are given in Table 29. The median 
(range) age of patients was 43 (18 to 79) years and majority (67.7%) were male. A substantial 
number of HIV positive patients were of black (45.3%) or white (37.8%) ethnicity. A total of 
53 countries of birth were represented; countries with at least three participants are shown in 
Table 29. Many patients (97/201, 48.3%) were in paid employment. 
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Table 29 Demographic characteristics of HIV positive cohort 
Characteristic Dosanjh category Total 
Culture 
confirmed 
TB 
Highly 
probable 
TB 
Clinically 
indeterminate 
Active TB 
excluded 
Median age (range), 
years 
43 (26–62) 40 (24–66) 55 (30–62) 44 (18–79) 43 (18–79) 
Male, n (%) 13 (72.2) 10 (71.4) 2 (50.0) 111 (67.3) 136 (67.7) 
Ethnic origin, n (%)      
Asian 1 (5.6) 2 (14.3) 0 (0.0) 3 (1.8) 6 (3.0) 
Black 12 (66.7) 7 (50.0) 2 (50.0) 70 (42.4) 91 (45.3) 
Hispanic 0 (0.0) 1 (7.1) 0 (0.0) 7 (4.2) 8 (4.0) 
Indian subcontinent 3 (16.7) 0 (0.0) 1 (25.0) 8 (4.8) 12 (6.0) 
Middle Eastern 1 (5.6) 0 (0.0) 0 (0.0) 2 (1.2) 3 (1.5) 
Mixed 0 (0.0) 1 (7.1) 0 (0.0) 4 (2.4) 5 (2.5) 
White 1 (5.6) 3 (21.4) 1 (25.0) 71 (43.0) 76 (37.8) 
Country of birth, n (%)      
UK 2 (11.1) 1 (7.1) 1 (25.0) 57 (34.5) 61 (30.3) 
Zimbabwe 1 (5.6) 2 (14.3) 0 (0.0) 16 (9.7) 19 (9.5) 
Nigeria 2 (11.1) 0 (0.0) 1 (25.0) 6 (3.6) 9 (4.5) 
India 2 (11.1) 0 (0.0) 1 (25.0) 4 (2.4) 7 (3.5) 
Uganda 0 (0.0) 0 (0.0) 0 (0.0) 6 (3.6) 6 (3.0) 
Ethiopia 2 (11.1) 2 (14.3) 0 (0.0) 1 (0.6) 5 (2.5) 
Ireland 0 (0.0) 0 (0.0) 0 (0.0) 5 (3.0) 5 (2.5) 
Kenya 0 (0.0) 1 (7.1) 0 (0.0) 4 (2.4) 5 (2.5) 
Portugal 0 (0.0) 0 (0.0) 0 (0.0) 5 (3.0) 5 (2.5) 
South Africa 0 (0.0) 1 (7.1) 0 (0.0) 4 (2.4) 5 (2.5) 
Brazil 0 (0.0) 1 (7.1) 0 (0.0) 3 (1.8) 4 (2.0) 
Jamaica 1 (5.6) 1 (7.1) 0 (0.0) 2 (1.2) 4 (2.0) 
Poland 0 (0.0) 0 (0.0) 0 (0.0) 4 (2.4) 4 (2.0) 
Angola 1 (5.6) 0 (0.0) 0 (0.0) 2 (1.2) 3 (1.5) 
Congo 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.8) 3 (1.5) 
Malawi 1 (5.6) 1 (7.1) 0 (0.0) 1 (0.6) 3 (1.5) 
Sierra Leone 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.8) 3 (1.5) 
Sri Lanka 1 (5.6) 0 (0.0) 0 (0.0) 2 (1.2) 3 (1.5) 
Thailand 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.8) 3 (1.5) 
Othera 5 (27.8) 4 (28.6) 1 (25.0) 32 (19.4) 42 (20.9) 
Median years in UK 
(range) 
9.6 (0.05–
33.5) 
10.1 (1.0–
37.1) 
8.8 (6.2–10.6) 11.9 (0.2–
60.3) 
11.6 (0.05–
60.3) 
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Characteristic Dosanjh category Total 
Culture 
confirmed 
TB 
Highly 
probable 
TB 
Clinically 
indeterminate 
Active TB 
excluded 
Profession, n (%)b      
Paid employment 9 (50.0) 6 (42.9) 1 (25.0) 81 (49.1) 97 (48.3) 
Unpaid employment 6 (33.3) 3 (21.4) 3 (75.0) 61 (37.0) 73 (36.3) 
Student 1 (5.6) 0 0 8 (4.8) 9 (4.5) 
Healthcare/laboratory 
worker 1 (5.6) 3 (21.4) 0 9 (5.5) 13 (6.5) 
Social/prison worker 1 (5.6) 1 (7.1) 0 3 (1.8) 5 (2.5) 
Sex worker 0 1 (7.1) 0 2 (1.2) 3 (1.5) 
Unknown 0 0 0 1 (0.6) 1 (0.5) 
aSummarises results from 34 countries with fewer than three patients.  
bSome patients had more than one profession. 
 
The clinical characteristics of the patients are presented in Table 30. Of the 201 patients, 71 
(35.3%) had no other co-morbidities. There were 10 (5.0%) patients with pre-existing 
diabetes, four (2.0%) with chronic/end stage renal failure and none were on 
immunosuppressive therapy. Vitamin D measurement was unknown for most (85.1%) 
patients (see Appendix 5, Table 55 for thresholds used to categorise vitamin D status). Table 
30 shows CD4 count grouped into four categories. CD4 count was missing for eight patients. 
Most of the 193 patients had a CD4 count ≥ 200 (46.8%). The median (range) CD4 count was 
285 (0-1228). The distribution of CD4 count in the cohort is shown in Figure 7.  
 
Table 31 gives the social history of patients. Smoking history was missing for one patient; 
almost half (48.8%) of the patients had never smoked while the remaining were ex (19.4%) 
or current (31.3%) smokers. Fourteen (7.0%) patients had a history of alcohol misuse and the 
history of recreational drug use was unknown for many (64.7%) patients. Few patients (6.0%) 
had a history of homelessness and 7.5% had a history of imprisonment.  
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Table 30 Clinical characteristics of HIV positive cohort 
Characteristic Dosanjh category Total 
Culture 
confirmed 
TB 
Highly 
probable TB 
Clinically 
indeterminate 
Active TB 
excluded 
Median height (range), m 1.7 (1.4–1.8) 1.8 (1.6–1.9) 1.7 (1.6–1.8) 1.7 (1.3–1.9) 1.7 (1.3–1.9) 
Median weight (range), kg 69 (52–91) 65 (42–116) 62 (57–110) 67 (43–112) 67 (42–116) 
Median BMI (range) 24 (18–48) 22 (16–40) 21 (21–34) 23 (12–39) 23 (12–48) 
BCG vaccinated, n (%) 15 (83.3) 12 (85.7) 4 (100.0) 136 (82.4) 167 (83.1) 
BCG scar visible, n (%)      
Yes 13 (72.2) 12 (85.7) 2 (50.0) 114 (69.1) 141 (70.1) 
No  0 0 0 17 (10.3)  17 (8.5)  
Unsure  2 (11.1) 0 2 (50.0) 17 (10.3)  21 (10.4)  
Missing  3 (16.7)  2 (14.3)  0 17 (10.3)  22 (10.9)  
Recent known TB contact, n (%) 3 (16.7) 2 (14.3) 1 (25.0) 19 (11.5) 25 (12.4) 
Other pre-existing conditions/co-
morbidities, n (%)a 
     
None 9 (50.0) 8 (57.1) 2 (50.0) 52 (31.5) 71 (35.3) 
Diabetes 2 (11.1) 0 1 (25.0) 7 (4.2) 10 (5.0) 
Hepatitis B 4 (22.2) 1 (7.1) 0 8 (4.8) 13 (6.5) 
Hepatitis C 0 0 0 10 (6.1) 10 (5.0) 
Chronic/end stage renal failure 0 0 1 (25.0) 3 (1.8) 4 (2.0)  
Cancer 0 0 0 7 (4.2) 7 (3.5) 
Organ transplantation 0 0 0 1 (0.6) 1 (0.5) 
Asthma 0 2 (14.3) 0 12 (7.3) 14 (7.0) 
Other 8 (44.4) 4 (28.6) 2 (50.0) 101 (61.2) 115 (57.2) 
Medication, n (%)a      
None/missing 4 (22.2) 7 (50.0) 0 46 (27.9) 57 (28.4) 
Chemotherapy 0 0 0 1 (0.6) 1 (0.5) 
Corticosteroids >15 mg/day 1 (5.6) 1 (7.1) 0 14 (8.5) 16 (8.0) 
Corticosteroids <15 mg/day 0 1 (7.1) 0 5 (3.0) 6 (3.0) 
Cyclosporine; tacralimus; 
everolimus 
0 0 0 1 (0.6)  1 (0.5) 
Methotrexate 0 0 0 1 (0.6) 1 (0.5) 
Other 18 (100.0) 14 (100.0) 4 (100.0) 164 (99.4) 200 (99.5) 
Unknown 0 0 0 1 (0.6) 1 (0.5) 
Vitamin D deficiency, n (%)      
Deficient 3 (16.7) 1 (7.1) 1 (25.0) 9 (5.5) 14 (7.0) 
Insufficient 1 (5.6) 2 (14.3) 0   2 (1.2) 5 (2.5) 
Normal 0  1 (7.1) 2 (50.0) 7 (4.2)  10 (5.0)  
Not Known 14 (77.8) 10 (71.4) 1 (25.0)  147 (89.1)  172 (85.6) 
CD4 count, n (%)      
<50 1 (5.6) 4 (28.6) 0 48 (29.1) 53 (26.4) 
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≥50 and <100 2 (5.6) 0 0 15 (9.1) 16 (8.0) 
≥100 and <200 5 (27.8) 3 (21.4) 2 (50.0) 20 (12.1) 30 (14.9) 
≥200 8 (44.4) 6 (42.9) 2 (50.0) 78 (47.3) 94 (46.8) 
Missing 3 (16.7) 1 (7.14) 0 4 (2.4) 8 (4.0) 
CD4 count (range) 293 (14-670) 267 (0-669) 370 (183-800) 283 (0-1228) 285 (0-1228) 
aSome patients had multiple co-morbidities and so the numbers do not add up to 201. The 
percentages are column percentages for each row. The same applies to medication. 
 
 
Figure 7 Distribution of CD4 counts in HIV positive sub study cohort 
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Table 31 Social history of HIV positive cohort 
Characteristic Dosanjh category Total 
Culture 
confirmed 
TB 
Highly 
probable 
TB 
Clinically 
indetermin
ate 
Active TB 
excluded 
Smoking history, n (%)      
Never smoked 13 (72.2) 7 (50.0) 3 (75.0) 75 (45.5) 98 (48.8) 
Ex-smoker 3 (16.7) 2 (14.3) 0 34 (20.6) 39 (19.4) 
Current smoker 2 (11.1) 5 (35.7) 1 (25.0) 55 (33.3) 63 (31.3) 
Unknown 0 0 0 1 (0.6) 1 (0.5) 
Pack years if current smoker, n 
(%) 
     
≤10 0 1 (20.0) 0 9 (16.4) 10 (15.9) 
11-20 0 0 0 2 (3.6) 2 (3.2) 
21-50 0 0 0 3 (5.5) 3 (4.8) 
Unknown 2 (100.0) 4 (80.0) 1 (100.0) 41 (74.5) 48 (76.2) 
History of alcohol use, n (%)      
Non-drinker  10 (55.6) 6 (42.9) 3 (75.0) 67 (40.6) 86 (42.8) 
Ex-drinker 1 (5.6) 1 (7.1) 0 17 (10.3) 19 (9.5) 
Current drinker 7 (38.9) 7 (50.0) 1 (25.0) 79 (47.9) 94 (46.8) 
Unknown 0 0 0 2 (1.2) 2 (1.0) 
Median units/week if current 
drinker (range) 5 (0–75) 8 (0–19) 10 5 (0–126) 5 (0–126) 
History of alcohol misuse, n (%) 1 (5.6) 0 0 13 (7.9) 14 (7.0) 
History of recreational drug use, n 
(%)   
     
Non-user 6 (33.3) 2 (14.3) 2 (50.0) 31 (18.8) 41 (20.4) 
Ex-user  1 (5.6) 0 0 7 (4.2) 8 (4.0) 
Current user 0 3 (21.4) 0 19 (11.5) 22 (11.0) 
Unknown 11 (61.1) 9 (64.3) 2 (50.0) 108 (65.5) 130 (64.7) 
History of homelessness, n (%) 1 (5.6) 1 (7.1) 0 10 (6.1) 12 (6.0) 
Median years homeless if currently 
or previously homeless (range) 0 12 – 5 (0–12) 5 (0–12) 
History of imprisonment, n (%) 0 1 (7.1) 0 14 (8.5) 15 (7.5) 
 
The frequency of symptoms is shown in Table 32 based on data from 86 patients. The main 
symptoms were cough, fever, night sweats, weight loss and lethargy. Patients generally 
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presented with multiple symptoms; the median (range) number of symptoms was 6 (6–10). 
Cough was often present (76.7%). 
 
Table 32 Symptoms at presentation for HIV positive cohort 
Symptoma Dosanjh category Total 
Culture 
confirmed 
TB 
Highly 
probable 
TB 
Clinically 
indeterminate 
Active 
TB 
excluded 
Cough, n (%) 7 (70.0) 2 (28.6) 1 (50.0) 56 (83.6) 66 (76.7) 
Fever, n (%) 7 (70.0) 3 (42.9) 2 (100.0) 34 (50.7) 46 (53.5) 
Night sweats, n (%) 5 (50.0) 5 (71.4) 0 40 (59.7) 50 (58.1) 
Weight loss, n (%) 5 (50.0) 7 (100.0) 1 (50.0) 35 (52.2) 48 (55.8) 
Haemoptysis, n (%) 1 (10.0) 1 (14.3) 0 9 (13.4) 11 (12.8) 
Lethargy, n (%) 4 (40.0) 4 (57.1) 1 (50.0) 33 (49.3) 42 (48.8) 
Other, n (%) 5 (50.0) 3 (42.9) 2 (100.0) 28 (41.8) 38 (44.2) 
Median number of 
symptoms (range) 6.5 (6–8) 6 (6–9) 7.5 (7–8) 6 (6–10) 6 (6–10) 
aBased on 86 patients. 
 
Final diagnosis in HIV positive patients 
The diagnostic tests performed during the diagnostic work up of patients are shown in Table 
33. Chest X-rays and culture were the most common tests performed (90.6% for each one). 
The number of T-SPOT.TB, QFT-GIT and TST tests performed as part of routine care at 
each centre is shown in Appendix 14 (see Table 75). These routine IGRA results were not 
used in the final diagnosis of patients in the IDEA study. TST was only performed in 12 
patients at three of the 11 centres; TST results were available for all 12 patients.  
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Table 33 Diagnostic tests performed in the diagnostic work up of active TB in HIV 
positive patients 
Test, n (%) Dosanjh category Total 
Culture 
confirmed TB 
Highly 
probable TB 
Clinically 
indeterminate 
Active TB 
excluded 
BAL investigation 5 (27.8) 4 (28.6) 3 (75.0) 68 (41.2) 80 (39.8) 
Chest X-ray 14 (77.8) 14 (100.0) 3 (75.0) 151 (91.5) 182 (90.5) 
CSF investigation 3 (16.7) 6 (42.9) 1 (25.0) 17 (10.3) 27 (13.4) 
CT 14 (77.8) 12 (85.7) 3 (75.0) 122 (73.9) 151 (75.1) 
Culture 18 (100.00) 13 (92.9) 3 (75.0) 148 (89.7) 182 (90.5) 
Histology or biopsy 3 (16.7) 5 (35.7) 0 49 (29.7) 57 (28.4) 
MRI 4 (22.2) 9 (64.3) 1 (25.0) 28 (17.0) 42 (20.9) 
PCR 10 (55.6) 5 (35.7) 1 (25.0) 42 (25.5) 58 (28.9) 
Smear test 14 (77.8) 14 (100.0) 2 (50.0) 139 (84.2) 169 (84.1) 
BAL, bronchoalveolar lavage; CSF, cerebrospinal fluid; CT, computed tomography; MRI, 
magnetic resonance imaging; PCR, polymerase chain reaction. 
 
The final diagnosis of active TB patients is summarised in Table 34. Of the 32 patients with 
active TB, 18 (56.3%) had smear negative TB. Thirteen patients (40.6%) had pulmonary TB, 
15 (46.9%) had extra pulmonary TB, while the remaining four (12.5%) had both forms of 
TB. The most common sites of infection were the lungs (53.1%) and lymph nodes (31.1%). 
The level of drug resistance was unknown or missing for 11 (34.4%) and the remaining 21 
(65.6%) had no drug resistance. Table 35 shows the final diagnosis of non-active TB patients. 
A patient may have multiple conditions but pneumonia was the most frequent diagnosis 
(40.0%). 
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Table 34 Final diagnosis of TB in HIV positive patients 
N (%) Category 1 
TB 
Category 2 
TB 
Total 
All TB  18 (56.3) 14 (43.7) 32 (100) 
Smear positive TB  8 (44.4) 1 (7.1) 9 (28.1) 
Smear negative TB  6 (33.3) 12 (85.7) 18 (56.3) 
Pulmonary TB  10 (55.6) 3 (21.4) 13 (40.6) 
Extra pulmonary TB  5 (27.8) 10 (71.4) 15 (46.9) 
Pulmonary/ extra pulmonary TB 3 (16.7) 1 (7.1) 4 (12.5) 
Site of infectiona    
Brain 0 2 (14.3) 2 (6.3) 
Central nervous system 0 1 (7.1) 1 (3.1) 
Lung 13 (72.2) 4 (28.6) 17 (53.1)  
Lymph node 4 (22.2) 6 (42.9) 10 (31.3) 
Miliary TB (disseminated) 3 (16.7) 0 3 (9.4) 
Pericardium 0 1 (7.1) 1 (3.1) 
Pleura 1 (5.6)  0 1 (3.1) 
Spine 1 (5.6) 1 (7.1) 2 (6.3) 
Multi drug resistance    
None 17 (94.4) 4 (28.6) 21 (65.6) 
Level of resistance unknown  0 10 (71.4) 10 (31.3) 
Missing 1 (5.6) 0 1 (3.1) 
aMultiple TB infection sites for some patients so percentages do not add up to 100%. 
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Table 35 Final diagnosis of non-TB in HIV positive patients 
Diagnosis N (%) 
Cancer 17 (10.3) 
Chest Infection 2 (1.2) 
LRTI 13 (7.9) 
LTBI - treatment indicated 1 (0.6) 
Pneumonia 66 (40.0) 
Sarcoidosis 3 (1.8) 
Other  75 (45.5)  
LRTI, lower respiratory tract infection; LTBI, latent TB infection. 
 
Test results for HIV positive patients 
Of the 201 patients, 194 (96.5%) patients had results for both T-SPOT.TB and QFT-GIT; 
reasons for missing T-SPOT.TB and QFT-GIT results are shown in Table 36. The cross 
classified results of the two tests are given in Appendix 14, Table 76. Table 37 shows the 
results for T-SPOT.TB, QFT-GIT and TST according to the four diagnostic categories. Table 
38 shows the cross classification of the two tests for those with (categories 1 and 2) and 
without active TB (category 4).  
 
Table 36 Reasons for missing IGRA results for HIV positive patients 
Reason QFT-GIT T-SPOT.TB 
No sample could be taken 1  
Sample destroyed for laboratory reasons  2 
Sample unsuitable for testing  4 
Total 1 6 
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Table 37 T-SPOT.TB and QFT-GIT results by final diagnosis in HIV positive cohort of patients 
Index test Dosanjh category Total 
1 2 3 4A 4B 4C 4D 4A-D 
T-SPOT.TB          
Positive 10 7 2 0 1 14 5 20 39 
Negative 5 3 2 1 1 57 42 101 111 
Indeterminate 3 3 0 1 0 19 19 39 45 
Missing 0 1 0 0 0 3 2 5 6 
Total 18 14 4 2 2 93 68 165 201 
Median SFCs ESAT-6 
(range) 
17 (0–462) 8 (0–395) 1 (0–3) 0 0 0 (0–66) 0 (0–74) 0 (0–74) 0 (0–462) 
Median SFCs CFP-10 
(range) 
6 (0–136) 0 (0–315) 3 (0–20) 0  8 (0–16) 0 (0–67) 0 (0–56) 0 (0–67) 0 (0–315) 
QFT-GIT          
Positive 11 6 1 0 1 8 2 11 29 
Negative 7 6 2 1 1 61 54 117 132 
Indeterminate 0 2 1 1 0 24 11 36 39 
Missing 0 0 0 0 0 0 1 1 1 
Total 18 14 4 2 2 93 68 165 201 
Median IFN-γ levels 
(range) 
0.76 (0–3.78) 0.03 (0–10) 0.01 (0–0.54) 0.04 (0–0.07) 1.33 (0–2.65) 0 (0–7.3) 0 (0–1.56) 0 (0–7.3) 0.01 (0–10) 
SFCs, spot forming cells. 
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Table 38 Cross-tabulation of T-SPOT.TB and QFT-GIT against final diagnosis in HIV positive cohort of patients 
TB positive (category 1 and 2) TB negative (category 4) 
N T-SPOT.TB N  T-SPOT.TB  
Positive Negative Indeterminate Missing Total Positive Negative Indeterminate Missing Total 
 
 
QFT-
GIT  
Positive 14 1 2 0 17  
 
QFT-
GIT  
Positive 5 3 3 0 11 
Negative 2 6 4 1 13 Negative 12 75 26 4 117 
Indeterminate 1 1 0 0 2 Indeterminate 3 22 10 1 36 
Missing 0 0 0 0 0 Missing 0 1 0 0 1 
Total 17 8 6 1 32 Total 20 101 39 5 165 
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Diagnostic accuracy of T-SPOT.TB and QFT-GIT in HIV positive cohort 
The proportion of indeterminate test results was 23.1% (45/195) for T SPOT.TB and 19.5% 
(39/200) for QFT-GIT. The difference between the two proportions was 3.6% (-4.5% to 
11.6%; P = 0.4). Sensitivity (95% CI) was 68.0% (48.4% to 82.8%) for T-SPOT.TB and 
56.7% (39.2% to 72.6%) for QFT-GIT (Table 39). The specificities were 83.5% (75.8% to 
89.0%) and 91.4% (85.3% to 95.1%). The PPVs for T-SPOT.TB and QFT-GIT were 46.0% 
(31.0% to 61.6%) and 60.7% (42.4% to 76.4%), and the NPVs were 92.7% (86.2% to 96.2%) 
and 90.0% (83.6% to 94.1%). 
 
Using only culture confirmed active TB cases, the sensitivities of T-SPOT.TB decreased 
slightly to 66.7% (41.7% to 84.8%) while that of QFT IT increased to 61.1% (38.6% to 
79.7%). When the analyses were restricted to only category 4D patients without active TB, 
specificities were higher than using all patients without active TB (Table 39). In sensitivity 
analyses with indeterminate test results included as test positives, the sensitivity (95% CI) of 
T-SPOT.TB was 74.2% (56.8% to 86.3%) and 59.4% (42.3% to 74.5%) for QFT-GIT. The 
specificity (95% CI) of T-SPOT.TB was 63.1% (55.4% to 70.2%) and 71.3% (64.0% to 
77.7%) for QFT-GIT. See Appendix 14, Table 77 for full results. 
 
The diagnostic performance of the two IGRAs is shown stratified by CD4 count in Table 40. 
The estimates within each stratum give results comparable to the entire cohort in terms of the 
higher sensitivity of T-SPOT.TB and higher specificity of QFT-GIT. However, the estimates 
are based on very small number of active TB and non-active TB cases and are presented 
solely for illustrative purposes.  
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Table 39 Diagnostic accuracy of T-SPOT.TB and QFT-GIT for diagnosis of active TB 
in HIV positive cohort 
Test performance T-SPOT.TB QFT-GIT 
n/N Estimate (95% CI) n/N Estimate (95% CI) 
Sensitivity for a diagnosis of 
active TB 
    
All TB 17/25 68.0 (48.4–82.8) 17/30 56.7 (39.2–72.6) 
Culture positive TB 10/15 66.7 (41.7–84.8) 11/18 61.1 (38.6–79.7) 
Culture negative TB 7/10 70.0 (39.7–89.2) 6/11 54.5 (28.0–78.7) 
Smear positive TB 4/8 50.0 (21.5–78.5) 6/9 66.7 (35.4–87.9) 
   Smear negative TB 9/13 69.2 (42.4–87.3) 8/16 50.0 (28.0–72.0) 
Pulmonary TB 7/10 70.0 (39.7–89.2) 9/13 69.2 (42.4–87.3) 
Extra pulmonary TB 8/11 72.7 (43.4–90.3) 6/14 42.9 (21.4–67.4) 
Specificity for a diagnosis of 
active TB 
    
Active TB excluded  101/121 83.5 (75.8–89.0) 117/128 91.4 (85.3–95.1) 
Active TB excluded, TST 
negative, no risk factors for 
LTBI 
42/47 89.4 (77.4–95.4) 54/56 96.4 (87.9–99.0) 
Predictive value     
Positive predictive value 17/37 46.0 (31.0–61.6) 17/28 60.7 (42.4–76.4) 
Negative predictive value 101/109 92.7 (86.2–96.2) 117/130 90.0 (83.6–94.1) 
Likelihood ratios     
Positive likelihood ratio  4.11 (2.54–6.66)  6.59 (3.46–12.6) 
Negative likelihood ratio  0.38 (0.22–0.68)  0.47 (0.31–0.72) 
LTBI, latent tuberculosis infection; TST, tuberculin skin test. 
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate 
IGRA results were excluded from these analyses. Sensitivity analyses with indeterminates as 
test positives are presented in Appendix 14, Table 77. 
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Table 40 Diagnostic accuracy of T-SPOT.TB and QFT-GIT stratified by CD4 count in 
HIV positive sub study cohort 
CD4 count T-SPOT.TB QFT-GIT 
n/N Estimate (95% CI) n/N Estimate (95% CI) 
Sensitivity for a diagnosis of active TB 
<50 1/3  33.3 (6.15–79.2) 1/4 25.0 (4.56–70.0) 
≥50 and <100 0/1  0.00 (0.00–79.4)  0/1 0.00 (0.00–79.4) 
≥100  and <200 5/6  83.3 (43.7–97.0) 4/7 57.1 (25.1–84.2) 
≥200 10/12  83.3 (55.2–95.3) 11/14 78.6 (52.4–92.4) 
Specificity for a diagnosis of active TB 
<50 26/29 89.7 (73.6–96.4) 26/29  89.7 (73.6–96.4) 
≥50 and <100 11/13 84.6 (57.8–95.7) 11/12  91.7 (64.6–98.5) 
≥100  and <200 10/13 76.9  (49.7–91.8) 14/15  93.3 (70.2–98.8) 
≥200 53/64 83.1 (72.2–90.3) 63/69  91.3 (82.3–96.0) 
Sensitivity and specificity are presented as percentages. 
 
Comparison of diagnostic accuracy of T-SPOT.TB and QFT-GIT in HIV positive 
cohort 
Excluding indeterminate IGRA results, there were 146 T-SPOT.TB results and 158 QFT-GIT 
results. The sensitivity of T-SPOT.TB was higher than that of QFT-GIT with a relative 
sensitivity (95% CI) of 1.12 (0.87 to 1.44). There was no statistical evidence of a difference 
(P = 0.4). In contrast, the specificity of T-SPOT.TB was significantly lower than that of QFT-
GIT with a relative specificity (95% CI) of 0.91 (0.84 to 0.99) (Table 41). When 
indeterminate IGRA results were included as test positives in a sensitivity analysis, the 
analysis included 191 T-SPOT.TB results and 196 QFT-GIT results. Unlike the primary 
analysis, there was no statistical evidence of a difference in specificity (Appendix 14, Table 
78). 
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Table 41 Comparison of diagnostic accuracy of T-SPOT.TB and QFT-GIT in HIV 
positive patients 
Test Na Sensitivity (95% CI) Nb Specificity (95% CI) 
T-SPOT.TB  25 62.8 (44.1–78.3) 121 83.4 (75.7–88.9) 
QFT-GIT  30 56.1 (38.3–72.4) 128 91.7 (85.4–95.4) 
Ratioc (95% CI); P value  1.12 (0.87–1.44); 0.4   0.91 (0.84–0.99); 0.02 
aNumber of test results amongst those with active TB. 
bNumber of test results amongst those without active TB. 
cRatio of the sensitivity (or specificity) of T-SPOT.TB to that of QFT-GIT. The natural 
outputs from generalized estimating equation models are odds ratios. Ratios of sensitivities 
(relative sensitivity) and ratios of specificities (relative specificity) were computed post 
estimation of the models. Confidence intervals were obtained using the delta method. 
Sensitivities and specificities are presented as percentages. 
 
Discussion 
Of the 263 patients recruited, 201 patients were included in the analyses. This is well below 
the target sample size of 390. Although T-SPOT.TB showed higher sensitivity in comparison 
to QFT-GIT, a relative increase of 12%, there was no statistical evidence of a difference in 
sensitivity. The sensitivity of QFT-GIT in the IDEA study was lower than that in other recent 
studies26-28 (see Appendix 12, Table 73).  
 
The indeterminate rate was lower for QFT-GIT (19.5%) compared to T-SPOT.TB (23.1%). 
The indeterminate results were mainly in those without active TB, with 92.3% (36/39) for 
QFT-GIT and 86.7% (39/45) for T-SPOT.TB. The impact of indeterminate results was 
explored in sensitivity analyses by including indeterminate results as test positives. There was 
a small increase in the sensitivity of QFT-GIT but a large increase in the sensitivity of 
T-SPOT.TB. This is due to the higher indeterminate rate for T-SPOT.TB (18.2%) amongst 
category 1 and 2 active TB cases compared to that of QFT-GIT (5.9%).   
 
 
 
  
 84 
 
Chapter 6 Economic evaluation methods 
In this chapter we present methods for assessment of the cost-effectiveness of IGRAs as rule 
out tests for active TB. That is, we consider using an IGRA as an initial test, with a negative 
result indicating that a patient does not have TB thus accelerating diagnosis of the actual 
cause of disease in such patients. The use of QFT-GIT and T-SPOT.TB was compared 
against current practice as determined by analysis of patient records. We considered which 
diagnostic tests were performed, their costs, and the time taken between decision points 
involving each test. The time taken to diagnose or rule out TB is a key consideration. Our 
report adheres to the Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) statement.29 
 
Decision tree model 
We developed a decision tree model to calculate the incremental costs and incremental health 
utilities (QALYs) of changing from current practice to using an IGRA as an initial rule out 
test. Current practice was determined by analysis of patient records. The model structure 
representing current practice is shown in Chapter 7. Adding a rule out test to the diagnostic 
pathway introduces additional delay in diagnosis of active TB in those patients who have the 
disease, as it introduces an additional step in the pathway. Patients who were not initially 
diagnosed with active TB have a follow up consultation after approximately two months; 
those who had a false negative rule out test result, i.e. they had TB incorrectly ruled out, can 
have TB identified at this point. The final diagnostic outcomes were the four categories 
described in Dosanjh et al,4 herein referred to as “Dosanjh categories” (see Appendix 2, Table 
52). The health economic analysis was undertaken from an NHS perspective. No discounting 
was required since the diagnostic process occurs over a relatively short time period. 
 
The model contained two levels of uncertainty: 
1. Individual level uncertainty – patient records revealed variation in the number and 
type of tests used for TB diagnosis, and time to diagnosis; and 
2. Parameter uncertainty – uncertainty in the costs of tests and procedures, and the 
sensitivity and specificity of IGRAs. 
 
A (balanced) bootstrap sample of TB and non TB patients was created for each simulation of 
the decision tree, which retained the subsample sizes. Individual patient costs and time to 
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diagnosis were jointly sampled to preserve the dependency between them. A Bayesian 
forward sampling approach generated values from all of these distributions to simulate a 
particular model outcome. This was then repeated in a Monte Carlo (MC) framework to 
obtain a sample of several thousand model runs which encapsulated the first order (patient 
variability) and second order (parameter) uncertainty in the model outputs. Table 42 
summarises the model parameters. The model was implemented in the statistical 
programming language R (R Core Team (2016). R: A language and environment for 
statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 
https://www.R-project.org/). 
 
Table 42 Decision tree model parameters and sensitivity analyses values 
a5% and 95% quantiles of the time to follow up visit observed in the IDEA clinical data. 
 
Distributional formulation of individual level/sample uncertainty 
The number of individuals who enter the diagnostic pathway was defined as 𝑛𝑛. Of these, we 
defined 𝑛𝑛+ as active TB cases and the remainder as non-active TB. We defined the 
probability of a given patient being an active TB case as 𝑛𝑛+/𝑛𝑛 (and so the probability of non-
active TB is 1 − (𝑛𝑛+/𝑛𝑛). This can therefore be considered a draw from a Bernoulli 
distribution and so for the total sample the Binomial distribution gives the number of TB 
cases in a sample population as 
Parameter Symbol Main model values Sensitivity range 
Rule out test unit cost (£) 𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 T-SPOT.TB or  
QFT-IT 
1–200 
Follow-up time for those not 
diagnosed with TB (days) 
𝑇𝑇𝐹𝐹𝐹𝐹 Direct estimate from 
IDEA clinical dataset 
54–127a 
Cohort active TB prevalence 𝑛𝑛+/𝑛𝑛 Direct estimate from 
IDEA clinical dataset 
0.1–0.5 
Rule out test time (days)  𝑇𝑇𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 Uniform(2,14)  
Quality of Life (QoL) detriment for 
active TB symptoms 
𝐷𝐷𝑄𝑄𝑟𝑟𝑄𝑄 Triangle(0.11,0.21,0.3
1)30, 31 
 
Current time to diagnosis by TB 
status 
𝑡𝑡𝑖𝑖 Direct estimate from 
IDEA clinical dataset 
From IDEA dataset 
Current combined cost of diagnosis 
by TB status 
𝑐𝑐𝑖𝑖 Direct estimate from 
IDEA clinical dataset 
From IDEA dataset 
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𝑋𝑋𝑇𝑇𝑇𝑇~𝐵𝐵𝐵𝐵𝑛𝑛�𝑛𝑛+ 𝑛𝑛� ,𝑛𝑛� 
𝑋𝑋~𝑇𝑇𝑇𝑇 = 𝑛𝑛 − 𝑋𝑋𝑇𝑇𝑇𝑇 
that is, 
𝑝𝑝�𝑋𝑋𝑇𝑇𝑇𝑇�
𝑛𝑛+ 𝑛𝑛� � = � 𝑛𝑛𝑋𝑋𝑇𝑇𝑇𝑇� �𝑛𝑛+ 𝑛𝑛� �𝑋𝑋𝑇𝑇𝑇𝑇�1 − 𝑛𝑛+ 𝑛𝑛� �(𝑛𝑛−𝑋𝑋𝑇𝑇𝑇𝑇). 
 
By the same principle, patients are then randomly split between those that are ruled out or not 
ruled out from the active TB and non-active TB subgroups. 
𝑋𝑋+
𝑇𝑇𝑇𝑇~𝐵𝐵𝐵𝐵𝑛𝑛(𝑝𝑝+,𝑋𝑋𝑇𝑇𝑇𝑇) 
𝑋𝑋−
𝑇𝑇𝑇𝑇 = 𝑋𝑋𝑇𝑇𝑇𝑇 − 𝑋𝑋+𝑇𝑇𝑇𝑇 
𝑋𝑋+
~𝑇𝑇𝑇𝑇~𝐵𝐵𝐵𝐵𝑛𝑛(1 − 𝑝𝑝−,𝑋𝑋~𝑇𝑇𝑇𝑇) 
𝑋𝑋−
~𝑇𝑇𝑇𝑇 = 𝑋𝑋~𝑇𝑇𝑇𝑇 − 𝑋𝑋+~𝑇𝑇𝑇𝑇 
This process results in a final random subdivision of the sample population into one of the 
end states. 
 
Health economics outcomes 
Each of the terminal nodes (outcomes) of the decision tree has an associated cost and health 
utility (measured in QALYs). Incremental QALY differences are due to differences in the 
time taken to start appropriate treatment leading to differences in morbidity. For simplicity of 
notation, we shall denote 1 − 𝐷𝐷𝑄𝑄𝑟𝑟𝑄𝑄 by �. For the patient cohort these were defined as 
𝐶𝐶𝑐𝑐𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑛𝑛𝑟𝑟 = 𝑐𝑐̅ 
𝐶𝐶𝑛𝑛𝑟𝑟𝑛𝑛𝑟𝑟𝑟𝑟 =  �𝑛𝑛+ 𝑛𝑛� �(𝑐𝑐̅ + 𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟) + �𝑛𝑛− 𝑛𝑛� �((1 − 𝑝𝑝−)𝑐𝑐̅ + 𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟) 
𝐸𝐸𝑐𝑐𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑛𝑛𝑟𝑟 = 𝑞𝑞𝑡𝑡̅ 
𝐸𝐸𝑛𝑛𝑟𝑟𝑛𝑛𝑟𝑟𝑟𝑟 =  �𝑛𝑛+ 𝑛𝑛� �𝑞𝑞(𝑡𝑡̅ + 𝑇𝑇𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 + (1 − 𝑝𝑝+)𝑇𝑇𝐹𝐹𝐹𝐹) +  �𝑛𝑛− 𝑛𝑛� �𝑞𝑞((1 − 𝑝𝑝−)𝑡𝑡̅ + 𝑇𝑇𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟) 
 
Estimation of costs used in the model 
The costs and distributions used in the sensitivity analyses are summarised in Table 43, Table 
44 and Table 45, using 2014/2015 prices. Where necessary, costs were inflated from previous 
years using  the Hospital and Community Health Service (HCHS) pay and price index32. 
Where uncertainty bounds were not available in the recent sources used, uncertainty ranges 
were informed by previous studies. Uniform distributions were used where upper and lower 
limits were available and Gamma distributions were used where the standard error of the 
average cost was available. 
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We calculated equivalent proportions of a mean value for lower and upper bounds because of 
the half real line, skew property of costs. For example, a lower bound of half and an upper 
bound of twice the point estimate values was used (see NICE clinical guidelines CG33 
(2006)33, Pareek et al34, NICE guidance NG33 (2010)35, 36). Skewed distributions were 
represented using a Gamma distribution. 
 
As the endpoint of the analysis is diagnosis of TB or ruling out TB, treatment costs after final 
diagnosis are out of scope. However, where a patient was started on TB treatment and then a 
lack of response to that treatment informed a decision that the patient did not in fact have TB, 
the cost of this treatment was included, since it is part of the cost of ruling out TB for those 
patients. 
 
Table 43 Health care professional consultation visit monetary costs incurred 
Consultation type Cost (£) Distribution Sources 
First visit: respiratory 
medicine, multi-professional 
241 Gamma(53.3,4.52) National tariff 2014–15, 
Annex 5A37 
167 (SE 33)  Hughes et al (2012)38 
Follow up visit: respiratory 
medicine, multi-professional 
143 Gamma(18.78,7.62) National tariff 2014–15, 
Annex 5A37 
167 (SE 33)  Hughes et al (2012)38 
SE, standard error. 
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Table 44 Test and sampling procedure costs for cost-effectiveness calculations 
Test Unit cost (£) Distribution Sources 
Culture 22.29 (SE 2.23) Gamma(100,0.22) Drobniewski et al (2015)39  
Sputum smear 
microscopy 
7 Gamma(106,0.07) NICE guidance NG33 (2016)40  
1.56 (SE 0.68)  Hughes et al (2012)38 
Tuberculin skin 
test 
17.48  Sutcliffe (2016)41 
16 [8, 32] Uniform(8,36) NICE guidance CG33 (2010)35, 36 
T-SPOT.TB 59.57  Sutcliffe (2016)41 
55 [45, 99] Uniform(50,106) NICE guidance CG33 (2010)35, 36 
QFT-GIT 58 [29, 87] Uniform(29,87) Pareek et al34 
Chest X-ray 35  NICE guidance NG33 (2016)40 
28 [19, 34] Uniform(23,43) NICE guidance CG33 (2010)35, 36 
Bronchoalveolar 
lavage 
23.24 NA St Mary’s R&D office 
[11.62, 46.48] Uniform(11.62, 46.48) Proportions from NICE clinical 
guidelines (2006)33, Pareek et al34, 
NICE guidance CG33 (2010)35, 36 
EBUS 2634 NA St Mary’s R&D office 
Bronchoscopy 
procedure 
612 NA St Mary’s R&D office 
[306, 1224] Uniform(306,1224) Proportions from NICE clinical 
guidelines (2006)33, Pareek et al34, 
NICE guidance CG33 (2010)35, 36 
Histology from 
biopsy 
25 NA St Mary’s R&D office 
[12.5, 50] Uniform(12.5,50) Proportions from NICE clinical 
guidelines (2006)33, Pareek et al34, 
NICE guidance CG33 (2010)35, 36 
Needle aspirate 90.21 NA St Mary’s R&D office 
[45.1, 180.42] Uniform(45.1,180.42) Proportions from NICE clinical 
guidelines (2006)33, Pareek et al34, 
NICE guidance CG33 (2010)35, 36 
Polymerase 
chain reaction  
202.45 NA St Mary’s R&D office 
[101.2, 404.9] Uniform(101.2,404.9) Proportions from NICE clinical 
guidelines (2006)33, Pareek et al34, 
NICE guidance CG33 (2010)35, 36 
EBUS, endobronchial ultrasound; SE, standard error. 
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Uncertainty distributions for each are estimated either for Uniform or Gamma distributions 
depending on the form of the data available. 
 
Table 45 Active TB treatment costs for the first 60 days  
Drug Dosage 
(mg/day)a 
Dosage by 
patient 
weight 
(mg/kg/day)a 
Batch 
costb (£) 
Quantity 
per batch 
(capsule or 
tablet)b 
Dosage per 
capsule or 
tabletb 
60-day 
total 
cost (£) 
Rifampicin 600 – 48 100 300 57.60 
Isoniazid 300 – 19.24 56 50 123.69 
Pyrazinamide 2000 – 38.34 30 500 306.72 
Ethambutol – 15 42.74 56 400 116.74 
aJoint Formulary Committee, 2016.  5.1.9 Antituberculosis drugs. In: Joint Formulary 
Committee. British National Formulary. 69. London: BMJ Group and Pharmaceutical Press.  
bNICE guidance NG33 (2016)40. 
 
Tests used in the diagnostic pathways are either specific to diagnosis of active TB, or, in the 
case of imaging tests (CT, MRI and positron emission tomography (PET)), can aid the 
diagnosis of multiple diseases. For patients who do not have TB, these imaging tests will be 
used to inform the ultimate diagnosis. 
 
The treatment costs for those who have TB ruled out after starting treatment are given in 
Table 45. Following the NICE guidelines for active TB management, it was assumed that 
such patients are on treatment until their two-month follow up appointment when they are 
reassessed for response to treatment. The regimen in this period is a daily treatment with 
rifampicin, isoniazid, pyrazinamide and ethambutol. From the NICE British National 
Formulary, adult dosages are fixed except for ethambutol, which is determined by patient 
weight. The mean weight at time of first presentation of 67.98 kg was used in the model. 
Table 46 summarises the sensitivity and specificity values previously given in Chapter 4 
along with values for the Beta-PERT distributions used for the probabilistic sensitivity 
analyses.
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Table 46 Diagnostic test performance and distributions for different patient strata 
Patient strata Test Indeterminate 
IGRA results 
Sensitivity 95% CI Beta distribution Specificity 95% CI Beta distribution 
All QFT-GIT Excluded 0.673 0.620–0.721 (147,72) 0.804 0.761–0.841 (315,77) 
All T-SPOT.TB Excluded 0.823 0.778–0.861 (299,64) 0.826 0.786–0.861 (293,60) 
All QFT-GIT Included 0.697 0.647–0.742 (147,64) 0.715 0.671–0.756 (145,58) 
All T-SPOT.TB Included 0.832 0.789–0.868 (290,59) 0.754 0.711–0.793 (348,112) 
HIV positive QFT-GIT Excluded 0.565 0.368–0.744 (15,11) 0.920 0.843–0.961 (67,6) 
HIV positive T-SPOT.TB Excluded 0.632 0.410–0.809 (14,8) 0.899 0.813–0.948 (74,7) 
HIV positive QFT-GIT Included 0.600 0.407–0.766 (17,11) 0.748 0.658–0.820 (70,24) 
HIV positive T-SPOT.TB Included 0.708 0.508–0.851 (18,7) 0.664 0.570–0.746 (73,36) 
HIV negative QFT-GIT Excluded 0.681 0.627–0.731 (147,69) 0.770 0.718–0.814 (226,68) 
HIV negative T-SPOT.TB Excluded 0.835 0.790–0.872 (287,57) 0.808 0.760–0.848 (250,59) 
HIV negative QFT-GIT Included 0.704 0.653–0.751 (146,61) 0.704 0.652–0.752 (208,88) 
HIV negative T-SPOT.TB Included 0.841 0.797–0.877 (280,53) 0.785 0.736–0.827 (264,72) 
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Chapter 7 Economic evaluation results  
Introduction 
This section presents the results of the economic evaluation. Firstly, a data analysis with a 
health economics focus is given. This demonstrates the patterns and variability in times and 
costs between patients that are implicit in the model parameter values. This also indicates 
why a simple direct estimation of the relevant summary statistics is not appropriate. The 
modelling results then follow. The main base case scenario results are presented.  
 
Results 
The idealised diagnostic pathway representing current practice is shown in Figure 8. Patient 
records were analysed to determine what proportion of patients followed the pathways in this 
diagram. For each Dosanjh category, the particular tests expected to be performed and their 
corresponding results were determined, and then compared with patient records. Table 47 and 
Table 48 present the frequencies of different tests performed, stratified by final diagnostic 
outcome. Importantly, the process of TB diagnosis rarely followed the idealised diagnostic 
pathways. Whilst culture, IGRAs (QFT-GIT and T-SPOT.TB), TST, sputum smear 
microscopy and chest X-ray were frequently used, there was substantial variation between 
patients. These results are presented graphically in Figure 9 where the number of patients 
who traverse each branch are indicated by the width of the branch. From the individual-level 
patient data, we used the empirical distributions of time to diagnosis and total test costs in the 
probabilistic sensitivity analysis in the following health economic evaluation. 
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Figure 8 Idealised TB diagnostic pathway
 Suspected active TB 
Symptoms of TB  
+ sputum available 
Symptoms of TB  
+ no sputum available 
IGRA/TST 
Chest X-ray 
Smear microscopy 
Culture 
IGRA/TST 
Chest X-ray 
TB excluded 
Dosanjh category 4 
All negative  
and 
No high risk factors  
(e.g. recent significant contact/ 
anti-TNF treatment) 
CT 
Bronchoalveolar lavage 
IGRA/TST positive 
and/or 
Chest X-ray positive 
Culture positive 
Smear negative 
Culture negative 
Smear negative 
Culture negative 
IGRA/TST/Chest  
X-ray/Smear negative 
Smear microscopy 
Culture 
 
IGRA/TST positive 
and/or 
Chest X-ray positive 
and 
Smear negative 
Smear positive 
Culture positive Culture negative 
Smear negative 
Culture negative 
Smear positive 
Key: 
 
IGRA – Interferon-gamma release assay 
TST – Tuberculin skin test 
CT – Computed tomography 
Active TB excluded 
Dosanjh category 4 
Active TB 
Dosanjh category 2 
Active TB 
Dosanjh category 1 
Active TB excluded 
Dosanjh category 4 
Active TB 
Dosanjh category 2 
Active TB 
Dosanjh category 1 
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Table 47 Test result combinations of culture, sputum smear microscopy and chest X-ray 
by final diagnosis 
Culture  Sputum smear  Chest X-ray Dosanjh category Total 
   1 2 3 4  
Not performed Not performed Not performed 0 0 3 13 16 
Not performed Not performed Indeterminate 0 0 2 13 15 
Not performed Not performed Negative 0 0 7 61 68 
Not performed Not performed Positive 0 3 0 1 4 
Not performed Negative Not performed 0 0 0 3 3 
Not performed Negative Indeterminate 0 0 1 2 3 
Not performed Negative Negative 0 0 1 6 7 
Not performed Negative Positive 0 0 0 1 1 
Indeterminate Not performed Negative 0 0 1 0 1 
Indeterminate Negative Negative 0 0 0 1 1 
Indeterminate Positive Positive 0 0 0 1 1 
Negative Not performed Not performed 0 0 2 8 10 
Negative Not performed Indeterminate 0 1 1 10 12 
Negative Not performed Negative 0 1 3 18 22 
Negative Not performed Positive 0 2 0 1 3 
Negative Negative Not performed 0 2 2 34 38 
Negative Negative Indeterminate 0 4 4 65 73 
Negative Negative Negative 0 7 16 235 258 
Negative Negative Positive 0 11 4 48 63 
Negative Positive Not performed 0 0 0 2 2 
Negative Positive Indeterminate 0 0 0 1 1 
Negative Positive Negative 0 0 0 4 4 
Negative Positive Positive 0 1 0 1 2 
Positive Not performed Not performed 1 0 0 0 1 
Positive Not performed Indeterminate 3 0 0 0 3 
Positive Not performed Positive 4 0 0 0 4 
Positive Negative Not performed 8 0 0 0 8 
Positive Negative Indeterminate 17 0 0 0 17 
Positive Negative Negative 14 0 0 0 14 
Positive Negative Positive 57 0 0 0 57 
Positive Positive Not performed 3 0 0 0 3 
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Positive Positive Indeterminate 5 0 0 0 5 
Positive Positive Negative 2 0 0 0 2 
Positive Positive Positive 47 0 0 0 47 
Total 161 32 47 529 769 
 
Table 48 Tests performed at least once in the in-practice routine suspected active TB 
diagnostic pathways.  
Test/sampling method Dosanjh category 
1 2 3 4 
Culture 161 (1.00) 29 (0.91) 33 (0.70) 429 (0.81) 
QuantiFERON GOLD In-Tube 15 (0.09) 8 (0.25) 9 (0.19) 45 (0.09) 
T-SPOT.TB 29 (0.18) 6 (0.19) 19 (0.40) 150 (0.28) 
Tuberculin skin testing 55 (0.34) 10 (0.31) 21 (0.45) 164 (0.31) 
Sputum smear microscopy 153 (0.95) 25 (0.78) 28 (0.60) 404 (0.76) 
Bronchoalveolar lavage 50 (0.31) 14 (0.44) 9 (0.19) 135 (0.26) 
Histology from biopsy 23 (0.14) 11 (0.34) 14 (0.30) 113 (0.21) 
Needle aspirate 28 (0.17) 6 (0.19) 10 (0.21) 60 (0.11) 
Polymerase chain reaction 70 (0.43) 5 (0.16) 7 (0.15) 84 (0.16) 
Chest X-ray 148 (0.92) 29 (0.91) 40 (0.85) 465 (0.88) 
Computed tomography 85 (0.53) 22 (0.69) 27 (0.57) 323 (0.61) 
Magnetic resonance imaging 16 (0.10) 3 (0.09) 7 (0.15) 57 (0.11) 
Positron emission tomography 1 (0.01) 0 (0) 5 (0.11) 13 (0.02) 
For each test, the proportion for each Dosanjh category is given in brackets. 
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Figure 9 Representation of numbers of patients undergoing various TB tests, stratified 
by final diagnosis  
CXR, chest X-ray; TST, tuberculin skin test. 
Patient numbers are shown on the branches. The frequencies of patients in each branch are 
proportional to the width of the branch. Upward branches are for negative test results or if the 
decision was taken not to take a test (for chest X-ray and culture) and the downwards 
branches are for positive results or a decision to test. 
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Table 49 gives distributional statistics of the cost of testing for each final diagnosis category. 
There are long right-hand tails, making single centrality summary statistics misleading.  
 
Table 49 Summary statistics for cost of diagnosis for the patient cohort by final 
diagnosis category 
Dosanjh 
category 
Diagnosis cost (£) 
 Lower quartile Median Mean Upper quartile 
1 292.31 (29.93) 442.92 (17.64) 469.77 (20.59) 640.03 (30.78) 
2 383.73 (66.96) 476.12 (29.6) 474.73 (37.87) 572.03 (53.04) 
3 254.08 (72.77) 502.04 (49.58) 535.48 (57.55) 644.12 (83.71) 
4 202 (17.21) 433.39 (7.69) 445.61 (12.25) 588.47 (17.75) 
1000 bootstrap samples were used to give means and standard errors (in brackets) for each 
statistic.  
 
The decision-tree model structure is shown in Figure 10, and includes true and false negative 
and positive rule out test results. Patients receiving a positive rule out test result (i.e. TB is 
not ruled out) then follow the standard diagnostic pathway, whilst patients receiving a 
negative rule out test result are regarded as not having TB. If the rule out test result is false 
negative then at the two-month follow up consultation their persistent symptoms leads to 
their entering the standard TB diagnostic pathway. 
 
For patients receiving the rule out test, for those who do not have TB, the rule out test, if true 
negative, results in faster diagnosis of the true cause of their illness; for other patients, the 
rule out test increases the delay in their ultimate diagnosis, both for those who have TB and 
those who do not.  
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Figure 10 Decision tree comparing current practice (“No rule out test”) with a 
diagnostic pathway incorporating an initial rule out test (“Rule out test”).  
The “standard pathway” branch represents the range of variation observed in the patient 
cohort. Probabilities are shown below branches following a circular chance node and costs 
are below branches following a square decision node. The rule out test is either T-SPOT.TB 
or QFT-GIT. 
 
Results of the cost-effectiveness analysis are summarised in Table 50. Figure 11 shows cost-
effectiveness planes for the use of T-SPOT.TB or QFT-GIT as rule out tests, for all patients, 
HIV negatives and HIV positives. Figure 12 and Figure 13 show the cost-effectiveness planes 
with uncertainty represented by ellipses showing the 95% and 50% ranges of uncertainty, 
respectively. 
 
Using IGRAs as a rule out test is likely to be cost-saving (except perhaps for T-SPOT.TB 
used with HIV positive patients) but also harmful to health. The magnitude of the health 
detriment is such that it would not be cost-effective if a QALY is valued at £20,000 or 
£30,000 (indicated by diagonal lines).  
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Table 50 Main results from cost-effectiveness analyses for entire patient cohort 
Patient strata Test Indeterminate 
test results 
Incremental 
QALYs 
Incremental 
cost (£1000) 
ICER 
(103) 
Prob(CE) at 
£20k / QALY 
Prob(CE) at 
£30k / QALY 
All QFT-GIT Excluded -6.22 -86.85 13.97 0.08 0.05 
All T-SPOT.TB Excluded -3.58 -78.81 22.01 0.26 0.22 
All QFT-GIT Included -6.50 -70.14 10.79 0.06 0.04 
All T-SPOT.TB Included -4.14 -65.12 15.73 0.21 0.17 
HIV positive QFT-GIT Excluded -7.14 -106.09 14.85 0.09 0.07 
HIV positive T-SPOT.TB Excluded -5.91 -86.87 14.70 0.12 0.08 
HIV positive QFT-GIT Included -7.86 -72.64 9.24 0.04 0.02 
HIV positive T-SPOT.TB Included -6.34 -42.11 6.64 0.04 0.03 
HIV negative QFT-GIT Excluded -6.66 -80.27 12.06 0.06 0.04 
HIV negative T-SPOT.TB Excluded -3.52 -75.31 21.40 0.26 0.21 
HIV negative QFT-GIT Included -6.47 -69.35 10.72 0.05 0.03 
HIV negative T-SPOT.TB Included -3.57 -71.45 20.04 0.24 0.19 
ICER, incremental cost-effectiveness ratio; Prob(CE), probability cost-effective; QALY, quality adjusted life years. 
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Figure 11 Cost-effectiveness planes comparing use of T-SPOT.TB or QFT-GIT as rule 
out tests with current practice 
Statistics were calculated for the entire patient cohort. The upper panels show results for T-
SPOT.TB while the lower panels show results for QFT-GIT. Left- and right-hand panels 
present results with indeterminate diagnostic outcomes excluded and included, respectively. 
Note that an indeterminate IGRA result should not be confused with a diagnostic 
categorisation of a patient as being “clinically indeterminate” with regard to having active 
TB, i.e., Dosanjh category 3.  The analyses considered all patients (light grey point), HIV 
positive patients (dark grey square) and HIV negative patients (black triangle), with each 
point showing the results of a single simulation result. The red points indicate the median 
values for each scenario. Diagonal lines indicate the cost-effectiveness thresholds of £20,000 
per QALY (thin red line) and £30,000 per QALY (thick blue line). 1000 simulations were run 
for each scenario. 
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Figure 12 Cost-effectiveness planes comparing use of T-SPOT.TB or QFT-GIT as rule 
out tests with current practice (95% density of simulation results) 
Statistics were calculated for the entire patient cohort. The upper panels show results for T-
SPOT.TB while the lower panels show results for QFT-GIT. Left- and right-hand panels 
present results with indeterminate diagnostic outcomes excluded and included, respectively.  
Ellipses show 95% density of simulation results. The analyses considered all patients (grey 
solid lines), HIV positive patients (grey dashed lines) and HIV negative patients (black dotted 
lines). The red points indicate the median values for each scenario. Diagonal lines indicate 
the cost-effectiveness thresholds of £20,000 per QALY (thin red line) and £30,000 per 
QALY (thick blue line). 1000 simulations were run for each scenario. 
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Figure 13 Cost-effectiveness planes comparing use of T-SPOT.TB or QFT-GIT as rule 
out tests with current practice (50% density of simulation results) 
Upper panels show results for T-SPOT.TB while lower panels show results for QFT-GIT. 
Left- and right-hand panels present results with indeterminate diagnostic outcomes excluded 
and included, respectively.  Ellipses show 50% density of simulation results. The analyses 
considered all patients (grey solid lines), HIV positive patients (grey dashed lines) and HIV 
negative patients (black dotted lines). The red points indicate the median values for each 
scenario. Diagonal lines indicate the cost-effectiveness thresholds of £20,000 per QALY (thin 
red line) and £30,000 per QALY (thick blue line). 1000 simulations were run for each 
scenario. 
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As the use of IGRAs as a rule out test is detrimental to health (due to the increased average 
time to diagnosis) but cost-saving, the cost-effectiveness acceptability curves (Figure 14) 
show high probability of rule out testing being cost-effective when the value of a QALY is 
low, with the probability declining steeply as the value of a QALY increases. This is because 
if a QALY has a low value then for a given cost-saving a relatively large loss of QALYs 
would be considered acceptable, whereas if a QALY has a high value then such a QALY loss 
would not be acceptable. If a QALY is valued at £20,000 then all scenarios <30% probability 
of being cost-effective and many of them have <10% probability. For £30,000 all scenarios 
<25% probability of being cost-effective but many of them are in single figures. Figure 15 
shows corresponding upper and lower 95% binomial confidence limits for the CEACs in 
Figure 14, calculated using the Normal approximation to the Binomial distribution. 
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Figure 14 Cost-effectiveness acceptability curves for T-SPOT.TB or QFT-GIT as rule 
out tests compared with current practice 
Upper panels show results for T-SPOT.TB while lower panels show results for QFT-GIT. 
Left- and right-hand panels present results with indeterminate IGRA result patients excluded 
and included, respectively. The analyses considered all patients (grey solid lines), HIV-
positive patients (grey dashed lines) and HIV-negative patients (black dotted lines). Vertical 
lines indicate thresholds of £20,000 per QALY (thin red line) and £30,000 per QALY (thick 
blue line). 
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Figure 15 Cost-effectiveness acceptability curves (with 95% CI values) for T-SPOT.TB 
or QFT-GIT as rule out tests compared with current practice 
Upper and lower 95% confidence interval values shown assuming Normal approximation to 
the Binomial distribution. Upper panels show results for T-SPOT.TB while lower panels 
show results for QFT-GIT. Left- and right-hand panels present results with indeterminate 
IGRA result patients excluded and included, respectively. The analyses considered all 
patients (grey solid lines), HIV-positive patients (grey dashed lines) and HIV-negative 
patients (black dotted lines). Vertical lines indicate thresholds of £20,000 per QALY (thin red 
line) and £30,000 per QALY (thick blue line). 
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Discussion 
An important finding of this study is that TB diagnosis rarely follows the idealised diagnostic 
pathways, meaning that costs and time delays until diagnosis may be very different from 
what economic analyses typically assume. In particular, costs of diagnosis may be typically 
underestimated, particularly when scanning is involved. Furthermore, there is considerable 
individual-level variation in the costs and time taken for TB diagnosis, which needs to be 
represented in the analysis. Hence, we included the empirical distributions of time to 
diagnosis and total test costs in the probabilistic sensitivity analysis in the health economic 
evaluation. 
 
The use of current IGRA tests for ruling out active TB would be unlikely to be considered 
cost-effective if a QALY were to be valued at £20,000 or £30,000. Whilst it is cost-saving, 
the health detriment is large. Health detriment occurs due to delay in diagnosing active TB, 
prolonging illness, for two reasons. Firstly, adding a rule out test to the diagnostic pathway 
adds a step and increases the costs and time taken to ultimate diagnosis for all patients except 
those who do not have TB and receive a true-negative rule out test result so that they do not 
undergo the remainder of TB-specific tests. Secondly, some patients with TB receive a false-
negative result of the rule out test, which delays their diagnosis of TB until after their follow-
up appointment. However, for patients who do not have TB, and who have TB correctly 
ruled-out by the initial test, the time to diagnosis of the cause of their illness is reduced, 
producing health gain, and there is a cost saving due to their not having further tests for TB. 
Whether there is a net health detriment or gain for the patient cohort as a whole depends on 
the prevalence of active TB in the patients, the performance characteristics of the rule out 
test, and the length of delay introduced by adding the initial rule out test. 
 
Limitations and generalisability 
The multi-centre design means that the study population is representative of the general 
population with clinically relevant risk of TB in the UK, and is therefore representative of the 
greatest TB burden in the country. In areas where TB rates are low, the patient populations 
might be substantially different and this has not been tested in the study. The model is 
flexible and is suitable for analysing rule out tests with a range of performance 
characteristics, and could also be applied to patient populations in lower-burden settings if 
suitable data were available. A limitation is that whilst we have quantified the health 
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detriment of delayed treatment due to prolonged morbidity we were unable to account for any 
additional detriment due to a potentially poorer prognosis, due to lack of suitable data. Also 
due to lack of data, the assumed time taken to apply the hypothetical rule-out test is an 
assumption based on expert opinion, and we have assumed that the time to follow-up of those 
patients who receive a negative hypothetical rule-out test result can be inferred from our 
existing data set. The timings of in-practice events were estimated from the study population. 
The variability in times between patients were explicitly included in the model. 
 
Conclusions and recommendations 
The use of current IGRA tests for ruling out active TB would be unlikely to be considered 
cost-effective if a QALY were to be valued at £20,000 or £30,000. Health detriment in 
patients with active TB whose diagnosis and treatment are delayed needs to be balanced 
against health gains in patients who do not have active TB whose diagnosis of the true cause 
of illness and commencement of appropriate treatment are accelerated, with consideration 
given to cost-savings of faster ruling out of active TB. Whilst the performance of current 
IGRA tests means they are not cost-effective, improved test technology or alternative 
algorithms using current technology could potentially have performance that is cost-effective. 
Future research recommendations are that improved testing technology, including 
combinations of tests, be investigated with an equivalent analysis. The knowledge-base in 
this field of research is improved data and understanding at the national and local level. 
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Chapter 8 Discussion  
 
Diagnostic accuracy findings for T-SPOT.TB and QFT-GIT were described in detail in 
Chapters 4 and 5, and the results of the economic evaluation were discussed in Chapter 7. 
Therefore, this chapter focuses on the principal findings, strengths and limitations of the 
study, and implications for health care and research. 
 
Principal findings 
This large multicentre study of a consecutive series of patients being investigated for possible 
TB is representative of routine clinical practice in the UK. The study clearly showed that 
T-SPOT.TB was more sensitive than QFT-GIT [relative sensitivity (95% CI): 1.22 (1.14 to 
1.31); P <0.001] but with similar specificities [relative specificity (95% CI): 1.02 (0.97 to 
1.08); P = 0.3]. For T SPOT.TB and QFT-GIT, the sensitivities (95% CI) were 82.3% (77.7% 
to 85.9%) and 67.3% (62.1% to 72.2%) while specificities (95% CI) were 82.6% (78.6% to 
86.1%) and 80.4% (76.1% to 84.1%), respectively. In the sub study of HIV positive patients, 
the highest risk subgroup for TB, T SPOT.TB also showed higher sensitivity in comparison 
to QFT-GIT (a relative increase of 12%) but there was no statistical evidence of a difference 
in sensitivity. The sensitivity of T-SPOT.TB in all patients (82.3%) or amongst HIV co-
infected patients (68.0%) is not of sufficient clinical utility as a ‘rule out’ test for the 
diagnosis of active TB in routine clinical practice and cannot be used in isolation as a rule out 
test. This is further supported by the economic evaluation. The use of current IGRA tests for 
ruling out active TB would be unlikely to be considered cost-effective if a QALY were to be 
valued at £20,000 or £30,000. There are cost-savings but the health detriment is large due to 
delay in diagnosing active TB.  
 
The specificities of the IGRAs were also not adequate for IGRAs to be recommended as rule 
in tests. However, in category 4D patients (active TB excluded, TST negative and no risk 
factors for LTBI), both T-SPOT.TB and QFT-GIT showed high specificities of 92.3% 
(85.4% to 96.4%) and 93.4% (86.4% to 96.9%), respectively. This suggests that IGRAs may 
have potential value for ruling in TB in settings with low probability of active TB. However, 
it should be noted that the number of category 4D patients was small.  
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For key subgroups in our main study cohort— patients with pre-existing diabetes, end-stage 
renal failure and iatrogenic immunosuppression —data were limited. Of the 845 patients 
included in our analyses, 88 (10.4%) had diabetes, 12 (1.4%) had chronic/end stage renal 
failure and five (0.6%) were on immunosuppressive therapy. Analysis of patients with and 
without diabetes showed that the sensitivities and specificities of both tests were higher in 
those without diabetes compared to those with diabetes. However, there was no statistical 
evidence of an effect on the relative test performance of T-SPOT.TB and QFT-GIT. 
Although this finding should be interpreted with caution due to the small number of active 
TB cases in the analyses, association between diabetes and IGRA performance has been 
reported. Faurholt-Jepsen et al42 reported an association between diabetes and lower levels of 
Mtb antigen-specific IFN-γ and the impact on QFT-GIT results. Our findings are similar even 
though diabetes was self-reported in the IDEA study. We found no study that has evaluated 
the effect of diabetes on the diagnostic performance of T-SPOT.TB; the IDEA study appears 
to be the first study to suggest differences in the performance of T-SPOT.TB between 
diabetic and non-diabetic patients. 
 
A new generation of QFT-GIT, QuantiFERON-TB Gold Plus (QFT-Plus), was recently 
launched. QFT-Plus includes a set of peptides designed to stimulate Mtb-specific CD8+ T-
cells.43 There is very little published evidence about the performance of the test. According to 
Barcellini et al43 who reported the first independent assessment of QFT-Plus, the test had 
sensitivity (95% CI) of 87.9% (80.8% to 92.7%) in 116 TB patients and specificity (95% CI) 
of 97.2% (92.0% to 99.0%) in 106 low-risk controls. In the IDEA study, next generation 
IGRAs utilising novel antigens showed potential as rule out tests. In particular the use of a 
combination of existing antigens—ESAT-6 and CFP-10— and the newer antigens—Rv3615c 
and Rv3879c—achieved a sensitivity of 89.9% (86.2% to 92.7%) based on all active TB 
cases and 94.4% (90.7% to 96.7%) amongst culture confirmed cases. Similar results were 
obtained for the two-antigen combination of CFP-10 and Rv3615c and the three-antigen 
combination of ESAT-6, CFP-10 and Rv3615c. The added value of Rv3615c to T-SPOT.TB 
was a 9% (5% to 12%) relative increase in sensitivity at the expense of specificity with a 
relative decrease of 7% (4% to 10%). The incremental gain in sensitivity to 90% is likely to 
be clinically useful in ruling out active TB. 
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Strengths and limitations 
To our knowledge, the IDEA study is the largest, prospective comparative accuracy study of 
the role of IGRAs for the diagnosis of active TB. Furthermore, we recruited a consecutive 
series of patients that were representative of UK clinical practice. We ensured completeness 
and quality of the data such that missing data were minimal. Thus this well designed and 
conducted study enabled robust and precise estimation of the relative performance of 
T-SPOT.TB and QFT-GIT in the main study cohort.  
 
Our study has wide applicability as we did not exclude key subgroups such as HIV positive 
patients but aimed to also compare the clinical performance of T-SPOT.TB and QFT-GIT in 
this population. In spite of not achieving the target sample size for the HIV positive 
subgroup, compared to the five comparative studies identified in a systematic review 
published in 2012 and our literature review,16 the IDEA study remains the largest prospective 
head-to-head comparison of the two IGRAs in an HIV co-infected population. 
 
The final diagnosis of TB is challenging in non-culture confirmed cases and relies on a 
combination of epidemiological, radiological and diagnostic parameters. We used a 
composite reference standard applied by a panel of experienced clinicians. The panel 
followed a strict protocol. In the group of patients with non-microbiologically defined highly 
probable TB, there was a rigorous process to ensure that the clinical panel reviewed all cases 
using case histories, imaging, other test results and follow up data to ensure categorisation 
was as accurate as possible. The panel was blinded to study and routine IGRA results to 
avoid potential for bias.  
 
The IDEA study has limitations. Firstly, due to the low number of bronchoalveolar samples 
performed we were unable to fully characterise the value of IGRAs using BAL fluid. 
Therefore, we did not fulfil the secondary objective of determining the diagnostic accuracy of 
the two IGRAs applied to bronchoalveolar lavage samples in patients with suspected 
pulmonary TB who were sputum smear-negative as stated in the protocol.  
 
Secondly, we did not address a secondary objective to analyse samples in order to determine 
whether there is a genetic component which might determine severity of disease progression. 
Using biobank samples obtained from the IDEA study, this work is now being undertaken as 
 110 
 
part of the NIHR-funded VANTDET (‘Validation of New Technologies for Diagnostic 
Evaluation of Tuberculosis’) programme to clinically validate novel immunologic biomarkers 
and proteomic and transcriptomic biosignatures as the next generation of diagnostic tests that 
may be capable of ruling out and ruling in a diagnosis of active TB.  
 
Thirdly, as already alluded to, we did not achieve our recruitment target for the HIV co-
infected population. The IDEA study was extended to facilitate recruitment and more centres 
were included. We did achieve our original target of 200 patients that was based on a 
prevalence of active TB of 50%. However, the final diagnosis of active TB in the 201 HIV 
positive patients included in the analyses of the sub study was even lower (32/201, 15.9%) 
than the 20% used in our revised sample size calculation.   
 
Fourthly, for the economic evaluation, we found that TB diagnosis rarely followed idealised 
diagnostic pathways, implying that costs and time delays until diagnosis may be very 
different from what economic analyses typically assume. In particular, costs of diagnosis may 
be typically underestimated, particularly when other modalities of imaging apart from plain 
chest radiology such as CT, ultrasound or MR scanning are involved. 
 
Implications for health care 
Despite the significantly higher diagnostic sensitivity of T-SPOT.TB over QFT-GIT, neither 
of the two IGRA can be used routinely as a reliable rule out test for suspected active TB in 
this patient population in secondary care. Both IGRAs were also not cost-effective in this 
setting.  However, in patients where there is a suspicion of TB but the pre-test probability is 
low, the negative predictive value of a negative T-SPOT.TB result would be correspondingly 
higher.  
 
The specificity of both IGRAs for a diagnosis of active TB was similar and too low to use as 
a rule in test. However, in patients with suspected active TB, a positive IGRA result could 
help in certain circumstances to keep TB in the differential diagnosis and guide further 
diagnostic testing towards confirming or excluding a diagnosis of TB. A positive result in the 
setting of an HIV-infected patient with suspected TB provides clinically useful information as 
specificity in this setting was higher than in HIV-negative patients, especially for QFT-GIT.  
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The incorporation of novel antigens into T-SPOT.TB, in particular Rv3615c, yielded a high 
sensitivity coupled with a modest reduction in specificity. The sensitivity and NPV of 90% in 
this high prevalence population in secondary care are compatible with the use of this assay to 
exclude a diagnosis of TB in patients with lower pre-test probabilities. The 95% sensitivity in 
culture confirmed TB is similar to that of the D-dimer assay which is routinely used a rapid 
rule out test for suspected venous thromboembolism in patients with a low to moderate pre-
test probability.  
 
Notably, replacing ESAT-6 with Rv3615c also conferred higher sensitivity than T-SPOT.TB. 
Indeed, the diagnostic sensitivity and NPV of 89% were similar to that achieved by the 
incorporation of Rv3615c alongside both ESAT-6 and CFP-10. This observation is relevant 
for TB control internationally because one of the leading TB vaccine candidates currently in 
clinical trials, H56/IC31, incorporates ESAT-6. The vaccine is protective in the nonhuman 
primate model and if it proves to be protective in humans, it is likely be licensed. If rolled 
out, vaccinated individuals will likely develop T cell responses to ESAT-6 which would give 
false-positive IGRA results, akin to the current scenario with BCG vaccination inducing 
false-positive TST results.  Replacing ESAT-6 with Rv3615c may be a potential solution 
because a CFP-10 and Rv3615c-based IGRA would have significantly higher sensitivity than 
existing IGRAs and specificity would not be compromised in H56/IC31-vaccinated 
individuals.  
 
Recommendations for research 
The next generation IGRAs evaluated in this study do not need to be re-evaluated in a UK 
routine practice setting because this study enabled an equally rigorous evaluation of these 
novel assays as it did for conventional IGRAs. Precise estimates of diagnostic accuracy were 
obtained. However, it would be of interest to evaluate these new assays and their 
combinations in distinct clinical settings with much lower or much higher prevalence of 
active TB. It will also be important to assess how these novel IGRAs perform in 
immunosuppressed subgroups, including HIV-infected persons, diabetic patients with chronic 
renal impairment and those on immunosuppressive therapy. A comparative accuracy study of 
the novel assays and QFT-Plus may also be needed to determine how their sensitivity 
compares in routine practice.  
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Appendices  
Appendix 1 Reporting checklist for diagnostic accuracy studies 
 
Table 51 
Standards for 
Reporting 
Diagnostic 
accuracy 
studies 
(STARD) 
checklistSection 
and Topic 
No Item 
Reported on page # 
TITLE OR 
ABSTRACT 
   
 1 Identification as a study of diagnostic accuracy using 
at least one measure of accuracy (such as sensitivity, 
specificity, predictive values, or AUC) 
i 
ABSTRACT    
 2 Structured summary of study design, methods, 
results, and conclusions  
i-ii 
INTRODUCTION    
 3 Scientific and clinical background, including the 
intended use and clinical role of the index test 
1-3 
 4 Study objectives and hypotheses 3-4 
METHODS    
Study design 5 Whether data collection was planned before the index 
test and reference standard were performed 
(prospective study) or after (retrospective study) 
5-6 
Participants 6 Eligibility criteria  5 
 7 On what basis potentially eligible participants were 
identified  
(such as symptoms, results from previous tests, 
inclusion in registry) 
5 
 8 Where and when potentially eligible participants 
were identified (setting, location and dates) 
6, 22 
 9 Whether participants formed a consecutive, random 
or convenience series 
6, Figure 1 
Test methods 10a Index test, in sufficient detail to allow replication 8-13 
 10b Reference standard, in sufficient detail to allow 
replication 
13-15 
 11 Rationale for choosing the reference standard (if 
alternatives exist) 
Not applicable  
 12a Definition of and rationale for test positivity cut-offs 
or result categories of the index test, distinguishing 
pre-specified from exploratory 
10, 12, 13 
 12b Definition of and rationale for test positivity cut-offs 13, Appendix 2 
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or result categories of the reference standard, 
distinguishing pre-specified from exploratory 
 13a Whether clinical information and reference standard 
results were available to the performers/readers of the 
index test 
9 
 13b Whether clinical information and index test results 
were available  
to the assessors of the reference standard 
13, 14 
Analysis 14 Methods for estimating or comparing measures of 
diagnostic accuracy 
17-19 
 15 How indeterminate index test or reference standard 
results were handled 
17 
 16 How missing data on the index test and reference 
standard were handled 
19 
 17 Any analyses of variability in diagnostic accuracy, 
distinguishing pre-specified from exploratory 
18 
 18 Intended sample size and how it was determined 15-17 
RESULTS    
Participants 19 Flow of participants, using a diagram 22-24, Figure 4 
 20 Baseline demographic and clinical characteristics of 
participants 
22-31, Tables  3-7, 
Appendix 4 
 21a Distribution of severity of disease in those with the 
target condition 
30-32, Table 9 
 21b Distribution of alternative diagnoses in those without 
the target condition 
31, 33, Table 10 
 22 Time interval and any clinical interventions between 
index test and reference standard 
14 
Test results 23 Cross tabulation of the index test results (or their 
distribution)  
by the results of the reference standard 
Tables 11, 13, 20, 
22, 37, 38, 60 
 24 Estimates of diagnostic accuracy and their precision 
(such as 95% confidence intervals) 
36-61, 80-83, 
Appendix 11 
 25 Any adverse events from performing the index test or 
the reference standard 
Not applicable 
DISCUSSION    
 26 Study limitations, including sources of potential bias, 
statistical uncertainty, and generalisability 
109-110 
 27 Implications for practice, including the intended use 
and clinical role of the index test 
110-111 
OTHER 
INFORMATION 
   
 28 Registration number and name of registry Not registered 
 29 Where the full study protocol can be accessed http://www.nets.nihr.
ac.uk/__data/assets/p
df_file/0011/51977/P
RO-08-106-02.pdf 
 30 Sources of funding and other support; role of funders xxi 
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Appendix 2 Composite reference standard for diagnosis of active TB 
Table 52 Diagnostic categories for active TB 
Diagnostic category Criteria 
1: Culture confirmed TB Microbiological culture of M. tuberculosis, AND 
suggestive clinical and radiological findings. 
2: Highly probable TB Clinical and radiological features highly suggestive of 
TB unlikely to be caused by other disease, AND a 
decision to treat made by a clinician, AND appropriate 
response to therapy, AND histology supportive if 
available. 
3: Clinically indeterminate Final diagnosis of TB neither highly probable, nor 
reliably excluded. 
4: Active TB excluded  
Subclassification  
     4A: Inactive TB Stable CXR changes, AND TST positivea (if done), 
AND bacteriologically negative (if done), AND no 
clinical evidence of active disease. 
     4B:  One or more risk factors for TB 
exposure†, TST positivea 
TST positivea, AND bacteriologically negative (if 
done) AND no clinical evidence of active disease. 
     4C: One or more risk factors for TB 
exposure†, TST negative 
History of TB exposure, AND TST negative (if done). 
     4D: No risk factors for TB exposureb, 
TST negative 
No history of TB exposure, AND TST negative (if 
done) 
CXR, chest radiograph; TB, tuberculosis; TST, tuberculin skin test.  
aTST with 15 mm threshold (Mantoux ≥15mm)  
bRisk factors for TB exposure: recent exposure to active TB patient, born in country of high 
prevalence or belonging to an ethnic group with a high prevalence of TB (Incidence 
>100/100,000, Rose et al25). 
identified and the patient was not subsequently diagnosed with TB within 6 months 
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Appendix 3 Protocol amendments 
Table 53 
Summary of 
protocol 
amendments
Amendment 
number (Date) 
Details of changes  
AM01: 
Substantial 
amendment 
(April 2011) 
1. Changed title of the project to a more memorable acronym after discussion with the 
project team. The new title was 'IGRA in Diagnostic Evaluation of Active TB' the 
'IDEA' project. protocol, patient information sheet and consent form changed 
accordingly. 
2. Addition of two new recruiting sites  
a. Heart of England NHS Foundation Trust with Dr Martin Dedicoat as PI 
b. Sandwell and West Birmingham Hospitals NHS Trust with Dr Naz Nathani as PI.  
A site specific information form was submitted for each site and R&D approval was 
obtained before commencing recruitment at the sites. 
3. Due to staff retirement/staff changes, the PIs at three sites changed after our original 
submission for ethics approval.  
AM02: 
Substantial 
amendment 
(October 2011) 
1. Correction of some grammatical and spelling errors in the protocol and patient 
information sheet. 
2. Updates to the contact information in the protocol and patient information sheet to 
include the study coordinator's details. 
3. The following changes were made to the protocol to provide further clarification to 
sites: 
a. Insertion of a summary of the eligibility criteria to ensure this stands out. 
Eligibility criteria were previously contained in the text of the protocol. 
b. Addition of Table 2 and further text to clarify research sampling time points and 
time windows for collection of samples. Baseline research samples must be taken 
after informed consent but no later than 48 hours after the start of treatment for TB 
or within seven days of consent, whichever occurs sooner. Follow up research 
samples will be taken at 2 months (+/7 days), and at 6 months (+/7 days) after 
recruitment. 
c. Clarification that surplus BAL samples will only be collected at Imperial College 
NHS Healthcare Trust, St Mary's Hospital. 
d. Clarification of the adverse event and serious adverse event reporting procedures to 
the study coordinator. 
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Table 53 
Summary of 
protocol 
amendments
Amendment 
number (Date) 
Details of changes  
4. The following changes were made to the patient information sheet: 
a. Insertion of local research nurse contact details to allow patients to gain further 
information on the study. This is in addition to the PI’s details currently present. 
b. The following sentence, “This provision does not apply to claims which arise as a 
result of HIV/AIDS or any related conditions.  This does not affect your legal rights 
to seek compensation'”, was added to correct the sponsor's indemnity and insurance 
information to reflect that HIV positive patients will be recruited into the study. 
5. Update to the consent form to reflect the change in the patient information sheet 
version and date. 
AM03: 
Substantial 
amendment 
(October 2012) 
1. Clarification in the protocol that participant's with previous history of TB (including 
previous TB treatment) are eligible for recruitment. 
2. Inclusion of instructions to investigators that the minimum diagnostic tests carried out 
for diagnosing TB should follow NICE and local guidelines in order to ensure all sites 
assess patients for active TB in the same manner. This was added to section 5.1 under 
patient recruitment. 
3. As a patient’s diagnosis is not known at the point of recruitment, clarified guidance 
was added to section 5.4 of the protocol to assist sites in patient follow up.  
4. Extension of the follow up visit time frame to +/-21 days from specified time point for 
the 2-month follow up and +/-28 days from specified time point for the 6-month 
follow up. 
5. Addition of a data collection section to summarise the data collection forms used in the 
study. 
6. Clarification of patient withdrawal as withdrawal of consent only. Patients with a non-
TB diagnosis are not considered as withdrawn from follow up. Information was 
provided on how to report the inability to follow up patients with a non- TB diagnosis. 
7. Addition of information about collection of samples of Mycobacteria from culture 
positive diagnostic tests. These samples will be bacteria grown in diagnostic tests. As 
these samples are not classified as ‘relevant material’ under the Human Tissue Act and 
are not samples directly from the patient, additional consent to collect this type of 
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Table 53 
Summary of 
protocol 
amendments
Amendment 
number (Date) 
Details of changes  
sample is not required for participants enrolled in the IDEA study. 
8. Details of the study's clinical panel that will be responsible for reviewing and 
confirming all patient diagnosis outcomes (see protocol section 9.3). 
9. The details of the Data Monitoring Committee (DMC) were altered to provide details 
of the Data Management Group (DMG) which will oversee data collection and disease 
prevalence. As there is no reason to stop the study on safety grounds and as there will 
not be any interim analyses, the DMG was formed as a more appropriate method of 
oversight of the data collected instead of a DMC. 
AM04: Non-
substantial 
(February 2013) 
1. Minor typographical errors were corrected. 
2. Addition of Ealing Hospital NHS Trust as a site in the study in order to obtain clinical 
information for patients recruited during diagnostic procedures performed under 
referral at one of our existing sites. The intention is to open this site in order to obtain 
clinical details of the patient’s final diagnosis and treatment in these cases. 
Recruitment of new participants will also occur at this site. 
3. Participant recruitment will be extended in order to achieve the 200 HIV positive, 
suspected active TB cases initially set out in the protocol. This will result in the overall 
sample size increasing beyond 1,012 (HIV and non-HIV participants). Extended 
recruitment will occur at a reduced number of sites until recruitment targets are 
achieved. The following sites will close to recruitment on 31/4/13 and continue the 
follow up phase until the end of the study.   
a. University of Leicester Hospitals NHS Trust 
b. Oxford University Hospitals NHS Trust 
c. St George’s Healthcare NHS Trust 
d. Heatherwood and Wexham Park Hospitals NHS Foundation Trust 
e. Sandwell and West Birmingham Hospitals NHS Trust 
Sites remaining open and continuing to recruit as normal include: 
a. Northwest London Hospitals NHS Trust 
b. Imperial College Healthcare NHS Trust 
c. Royal Free Hampstead NHS Trust 
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Table 53 
Summary of 
protocol 
amendments
Amendment 
number (Date) 
Details of changes  
d. Chelsea and Westminster Hospital NHS Foundation Trust 
e. Heart of England NHS Foundation Trust 
AM05: 
Substantial 
amendment  
(October 2013) 
1. From preliminary data , the proportion of HIV positive patients with a final diagnosis 
of active TB is lower than anticipated. Thus the revised required population size for 
this subgroup of HIV positive patients with suspected active TB is 390, as detailed in a 
new paragraph in section 9.2.  
2. The study was extended by twelve months to achieve this increase in sample size. The 
study duration stated in the protocol was therefore been increased from 3 to 4 years.  
3. A number of existing IDEA sites will stay open for the extension. In addition, four 
new sites were added:  
a. University College London Hospitals NHS Foundation Trust (PI: Dr Robert 
Miller) 
b. King’s College Hospital NHS Foundation Trust (PI: Dr Frank Post)  
c. Barts Health NHS Trust (covering St. Bartholomew’s hospital) (PI: Dr Guy Baily) 
d. Lewisham and Greenwich NHS Trust (covering Queen Elizabeth Hospital) (PI: Dr 
Palchaudhuri Paramita)  
4. Dr Melanie Scott, the study coordinator, went on maternity leave and so contact details 
were added for Dr Hilary Whitworth (maternity cover).  
5. Dr Howard Branley was added as the PI for Ealing Hospital NHS Trust and the 
reasons for addition of the site was clarified.  
AM06: 
Substantial 
amendment 
(April 2014) 
1. The lead Research Nurse was changed from Dr Lee Potiphar to Mrs Amarjit Badhan  
2. The PI at Bart’s NHS Trust was changed from Dr Guy Bailey to Dr Rebecca 
O’Connell. 
3. The following amendment was made to section 5.3: “In some circumstances, other 
appropriately qualified staff may carry out recruitment procedures usually performed 
by a Research Nurse (identifying patients, taking informed consent, taking blood, 
completing CRFs).” 
4. Minor typographical errors were amended. 
AM07: 1. The following amendments were made to participant follow up in section 5.4:  
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Table 53 
Summary of 
protocol 
amendments
Amendment 
number (Date) 
Details of changes  
Substantial 
amendment 
(February 2015) 
a. For some patients, additional follow up data may be collected for up to 2 years if 
requested by expert clinical panel). 
b. Imperial College London, TB Research Centre will hold copies of all consent 
forms for patients recruited to IDEA and hold their personal identifiable data. This 
will be stored in a locked cabinet in a secured room with limited access. 
c. Recurrence of TB cases within 2 years will be verified from the London 
Tuberculosis Register and Enhanced Tuberculosis Surveillance.  
2. The following amendment was made to data collection in section 5.5: “The study team 
will retrospectively collate data on patient hospital admissions, including dates of 
admission and discharge. This data will be collected by research nurses using patient 
notes and hospital inpatient records.” 
3. The study was extended by 10 months to allow for the health economic analysis to be 
performed. The revised study end date was 31/12/2015. 
4. The PI at Ealing Hospital NHS Trust was changed from Dr Howard Branley to Dr 
William Lynn. 
5. The study coordinator was changed to Dr Hilary Whitworth. 
6. Minor typographical errors were amended. 
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Appendix 4 Country of birth of patients  
Table 54 Country of birth of all patients included in the analyses 
 Dosanjh category Total 
Country of Birth  Culture 
confirmed TB 
Highly 
probable TB 
Clinically 
indeterminate 
Active TB 
excluded 
 
Afghanistan 3 0 0 3 6 
Algeria 0 0 0 2 2 
Angola 1 0 0 1 2 
Antigua and Barbuda 0 0 0 1 1 
Argentina 0 0 0 2 2 
Bangladesh 4 1 1 13 19 
Belarus 0 0 0 1 1 
Belgium 1 0 0 0 1 
Bolivia 1 0 0 1 2 
Brazil 0 0 0 6 6 
Burundi 2 0 0 0 2 
Cameroon 0 0 0 1 1 
Chile 0 0 0 1 1 
China 1 0 0 0 1 
Colombia 1 0 0 0 1 
Congo 1 0 0 2 3 
Cyprus 0 0 0 3 3 
Denmark 0 0 0 1 1 
Djibouti 0 0 0 1 1 
Ecuador 0 0 0 1 1 
Egypt 0 0 0 1 1 
Eritrea 5 2 3 3 13 
Estonia 0 0 0 1 1 
Ethiopia 2 2 0 4 8 
France 0 0 0 2 2 
Gambia 0 0 0 1 1 
Germany 0 0 0 2 2 
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 Dosanjh category Total 
Country of Birth  Culture 
confirmed TB 
Highly 
probable TB 
Clinically 
indeterminate 
Active TB 
excluded 
 
Ghana 0 1 0 6 7 
Grenada 1 0 0 0 1 
Guinea-Bissau 0 0 0 1 1 
Hong Kong 1 0 0 1 2 
India 117 42 5 62 226 
Indonesia 1 0 0 0 1 
Iran 0 0 0 5 5 
Iraq 1 0 0 4 5 
Ireland 4 1 0 6 11 
Italy 0 0 1 2 3 
Jamaica 5 1 2 6 14 
Kazakhstan 1 0 0 0 1 
Kenya 5 2 0 19 26 
Kuwait 2 0 1 0 3 
Libya 1 0 0 0 1 
Lithuania 0 0 0 1 1 
Malawi 1 2 1 1 5 
Mauritius 0 0 0 1 1 
Morocco 1 0 0 4 5 
Mozambique 0 0 0 1 1 
Nepal 7 5 0 5 17 
Niger 0 0 0 1 1 
Nigeria 7 1 0 4 12 
Pakistan 14 8 4 27 53 
Philippines 9 5 1 6 21 
Poland 1 1 1 10 13 
Portugal 1 0 0 2 3 
Romania 3 0 2 1 6 
Saudi Arabia 0 0 0 1 1 
Sierra Leone 0 0 0 3 3 
 134 
 
 Dosanjh category Total 
Country of Birth  Culture 
confirmed TB 
Highly 
probable TB 
Clinically 
indeterminate 
Active TB 
excluded 
 
Somalia 10 9 3 16 38 
South Africa 1 2 1 5 9 
Spain 0 0 1 0 1 
Sri Lanka 7 0 1 13 21 
Sudan 1 0 0 4 5 
Swaziland 0 1 0 1 2 
Sweden 0 0 0 1 1 
Switzerland 0 0 0 1 1 
Syria 0 0 0 1 1 
Tanzania 1 0 1 1 3 
Thailand 0 1 0 2 3 
Uganda 2 0 1 8 11 
United Kingdom 32 11 12 138 193 
United States of America 0 2 0 1 3 
Uruguay 0 0 0 1 1 
Yemen 0 0 0 1 1 
Zambia 1 0 0 1 2 
Zimbabwe 1 2 1 10 14 
Total 261 102 43 439 845 
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Appendix 5 Thresholds used by centres for defining vitamin D status 
 
Table 55 Definition of vitamin D status by recruiting centre 
Hospital Trust Deficient  Insufficient  Normal  
Imperial College Healthcare NHS Trust <40 nmoI/L 40 -70  70 to 150 nmoI/L 
Heart of England NHS Foundation Trust <30  nmoI/L Nil  >49.9 nmoI/L  
Chelsea and Westminster Hospital NHS 
Foundation Trust <40  nmoI/L 40 to 70     70 to 150 nmoI/L 
Royal Free Hampstead NHS Trust <25  nmoI/L 25 to 75  >75 nmol/L            
St George's Healthcare NHS Trust <50  nmoI/L Nil 50 to 200 nmoI/L 
Heatherwood and Wexham Park Hospitals 
NHS Foundation Trust <50  nmoI/L Nil 50 to 150 nmoI/L 
University of Leicester Hospitals NHS Trust <25  nmoI/L 25 to 50  >50 nmoI/L 
Northwest London Hospitals NHS Trust <12.5 nmoI/L 12.5 to 50       50 to 140 nmoI/L 
Oxford University Hospitals NHS Trust <50  nmoI/L Nil >50 nmoI/L 
Sandwell and West Birmingham Hospitals 
NHS Trust <30 nmoI/L 30 to 50  >50 nmoI/L 
King’s College Healthcare Trust <20 ug/l Not specified  20 to 50 ug/L. 
Bart’s Healthcare Trust <30 nmoI/L 30 to 50  80 to 150 nmoI/L 
Ealing Hospital  <25 nmoI/L 25 to 50  51 to 163 nmoI/L 
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Appendix 6 IGRAs and TST performed in routine work up of active TB – main 
study cohort 
 
Table 56 Hospital trusts performing T-SPOT.TB, QFT-GIT and/or TST in the diagnostic 
work up of active TB in all patients 
Hospital Trust Tests performed Na 
T-SPOT.TB QFT-GIT TST 
Imperial College Healthcare NHS Trust 125 14 87 238 
Heart of England NHS Foundation Trust  29 28 21 83 
Chelsea and Westminster Hospital NHS Foundation 
Trust  26 0 0 40 
Royal Free Hampstead NHS Trust  1 2 0 41 
St George's Healthcare NHS Trust  29 1 29 43 
University of Leicester Hospitals NHS Trust  4 22 0 100 
Northwest London Hospitals NHS Trust  2 2 191 257 
Oxford University Hospitals NHS Trust  0 0 0 2 
Sandwell and West Birmingham Hospitals NHS Trust  6 2 8 41 
Total 222 71 336b 845 
aNumber of patients included from each centre in the analyses of the IDEA study. 
bTST results available for 322 of the 336 patients. Results were missing for four, eight and two 
patients from Imperial College Healthcare NHS Trust, Northwest London Hospitals NHS Trust 
and Sandwell and West Birmingham Hospitals NHS Trust, respectively. 
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Appendix 7 Additional T-SPOT.TB and QFT-GIT results in all patients in main 
study cohort 
 
Table 57 Cross tabulation of T-SPOT.TB and QFT-GIT results in all patients in main 
study cohort 
N (%) T-SPOT.TB 
Positive Negative Indeterminate Missing Total 
QFT-
GIT 
Positive 243 (69.0) 45 (11.3) 13 (22.8) 7 (19.4) 308 (36.4) 
Negative 85 (24.1) 307 (76.8) 35 (61.4) 6 (16.7) 433 (51.2) 
Indeterminate 23 (6.5) 45 (11.2) 9  (15.8) 2 (5.6) 79 (9.3) 
Missing 1 (0.3) 3 (0.8) 0  21 (58.3) 25 (3.0) 
Total 352 (100) 400 (100) 57 (100) 36 (100) 845 (100) 
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Table 58 Diagnostic accuracy of T-
SPOT.TB and QFT-GIT: 
sensitivity analyses with 
indeterminate IGRA results 
included Test performance 
T-SPOT.TB QFT-GIT 
n/N Estimate  
(95% CI) 
n/N Estimate  
(95% CI) 
Sensitivity for a diagnosis of active TB     
All TB 287/345 83.2 (78.9–86.8) 246/353 69.7 (64.7–74.2) 
Culture positive TB 213/246 86.6 (81.8–90.3) 184/252 73.0 (67.2–78.1) 
Culture negative TB 62/85 72.9 (62.7–81.2) 51/86 59.3 (48.7–69.1) 
Smear positive TB 52/62 83.9 (72.8–91.0) 52/66 78.8 (67.5–86.9) 
   Smear negative TB 192/229 83.8 (78.5–88.0) 159/232 68.5 (62.3–74.2) 
Pulmonary TB 95/121 78.5 (70.4–84.9) 90/126 71.4 (63.0–78.6) 
Extra pulmonary TB 155/183 84.7 (78.8–89.2) 127/185 68.6 (61.6–74.9) 
Specificity for a diagnosis of active TB     
Active TB excluded  319/423 75.4 (71.1–79.3) 304/425 71.5 (67.1–75.6) 
Active TB excluded, TST negative, no 
risk factors for LTBI 
87/111 78.4 (69.8–85.0) 85/110 77.3 (68.6–84.1) 
Predictive values     
Positive predictive value 287/391 73.4 (68.8–77.5) 246/367 67.0 (62.1–71.6) 
Negative predictive value 319/377 84.6 (80.6–87.9) 304/411 74.0 (69.5–78.0) 
Likelihood ratios     
Positive likelihood ratio  3.38 (2.85–4.03)  2.45 (2.07–2.89) 
Negative likelihood ratio  0.22 (0.18–0.28)  0.42 (0.36–0.50) 
LTBI, latent tuberculosis infection; TST, tuberculin skin test. 
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate IGRA 
results were included as test positives in these analyses. 
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Table 59 Comparison of T-SPOT.TB and QFT-GIT: sensitivity analysis with indeterminate 
IGRA results included 
Test Na Sensitivity (95% CI) Nb Specificity (95% CI) 
T-SPOT.TB  345 83.3 (78.9–86.8) 386 75.4 (71.1–79.3) 
QFT-GIT  353 69.7 (64.7–74.3) 378  71.6 (67.1–75.7) 
Ratioc (95% CI); P value  1.19 (1.12–1.28); <0.001  1.05 (0.98–1.13);  0.1 
aNumber of test results amongst those with active TB. 
bNumber of test results amongst those without active TB. 
cRatio of the sensitivity (or specificity) of T-SPOT.TB to that of QFT-GIT. The natural outputs 
from generalized estimating equation models are odds ratios. Ratios of sensitivities (relative 
sensitivity) and ratios of specificities (relative specificity) were computed post estimation of the 
models. Confidence intervals were obtained using the delta method. 
Sensitivities and specificities are presented as percentages.
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Appendix 8 Additional T-SPOT.TB and QFT-GIT results in HIV positive and HIV negative patients in main study 
cohort 
 
Table 60 T-SPOT.TB and QFT-GIT results by active TB status in HIV positive patients in main study cohort 
Index test result Dosanjh category Total 
1 2 3 4A 4B 4C 4D 4A-D 
T-SPOT.TB          
Positive 7 5 0 0 0 7 1 8 20 
Negative 4 3 2 0 1 42 28 71 80 
Indeterminate 2 3 0 1 0 11 16 28 33 
Missing 0 1 0 0 0 1 0 1 2 
Total 13 12 2 1 1 61 45 108 135 
Median SFCs 
ESAT-6 (range) 
10 (0–94) 8 (0–395) 0 0 0 0 (0–42) 0 (0–69) 0 (0–69) 0 (0–395) 
Median SFCs 
CFP-10 (range) 
2 (0–136) 0 (0–315) 0 0 0 0 (0–37) 0 (0–44) 0 (0–44) 0 (0–315) 
QFT-GIT          
Positive 8 5 0 0 0 5 2 7 20 
Negative 5 5 1 1 1 42 36 80 91 
Indeterminate 0 2 1 0 0 14 6 20 23 
Missing 0 0 0 0 0 0 1 1 1 
Total 13 12 2 1 1 61 45 108 135 
Median IFN-γ 
levels (range) 
0.95 (0–3.78) 0.01 (0–10) 0.01 (0-0.02) 0.07 0 0.01 (0–3.82) 0.01 (0–1.56) 0.01 (0–3.82) 0.02 (0–10) 
SFCs, spot forming cells.
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Table 61 Cross tabulation of T-SPOT.TB and QFT-GIT results in HIV positive patients in 
main study cohort 
N (%) T-SPOT.TB 
Positive Negative Indeterminate Missing Total 
QFT-
GIT 
Positive 13 (65.0) 3 (3.8) 4 (12.1) 0  20 (14.8) 
Negative 5 (25.0) 60 (75.0) 24 (72.7) 2 (100.0) 91 (67.4) 
Indeterminate 2 (10.0) 16 (20.0) 5 (15.2) 0  23 (17.0) 
Missing 0  1 (1.3) 0  0  1 (0.7) 
Total 20 (100.0) 80 (100.0) 33 (100.0) 2 (100.0) 135 (100.0) 
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Table 62 Diagnostic accuracy of T-SPOT.TB and QFT-GIT in HIV positive patients in 
main study cohort: sensitivity analyses with indeterminate IGRA results included 
Test performance T-SPOT.TB QFT-GIT 
n/N Estimate  
(95% CI) 
n/N Estimate  
(95% CI) 
Sensitivity for a diagnosis of active TB     
All TB 17/24 70.8 (50.8–85.1) 15/25 60.0 (40.7–76.6) 
Culture positive TB 9/13 69.2 (42.4–87.3) 8/13 61.5 (35.5–82.3) 
Culture negative TB 8/11 72.7 (43.4–90.3) 7/11 63.6 (35.4–84.8) 
Smear positive TB 2/5 40.0 (11.8–76.9) 3/5 60.0 (23.1–88.2) 
   Smear negative TB 11/15 73.3 (48.0–89.1) 9/15 60.0 (35.7–80.2) 
Pulmonary TB 6/8 75.0 (40.9–92.9) 5/8 62.5 (30.6–86.3) 
Extra pulmonary TB 9/12 75.0 (46.8–91.1) 7/13 53.8 (29.1–76.8) 
Specificity for a diagnosis of active TB     
Active TB excluded  71/107 66.4 (57.0–74.6) 80/107 74.8 (65.8–82.0) 
Active TB excluded, TST negative, no 
risk factors for LTBI 
28/45 62.2 (47.6–74.9) 36/44 81.8 (68.0–90.5) 
Predictive values     
Positive predictive value 17/53 32.1 (21.1–45.5) 15/42 35.7 (23.0–50.8) 
Negative predictive value 71/78 91.0 (82.6–95.6) 80/90 88.9 (80.7–93.9) 
Likelihood ratios     
Positive likelihood ratio  2.11 (1.46–3.05)  2.38 (1.51–3.76) 
Negative likelihood ratio  0.44 (0.23–0.83)  0.54 (0.33–0.88) 
LTBI, latent tuberculosis infection; TST, tuberculin skin test. 
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate IGRA 
results were included these analyses as test positives. 
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Table 63 Diagnostic accuracy of T-SPOT.TB and QFT-GIT in HIV negative patients in 
main study cohort: sensitivity analyses with indeterminate IGRA results included 
Test performance T-SPOT.TB QFT-GIT 
n/N Estimate  
(95% CI) 
n/N Estimate  
(95% CI) 
Sensitivity for a diagnosis of active TB     
All TB 270/321 84.1 (79.7–87.7) 231/328 70.4 (65.3–75.1) 
Culture positive TB 204/233 87.6 (82.7-91.2) 176/239 73.6 (67.7-78.8) 
Culture negative TB 54/74 73.0 (61.9-81.8) 44/75 58.7 (47.4-69.1) 
Smear positive TB 50/57 87.7 (76.8-93.9) 49/61 80.3 (68.7-88.4) 
   Smear negative TB 181/214 84.6 (79.1-88.8) 150/217 69.1 (62.7-74.9) 
Pulmonary TB 89/113 78.8 (70.3-85.3) 85/118 72.0 (63.3-79.3) 
Extra pulmonary TB 146/171 85.4 (79.3-89.9) 120/172 69.8 (62.5-76.1) 
Specificity for a diagnosis of active TB     
Active TB excluded  248/316 78.5 (73.6–82.7) 224/318 70.4 (65.2–75.2) 
Active TB excluded, TST negative, no 
risk factors for LTBI 
59/66 89.4 (79.7-94.8) 49/66 74.2 (62.6-83.3) 
Predictive values     
Positive predictive value 270/338 79.9 (75.3–83.8) 231/325 71.1 (65.9–75.7) 
Negative predictive value 248/299 82.9 (78.3–86.8) 224/321 69.8 (64.6–74.6) 
Likelihood ratios     
Positive likelihood ratio  3.91 (3.15–4.85)  2.38 (1.98–2.86) 
Negative likelihood ratio  0.20 (0.16–0.26)  0.42 (0.35–0.50) 
LTBI, latent tuberculosis infection; TST, tuberculin skin test. 
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate IGRA 
results were included these analyses as test positives. 
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Appendix 9 Additional T-SPOT.TB and QFT-GIT results in patients with diabetes in main study cohort 
 
Table 64 T-SPOT.TB and QFT-GIT results by active TB status in patients with diabetes in main study cohort 
Index test result Dosanjh category Total 
1 2 3 4A 4B 4C 4D 4A-D  
T-SPOT.TB          
Positive 14 3 2 0 2 8 1 11 30 
Negative 7 1 4 1 4 27 6 38 50 
Indeterminate 1 1 2 0 0 0 0 0 4 
Missing 0 0 0 0 0 4 0 4 4 
Total 22 5 8 1 6 39 7 53 88 
Median SFCs 
ESAT-6 (range) 
8 (0–123) 12 (1–26) 0 (0–4) 0 0 (0–9) 0 (0–83) 0 (0–22) 0 (0–83) 0 (0–123) 
Median SFCs 
CFP-10 (range) 
5 (0–275) 51 (2–103) 1 (0–20) 0 0 (0–20) 0 (0–120) 0 (0–4) 0 (0–120) 1 (0–275) 
QFT-GIT          
Positive 12 3 2 0 1 8 1 10 27 
Negative 10 2 5 1 5 27 4 37 54 
Indeterminate 0 0 1 0 0 2 2 4 5 
Missing 0 0 0 0 0 2 0 2 2 
Total 22 5 8 1 6 39 7 53 88 
Median IFN-γ 
levels (range) 
0.39 (0–10) 1.1 (0.11–5.84) 0.07 (0–3.58) 0 0.01 (0–0.84) 0.01 (0–10) 0 (0–5.92) 0 (0–10) 0.07 (0–10) 
SFCs, spot forming cells
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Table 65 Cross tabulation of T-SPOT.TB and QFT-GIT results in patients with diabetes 
N (%) T-SPOT.TB 
Positive Negative Indeterminate Missing Total 
QFT-
GIT 
Positive 19 (63.3) 5 (10.0) 2 (50.0) 1 (25.0) 27 (30.7) 
Negative 10 (33.3) 41 (82.0) 2 (50.0) 1 (25.0) 54 (61.4) 
Indeterminate 1 (3.3) 4 (8.0) 0 0 5 (5.7) 
Missing 0 0 0 2 (50.0) 2 (2.3) 
Total 30 (100.0) 50 (100.0) 4 (100.0) 4 (100.0) 88 (100.0) 
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Table 66 Diagnostic accuracy of T-SPOT.TB and QFT-GIT in patients with diabetes in 
main study cohort: sensitivity analyses with indeterminate IGRA results included 
Test performance T-SPOT.TB QFT-GIT 
n/N Estimate  
(95% CI) 
n/N Estimate  
(95% CI) 
Sensitivity for a diagnosis of active TB     
All TB 19/27 70.4 (51.5–84.2) 15/27 55.6 (37.3–72.4) 
Culture positive TB 15/22 68.2 (47.3–83.6) 12/22 54.5 (34.7–73.1) 
Culture negative TB 4/5 80.0 (37.6–96.4) 3/5 60.0 (23.1–88.2) 
Smear positive TB 6/8 75.0 (40.9–92.9) 5/8 62.5 (30.6–86.3) 
   Smear negative TB 11/16 68.8 (44.4–85.8) 7/16 43.8 (23.1–66.8) 
Pulmonary TB 5/9 55.6 (26.7–81.1) 5/9 55.6 (26.7–81.1) 
Extra pulmonary TB 11/14 78.6 (52.4–92.4) 8/14 57.1 (32.6–78.6) 
Specificity for a diagnosis of active TB     
Active TB excluded  38/49 77.6 (64.1–87.0) 37/51 72.6 (59.1–82.9) 
Active TB excluded, TST negative, no 
risk factors for LTBI 
6/7 85.7 (48.7–97.4) 4/7 57.1 (25.0–84.2) 
Predictive values     
Positive predictive value 19/30 63.3 (45.5–78.1) 15/29 51.7 (34.4–68.6) 
Negative predictive value 38/46 82.6 (69.3–90.9) 37/49 75.5 (61.9–85.4) 
Likelihood ratios     
Positive likelihood ratio  3.14 (1.76–5.57)  2.02 (1.16–3.54) 
Negative likelihood ratio 19/27 70.4 (51.5–84.2) 15/27 55.6 (37.3–72.4) 
LTBI, latent tuberculosis infection; TST, tuberculin skin test. 
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate 
IGRA results were included these analyses as test positives. 
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Appendix 10 Additional results for evaluations of next generation IGRAs in main study cohort 
 
Table 67 Diagnostic accuracy of next generation IGRAs: sensitivity analyses based on all patients in main study cohort 
Test performance Rv3615c Rv3879c Rv3873 Rv2654 
n/N Estimate (95% CI) n/N Estimate (95% CI) n/N Estimate (95% CI) n/N Estimate (95% CI) 
Sensitivity for a diagnosis of 
active TB 
        
All TB 274/345 79.4 (74.8–83.4) 148/345 42.9 (37.8–48.2) 135/345 39.1 (34.1–44.4) 146/345 42.3 (37.2–47.6) 
Culture positive TB 208/246 84.6 (79.5–88.5) 108/246 43.9 (37.8–50.2) 100/246 40.7 (34.7–46.9) 108/246 43.9 (37.8–50.2) 
Culture negative TB 56/85 65.9 (55.3–75.1) 53/85 62.4 (51.7–71.9) 30/85 35.3 (26.0–45.9) 32/85 37.6 (28.1–48.3) 
Smear positive TB 52/62 83.9 (72.8–91.0) 28/62 45.2 (33.4–57.5) 25/62 40.3 (29.0–52.7) 21/62 33.9 (23.3–46.3) 
   Smear negative TB 179/229 78.2 (72.4–83.0) 103/229 45.0 (38.7–51.5) 88/229 38.4 (32.4–44.9) 103/229 45.0 (38.7–51.5) 
Pulmonary TB 94/121 77.7 (69.5–84.2) 44/121 36.4 (28.3–45.2) 37/121 30.6 (23.1–39.3) 50/121 41.3 (32.9–50.2) 
Extra pulmonary TB 144/183 78.7 (72.2–84.0) 84/183 45.9 (38.8–53.1) 77/183 42.1 (35.2–49.3) 76/183 41.5 (34.6–48.8) 
Specificity for a diagnosis of 
active TB 
        
Active TB excluded  320/423 75.7 (71.3–79.5) 359/423 84.9 (81.1–88.0) 366/423 86.5 (82.9–89.5) 352/423 83.2 (79.4–86.5) 
Active TB excluded, TST 
negative, no risk factors for 
LTBI 
86/111 77.5 (68.9–84.3) 90/111 81.1 (72.8–87.3) 92/111 82.9 (74.8–88.8) 88/111 79.3 (70.8–85.8) 
Predictive values         
Positive predictive value 274/377 72.7 (68–76.9) 148/212 69.8 (63.3–75.6) 135/192 70.3 (63.5–76.3) 146/217 67.3 (60.8–73.2) 
Negative predictive value 320/391 81.8 (77.7–85.4) 359/556 64.6 (60.5–68.4) 366/576 63.5 (59.5–67.4) 352/551 63.9 (59.8–67.8) 
Likelihood ratios         
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Positive likelihood ratio  3.26 (2.73–3.89)  2.83 (2.19–3.66)  2.93 (2.23–3.86)  2.52 (1.97–3.22) 
Negative likelihood ratio  0.27 (0.22–0.34)  0.67 (0.61–0.74)  0.70 (0.64–0.77)  0.69 (0.63–0.77) 
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Table 67 continued 
Test performance ESAT-6 CFP-10 
n/N Estimate (95% CI) n/N Estimate (95% CI) 
Sensitivity for a diagnosis of 
active TB 
    
All TB 246/345 71.3 (66.3–75.8) 253/345 73.3 (68.4–77.7) 
Culture positive TB 183/246 74.4 (68.6–79.4) 189/246 76.8 (71.2–81.7) 
Culture negative TB 51/85 60.0 (49.4–69.8) 273/340 80.3 (75.7–84.2) 
Smear positive TB 43/62 70.3 (58.2–80.1) 46/62 74.2 (62.1–83.4) 
   Smear negative TB 167/229 72.9 (66.8–78.3) 169/229 73.8 (67.7–79.1) 
Pulmonary TB 81/121 69.4 (57–79.4) 83/121 68.6 (59.9–76.2) 
Extra pulmonary TB 134/183 73.2 (66.4–79.1) 138/183 75.4 (68.7–81.1) 
Specificity for a diagnosis of 
active TB 
    
Active TB excluded  339/423 80.1 (76.1–83.7) 333/423 78.7 (74.6–82.4) 
Active TB excluded, TST 
negative, no risk factors for 
LTBI 
87/111 78.4 (69.8–85.0) 90/111 81.1 (72.8–87.3) 
Predictive values     
Positive predictive value 246/330 74.5 (69.6–78.9) 255/343 74.3 (69.5–78.7) 
Negative predictive value 339/438 77.4 (73.3–81.1) 333/425 78.4 (74.2–82.0) 
Likelihood ratios     
Positive likelihood ratio  3.59 (2.93–4.40)  3.45 (2.84–4.19) 
Negative likelihood ratio  0.36 (0.30–0.43)  0.35 (0.28–0.41) 
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LTBI, latent tuberculosis infection; TST, tuberculin skin test. Sensitivity, specificity and predictive values are presented as percentages.  
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Table 68 Diagnostic accuracy of IGRA combinations: sensitivity analyses based on all patients in main study cohort 
Test performance ESAT6 + CFP10 + Rv3615c 
+ Rv3879c 
ESAT6 + CFP10 + Rv3615c CFP10 + Rv3615c + Rv3879c CFP10 + Rv3615c 
 
n/N Estimate (95% CI) n/N Estimate (95% CI) n/N Estimate (95% CI) n/N Estimate (95% CI) 
Sensitivity for a diagnosis of active 
TB 
        
All TB 312/345 90.4 (86.9–93.1) 312/345 90.4 (86.9–93.1) 309/345 89.6 (85.9–92.4) 307/345 89.0 (85.2–91.9) 
Culture positive TB 233/246 94.7 (91.2–96.9) 233/246 94.7 (91.2–96.9) 232/246 94.3 (90.7–96.6) 231/246 93.9 (90.2–96.3) 
Culture negative TB 66/85 77.6 (67.7–85.2) 66/85 77.6 (67.7–85.2) 65/85 76.5 (66.4–84.2) 64/85 75.3 (65.2–83.2) 
Smear positive TB 59/62 95.2 (86.7–98.3) 59/62 95.2 (86.7–98.3) 59/62 95.2 (86.7–98.3) 59/62 95.2 (86.7–98.3) 
   Smear negative TB 205/229 89.5 (84.9–92.9) 205/229 89.5 (84.9–92.9) 203/229 88.6 (83.9–92.1) 201/229 87.8 (82.9–91.4) 
Pulmonary TB 109/121 90.1 (83.5–94.2) 109/121 90.1 (83.5–94.2) 109/121 90.1 (83.5–94.2) 108/121 89.3 (82.5–93.6) 
Extra pulmonary TB 164/183 89.6 (84.4–93.3) 164/183 89.6 (84.4–93.3) 161/183 88.0 (82.5–91.9) 160/183 87.4 (81.8–91.5) 
Specificity for a diagnosis of active 
TB 
        
Active TB excluded  290/423 68.6 (64.0–72.8) 296/423 70.0 (65.4–74.2) 296/423 70.0 (65.4–74.2) 302/423 71.4 (66.9–75.5) 
Active TB excluded, TST 
negative, no risk factors for LTBI 
82/111 73.9 (65.0–81.2) 84/111 75.7 (66.9–82.7) 84/111 75.7 (66.9–82.7) 83/111 74.8 (66.0–81.9) 
Predictive values         
Positive predictive value 312/445 70.1 (65.7–74.2) 312/439 71.1 (66.7–75.1) 309/436 70.9 (66.4–74.9) 307/428 71.7 (67.3–75.8) 
Negative predictive value 290/323 89.8 (86.0–92.6) 296/329 90.0 (86.3–92.8) 296/332 89.2 (85.4–92.1) 302/340 88.8 (85.0–91.8) 
Likelihood ratios         
Positive likelihood ratio  2.88 (2.49–3.33)  3.01 (2.59–3.50)  2.98 (2.57–3.47)  3.11 (2.66–3.63) 
Negative likelihood ratio  0.14 (0.10–0.19)  0.14 (0.10–0.19)  0.15 (0.11–0.20)   0.15 (0.11–0.21) 
LTBI, latent tuberculosis infection; TST, tuberculin skin test. Sensitivity, specificity and predictive values are presented as percentages. 
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Table 69 Comparison of sensitivity of novel IGRA combinations and T-SPOT.TB: 
sensitivity analysis based on all patients in main study cohort 
Test   Na Sensitivity 
(95% CI) 
Relative sensitivityb  
(95% CI) 
P value 
T-SPOT.TB (ESAT-6 + CFP-10) 345 83.3 (79.0–86.9) – – 
CFP10 + Rv3615c 345 89.0 (85.2–91.9) 1.07 (1.03–1.11) <0.001 
CFP10 + Rv3615c + Rv3879c 345 89.6 (85.9–92.4) 1.08 (1.04–1.11) <0.001 
ESAT6 + CFP10 + Rv3615c 345 90.4 (86.8–93.1) 1.09 (1.05–1.12) <0.001 
ESAT6 + CFP10 + Rv3615c + Rv3879c 345 90.5 (86.9–93.2) 1.09 (1.05–1.12) <0.001 
a Number of test results. 
bSensitivity of combination test divided by sensitivity of T-SPOT.TB. 
Indeterminate test results were included as test positives. 
 
Table 70 Comparison of specificity of novel IGRA combinations and T-SPOT.TB: 
sensitivity analysis based on all patients in main study cohort 
Test Na  Specificity  
(95% CI) 
Relative specificityb 
(95% CI) 
P value 
T-SPOT.TB (ESAT-6 + CFP-10) 423 75.4 (71.1–79.3) – – 
CFP10 + Rv3615c 423 71.4 (66.9–75.5) 0.95 (0.92–0.98) 0.002 
CFP10 + Rv3615c + Rv3879c 423 70.0 (65.4–74.2) 0.93 (0.89–0.96) <0.001 
ESAT6 + CFP10 + Rv3615c 423 70.0 (65.4–74.2) 0.93 (0.90–0.96) <0.001 
ESAT6 + CFP10 + Rv3615c + Rv3879c 423 68.6 (64.0–72.8) 0.91 (0.88–0.94) <0.001 
aNumber of test results. 
bSpecificity of combination test divided by sensitivity of T-SPOT.TB. 
Indeterminate test results were included as test positives. 
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Appendix 11 Evaluations of TST 
 
Diagnostic accuracy of TST at different thresholds 
At induration thresholds of ≥5mm, ≥10mm and the stratified threshold (≥6mm for 
unvaccinated and ≥15mm for BCG vaccinated patients), TST had sensitivities of 95.4% 
(90.9% to 97.8%), 94.8% (90.0% to 97.3%) and 93.5% (88.4% to 96.4%) in culture positive 
and highly probable active TB patients (Table A1). In all non-active TB patients, the 
specificities for thresholds of ≥5mm, ≥10mm and the stratified threshold were 50.3% (42.4% 
to 58.3%), 55.7% (47.7% to 63.4%) and 66.4% (58.5% to 73.5%). TST gave high NPVs at 
the three thresholds; the NPV at the stratified threshold was 90.8% (83.9% to 94.9%). 
Sensitivities were higher for extra pulmonary TB compared to pulmonary TB. There were 
large differences in specificity when analyses were restricted to category 4D non-active TB 
patients (Table 71) but very little change in the sensitivities when the analyses were limited to 
culture positive patients. For further results of sensitivity analyses excluding highly probable 
(category 2) cases, see Table 72. 
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Table 71 Diagnostic accuracy of TST at different thresholds 
Test performance ≥5mm threshold ≥10mm threshold Stratified thresholda 
n/N Estimate (95% CI) n/N Estimate (95% CI) n/N Estimate (95% CI) 
Sensitivity for a diagnosis of active TB       
All TB 146/153 95.4 (90.9–97.8) 145/153 94.8 (90.0–97.3) 143/153 93.5 (88.4–96.4) 
Culture positive TB 98/104 94.2 (88.0–97.3) 98/104 94.2 (88.0–97.3) 96/104 92.3 (85.6–96.1) 
Culture negative TB 43/44 97.7 (88.2–99.6) 42/44 95.4 (84.9–98.7) 42/44 95.5 (84.9–98.7) 
Smear positive TB 23/26 88.5 (71.0–96.0) 23/26 88.5 (71.0–96.0) 23/26 88.5 (71.0–96.0) 
   Smear negative TB 106/110 96.4 (91.0–98.6) 105/110 95.5 (89.9–98.0) 104/110 94.6 (88.6–97.5) 
Pulmonary TB 42/47 89.4 (77.4–95.4) 42/47 89.4 (77.4–95.4) 40/47 85.1 (72.3–92.6) 
Extra pulmonary TB 89/90 98.9 (93.8–99.8) 89/90 98.9 (94.0–99.8) 88/90 97.8 (92.3–99.4) 
Specificity for a diagnosis of active TB       
Active TB excluded  75/149 50.3 (42.4–58.3) 83/149 55.7 (47.7–63.4) 99/149 66.4 (58.5–73.5) 
Active TB excluded, TST negative, no 
risk factors for LTBI 
16/21 76.2 (54.9–89.4) 18/21 85.7 (65.4–95.0) 21/21 100.0 (84.5–100.0) 
Predictive values       
Positive predictive value 146/220 66.4 (59.9–72.3) 145/211 68.7 (62.2–74.6) 143/193 74.1 (67.5–79.8) 
Negative predictive value 75/82 91.5 (83.4–95.8) 83/91 91.2 (83.6–95.5) 99/109 90.8 (83.9–94.9) 
Likelihood ratios       
Positive likelihood ratio  1.92 (1.63–2.27)  2.14 (1.78–2.57)  2.79 (2.21–3.51) 
Negative likelihood ratio  0.09 (0.04–0.19)  0.09 (0.05–0.19)  0.10 (0.05–0.18) 
LTBI, latent tuberculosis infection; TST, tuberculin skin test. 
aAccording to BCG vaccination status: ≥6mm for unvaccinated and ≥15mm for vaccinated patients. 
Sensitivity, specificity and predictive values are presented as percentages. 
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Table 72 Diagnostic accuracy of TST: sensitivity analyses excluding highly probable (category 2) active TB cases  
Test performance ≥5mm threshold ≥10mm threshold Stratified thresholda 
n/N Estimate (95% CI) n/N Estimate (95% CI) n/N Estimate (95% CI) 
Sensitivity for a diagnosis of active TB       
Culture positive TB 98/104 94.2 (88.0–97.3) 98/104 94.2 (88.0–97.3) 96/104 92.3 (85.6–96.1) 
Smear positive TB 21/24 87.5 (69.0–95.7) 21/24 87.5 (69.0–95.7) 21/24 87.5 (69.0–95.7) 
   Smear negative TB 68/71 95.8 (88.3–98.6) 68/71 95.8 (88.3–98.6) 66/71 93.0 (84.6–97.0) 
Pulmonary TB 36/42 85.7 (72.2–93.3) 36/40 90.0 (76.9–96.0) 34/40 85.0 (70.9–92.9) 
Extra pulmonary TB 49/50 98.0 (89.5–99.6) 49/50 98.0 (89.5–99.6) 49/50 98.0 (89.5–99.6) 
Specificity for a diagnosis of active TB       
Active TB excluded  75/149  50.3 (42.4–58.3) 83/149 55.7 (47.7–63.4) 99/149 66.4 (58.5–73.5) 
Active TB excluded, TST negative, no 
risk factors for LTBI 
16/21 76.2 (54.9–89.4) 18/21 85.7 (65.4–95.0) 21/21 100.0 (84.5–100.0) 
Predictive values       
Positive predictive value 98/172 57.0 (50.0–64.1) 98/164 59.8 (52.1–67) 96/146 65.8 (57.7–73.0) 
Negative predictive value 75/81 92.6 (84.8–96.6) 83/89 93.3 (86.1–96.9) 99/107 92.5 (85.9–96.2) 
Likelihood ratios       
Positive likelihood ratio  1.90 (1.60–2.25)  2.13 (1.77–2.56)  2.75 (2.18–3.47) 
Negative likelihood ratio  0.12 (0.05–0.25)  0.10 (0.05–0.23)  0.12 (0.06–0.23) 
LTBI, latent tuberculosis infection; TST, tuberculin skin test. 
aAccording to BCG vaccination status: ≥6mm for unvaccinated and ≥15mm for vaccinated patients. 
Sensitivity, specificity and predictive values are presented as percentages. Exclusion of category 2 active TB cases does not affect 
estimation of specificities. Specificities were included in this table merely for completeness. 
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Combinations of TST and IGRAs 
TST and T-SPOT.TB had a combined sensitivity (95% CI) of 97.7% (93.5% to 99.2%) and 
specificity (95% CI) of 62.0% (53.4% to 69.9%). Results were similar for the combination 
of TST and QFT-GIT, with a sensitivity of 96.9% (92.4% to 98.8%) and specificity of 
59.7% (51.1% to 67.8%). Figure 16 shows sequential likelihood ratios for a testing strategy 
of TST followed by either T-SPOT.TB or QFT-GIT. A positive result for both TST and 
IGRAs gave positive likelihood ratios of 5.80 (3.90 to 10.0) for TST followed by 
T-SPOT.TB and 4.77 (3.25 to 8.16) for TST followed by QFT-GIT. When both tests in a 
combination were negative, the negative likelihood ratios were 0.04 (0.01 to 0.09) for TST 
followed by T-SPOT.TB and 0.05 (0.01 to 0 0.11) for TST followed by QFT-GIT. 
 
In sensitivity analyses excluding highly probable active TB cases (i.e. analyses of only 
culture confirmed active TB cases and all non-active TB cases), the sensitivities and 
specificities of the combinations were largely unchanged. TST and T-SPOT.TB had a 
combined sensitivity (95% CI) of 97.7% (92.1% to 99.4%) and specificity (95% CI) of 
62.0% (53.4% to 69.9%). For the combination of TST and QFT-GIT, sensitivity was 96.6% 
(90.5% to 98.8%) and specificity was 59.7% (51.1% to 67.8%). As can be seen in Figure 17, 
sequential likelihood ratios were generally similar to those from the analyses including both 
cultured confirmed and highly probable active TB cases (Figure 16). 
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Figure 16 Diagnostic performance of combinations of TST with T-SPOT.TB or QFT-
GIT 
The analyses were based on 260 patients in whom results were available for both TST and 
T-SPOT.TB, and for both TST and QFT-GIT. Those with indeterminate IGRA results were 
excluded from the analyses. The likelihood ratios are presented with 95% CIs. The stratified 
threshold was used to determine the positivity of TST. The top figure shows a sequence of 
testing in which T-SPOT.TB follows TST. The bottom figure shows a sequence of testing in 
which QFT-GIT follows TST. The difference in the confidence interval of the positive 
likelihood ratio for TST is due to stochastic variation in the bootstrap method used for the 
computation of the likelihood ratios.  
 
 
 
T-SPOT.TB+ TST+ & T-SPOT.TB+
ATB
Not 
ATB
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Not 
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131 129 260 T-SPOT.TB+ TST– & T-SPOT.TB+
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Not 
ATB
LR = 12.0 (4.20–56.7) n=8,  LR = 0.98 (0.10–6.00)
TST– T-SPOT.TB+ 4 4 8
LR = 0.08 (0.03–0.15) T-SPOT.TB– 3 80 83
7 84 91 T-SPOT.TB– TST– & T-SPOT.TB–
LR = 0.45 (0.15–0.81) n=83,  LR = 0.04 (0.01–0.09)
QFT-IT+ TST+ & QFT-IT+
ATB
Not 
ATB
LR = 1.76 (1.26–2.68) n=111,  LR = 4.77 (3.25–8.16)
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Figure 17 Diagnostic performance of combinations of TST with T-SPOT.TB or QFT-
GIT: sensitivity analyses excluding highly probable TB cases 
The analyses were based on 217 patients in whom results were available for both TST and 
T-SPOT.TB, and for both TST and QFT-GIT. Those with highly probable active TB were 
excluded from the analyses. The likelihood ratios are presented with 95% CIs. The stratified 
threshold was used to determine the positivity of TST. The top figure shows a sequence of 
testing in which T-SPOT.TB follows TST. The bottom figure shows a sequence of testing in 
which QFT-GIT follows TST. The difference in the confidence interval of the positive 
likelihood ratio for TST is due to stochastic variation in the bootstrap method used for the 
computation of the likelihood ratios.  
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ATB
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TST– 6 84 90
88 129 217 QFT-IT+ TST– & QFT-IT+
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LR = 6.00 (1.69–19.4) n=10,  LR = 0.63 (0.00–2.12)
TST– QFT-IT+ 3 7 10
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Appendix 12 Studies of IGRAs for diagnosis of active TB  
Table 73 Summary of studies of IGRAs for diagnosis of active TB published between 1st January 2013 and 16th March 2016 
Reference Study design Population   Setting (recruitment 
period) 
T-SPOT.TB QFT-GIT TST 
Adewole 201344 Prospective study of 
QFT-GIT compared to 
TST for diagnosis of 
pulmonary active TB. 
61 smear positive TB cases 
[mean age (SD): 35.1 (4.3) years] 
and 41 healthy disease free 
controls [mean age (SD): 27.8 
(2.1) years] were enrolled and 
analysed.   
Nigeria (full text 
unavailable so unable 
to extract more 
information) 
NE Sensitivity: 76.0 (61.8–85.2)                                             
Specificity: 63.7 (46.0–76.0)     
Indeterminate rate: 3.5%                                          
Sensitivity: 96.6% (88.5–98.3)                                                     
Specificity: 30.0 (20.0–56.0) 
Jeon 201345 Retrospective analysis 
of laboratory and 
clinical records to 
evaluate factors 
associated with 
indeterminate and 
negative QFT-GIT 
results in active TB 
patients. 
1,301 patients including 168 
confirmed active TB cases [mean 
age (SD) of active TB cases: 54.8 
(20.1) years]. 
Kyung 
Hee University 
Hospital, Seoul, 
Korea (September 
2009 and April 2012)  
NE Sensitivity: 76.8 (69.8–82.5) 
Specificity: 58.3 (55.3–61.4) 
Indeterminate rate: 8% 
NE 
Jia 201346  Prospective study of 
T-SPOT.TB for 
diagnosis of 
osteoarticular TB. 
145 enrolled and all were HIV 
negative. 18 possible cases and 
17 indeterminates were excluded. 
86 culture confirmed or probable 
patients [age range: 18–76 years] 
with osteoarticular TB and 24 
without active TB [age range: 
16–80 years] were analysed.  
Beijing Chest 
Hospital, China (July 
2011 to June 2012) 
Sensitivity: 94.2 (87.1–97.5)                                         
Specificity: 70.8 (50.8–85.1) 
No indeterminates. 
NE NE 
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Reference Study design Population   Setting (recruitment 
period) 
T-SPOT.TB QFT-GIT TST 
Khalil 201347 Comparison of QFT-
GIT and TST for 
diagnosis of pulmonary 
active TB. 
50 pulmonary active TB cases 
[mean age (SD): 41.8 (19.0) 
years]. 
Fauji Foundation 
Hospital, Rawalpindi, 
Pakistan (July 2011 
to January 2012) 
NE Sensitivity: 80                                                            Sensitivity: 28 
Kim 201348  Retrospective study of 
QFT-GIT for diagnosis 
of genitourinary 
tuberculosis (GUTB). 
57 patients [mean age (range): 52 
(17–88) years] with clinical or 
radiologic features suspicious of 
GUTB. 
Urology clinic in 
Korea (March 2009 
to August 2011) 
NE Sensitivity: 63.3 (45.5–78.1)  
Specificity: 59.3 (40.7–75.5)                                         
NE 
Lagrange 201327.  
 
 
Prospective study of 
QFT-GIT compared to 
TST for diagnosis of 
TB, stratified by HIV 
status. 
2,213 patients were enrolled. 
QFT-GIT was performed for 96 
patients [median age (IQR): 38.0 
(30.5–42.0) years] with 
pulmonary active TB and 180 
non-active TB cases. Of the 276 
patients, TST was performed in 
53 active TB cases and 82 non-
active TB cases. 
Nine centres  in India 
(January 2006 to July 
2008) 
NE HIV positive 
Sensitivity: 66.7 (48.2–82.0)  
Specificity: 64.8 (50.6–77.3) 
HIV negative 
Sensitivity: 95.0 (75.1–99.9) 
Specificity: 25.0 (10.7–44.9) 
Total 
Sensitivity: 77.4 (63.8–87.7) 
Specificity: 51.2 (39.9–62.4) 
Results above are from 135 
patients where data were 
available for both QFT-GIT 
and TST. Indeterminate rate 
amongst the 276 patients: 7%                                            
HIV positive 
Sensitivity: 51.5 (33.5–69.2)                            
Specificity: 83.3 (70.7–92.1)   
HIV negative                           
Sensitivity: 85.0 (62.1–96.8) 
Specificity: 57.1 (37.2–75.5)   
Total 
Sensitivity: 64.2 (49.8–76.9) 
Specificity: 74.4 (63.3–82.4) 
Threshold: ≥10mm                         
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Reference Study design Population   Setting (recruitment 
period) 
T-SPOT.TB QFT-GIT TST 
Lavender 201349 
 
Retrospective review of 
clinical records of 
patients with QFT-GIT 
results for diagnosis of 
active TB. 
415 QFT-GIT requested of which 
120 were excluded. 295 patients 
[median age (range): 40 (16–90) 
years] with and without HIV 
infection were analysed. 
Newcastle-upon-
Tyne Hospitals, UK 
(clinical records of 
patients who had 
QFT-GIT requested 
between 29 June 
2005 and 28 October 
2010) 
NE Sensitivity: 71.4 (59.3–81.1) 
Specificity: 81.0 (75.5–85.6)  
NE 
Lei 201350  
 
Case control study of 
T-SPOT.TB for 
differential diagnosis of 
intestinal TB and 
Crohn’s Disease. 
88 patients with intestinal TB 
[mean age (SD): 36.2 (14.1) 
years] and 103 with Crohn’s 
Disease [mean age (SD): 37.0 
(15.7) years] 
Inflammatory Bowel 
Disease Center, 
Zhongnan Hospital, 
China (2003 to 2011) 
Sensitivity: 86 (75–96)                                       
Specificity: 93 (86–99)                                                    
 
NE Sensitivity: 60 (49–71)                                                       
Specificity: 80 (71–89) 
Threshold: ≥10mm 
Liu 201351  Prospective study of T-
SPOT.TB for diagnosis 
of pleural TB.  
168 patients were enrolled but 70 
were excluded due to no final 
diagnosis. 98 subjects with 
pleural effusion and no HIV co-
infection were analysed. 55 
patients [median age (range): 39 
(25–59) years] had pleural TB 
and 43 patients [median age 
(range): 39 (25–59) years] 
without pleural TB. 
Beijing Chest 
Hospital, China (May 
2012 to June 2013) 
Sensitivity: 92.7 (82.7–97.1)                                          
Specificity: 62.8 (47.9–76.0) 
Indeterminate rate: 2% 
(These are results from 
analysis of peripheral blood 
samples) 
NE NE 
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Reference Study design Population   Setting (recruitment 
period) 
T-SPOT.TB QFT-GIT TST 
Lodha 201352  Prospective study 
comparing QFT-GIT 
with TST for diagnosis 
of intrathoracic 
childhood TB. 
362 children [median age (IQR): 
115.5 (73–144) months] were 
enrolled in an RCT of 
micronutrient supplementation in 
children with intrathoracic TB. 
Two tertiary care 
hospitals in India 
(recruitment period 
not reported). 
NE Sensitivity: 82.0 (77.8–85.6)                             Sensitivity: 93.0 (90.0–95.5) 
Threshold: ≥10mm 
Mahomed 
201353 
Prospective study 
screening for active TB 
in adolescents.  
6,363 adolescents [age range: 
12–16 years] screened. 21 had 
active TB. TST and QFT-GIT 
results were available for 5,071 
and 5,524 adolescents, 
respectively. 
11 high schools in 
Worcester, South 
Africa (2005 
to 2007) 
NE Sensitivity: 93.8 (78.8–100.0)                                                   
Specificity: 46.8 (36.3–57.2) 
Sensitivity: 84.6 (61.9–100.0) 
Specificity: 58.1 (49.5–66.7) 
Threshold: ≥10mm 
Danel 201426 Nested cohort study of 
QFT-GIT for ruling out 
active TB in HIV 
positive adults. 
975 adults in Cote d’Ivoire 
[median age: 35 years], 25 with 
active TB on day zero. 
9 clinical centres in 
Abidjan, Cote 
d’Ivoire (March 2008 
to August 2009) 
NE Sensitivity: 88.0 (75.3–100.0)                                            
Specificity: 66.6 (63.6–69.6)  
Indeterminate rate: 3% 
NE
Fei 2014 54 Case control study of 
T-SPOT.TB compared 
to TST for diagnosis of 
laryngeal TB. 
83 patients with laryngeal TB 
and 52 patients with vocal cord 
polyps as controls [age range: 
31–66 years], all without HIV 
infection. 
China (August 2007 
to December 2012) 
Sensitivity: 90.4 (82.1–95.0)                                      
Specificity: 92.3 (81.8–97.0)                                                      
NE Sensitivity: 50.6 (40.1–61.1)                                                         
Specificity: 61.5 (48.0–73.5)   
Threshold: ≥5mm 
 163 
 
Reference Study design Population   Setting (recruitment 
period) 
T-SPOT.TB QFT-GIT TST 
Garazzino 
201455 
Retrospective 
multicentre study of 
children (0–24 months) 
tested at least once with 
QFT-GIT and/or TST 
for active TB. 
823 children [median age 
(range): 13.4 (8.4–18.9) months], 
105 with confirmed TB. Results 
for both TST and QFT-GIT were 
available for 616 children. 
18 paediatric centres 
in Italy. 
NE Sensitivity: 91.1                                              
Specificity: 98.1 
(Results above are for the 
subset of patients with both 
QFT-GIT and TST results) 
Indeterminate rate in entire  
cohort with QFT-GIT: 4.3%                                          
Sensitivity: 85.1                                              
Specificity: 97.9 
Threshold: ≥5mm 
Kim 201456 
 
Prospective study of 
T-SPOT.TB for 
diagnosis of active TB.  
134 patients [mean age (SD): 
55.9 (20.2) years] suspected of 
active TB and 62 healthy adults 
[mean age (SD): 30.6 (8.5) years] 
were consecutively recruited. All 
had been BCG vaccinated at a 
very young age. All received 
T-SPOT.TB while 53 had TST 
results. 
Hallym University 
Han-gang Sacred 
Heart Hospital, Korea  
(June 2008 to June 
2010) 
Sensitivity: 87.8 (74.5–94.7)                                     
Specificity: 44.1(34.4–54.2)                                                    
Specificity in healthy adults: 
75.8 (63.8–84.8) 
 
NE Sensitivity: 70.0 (48.1–85.5) 
Specificity: 48.5 (32.5–64.8) 
Specificity in healthy adults: 
40.3 (29.0–52.7) 
Threshold: ≥10mm 
Kim 201457 Prospective study of 
QFT-GIT for diagnosis 
of miliary TB. 
44 patients [mean age (SD): 64 
(19) years] with miliary TB. 
Kyungpook National 
University Hospital, 
Daegu, South Korea 
(September 2009 to 
July 2013) 
NE Sensitivity: 68.2 (53.4–80.0) 
Indeterminate rate:16% 
NE 
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Reference Study design Population   Setting (recruitment 
period) 
T-SPOT.TB QFT-GIT TST 
Park 201458 Retrospective study of 
QFT-GIT and TST for 
diagnosis of smear 
negative active PTB. 
224 sputum smear negative PTB 
suspects, 94 confirmed as having 
active PTB [mean age (SD): 46.5 
(20.4) years] and 130 confirmed 
as non PTB [mean age (SD): 56.6 
(18.3) years]. 106 patients 
received TST. 
Gangnam Severance 
Hospital, Seoul, 
Korea (October 2007 
to April 2013) 
NE Sensitivity: 81.9 (74.1–89.7)                                               
Specificity: 62.3 (54.0–70.6)                                              
Sensitivity: 58.1 (45.8–70.4)                                                      
Specificity: 63.6 (49.4–77.9) 
Threshold: ≥10mm 
Sauzullo 201428 Prospective study of 
QFT-GIT in HIV 
patients with active TB. 
44 HIV patients [median age 
(range): 42 (31–62) years] with 
active TB. 
Department of Public 
Health and Infectious 
Diseases, Sapienza 
University, Rome, 
Italy (September 
2008 to 2012) 
NE Sensitivity: 65.9 (51.1–78.1) 
with indeterminates included as 
negatives 
Indeterminate rate: 22.7% 
 
Sensitivity: 54.5 (40.1–68.3) 
Schopfer 201459  QFT-GIT evaluated in  
children with 
microbiologically 
confirmed TB 
52,400 children were admitted to 
hospital, of which 405 children 
had TB, including 91 children 
with microbiologically confirmed 
TB. 81 of these were tested with 
QFT-GIT.  
Jayavarman VII 
Hospital, a large 
paediatric referral 
hospital in Cambodia 
(July 2005 to March 
2006) 
NE Sensitivity: 53.1 (42.3–63.6) NE 
Wang 201460 Retrospective study of 
T-SPOT.TB for 
diagnosis of paediatric 
TB. 
102 patients with TB, aged ≤15 
years. 
China (March 2012 
to September 2013) 
Sensitivity: 58.8 (49.1–67.9) NE NE 
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Reference Study design Population   Setting (recruitment 
period) 
T-SPOT.TB QFT-GIT TST 
Wlodarczyk 
201461 
Study of QFT-GIT and 
TST for diagnosis of 
PTB.  
126 adult patients admitted with 
a clinical diagnosis of 
pneumonia. Of these, 43 were 
culture positive [mean age (SD): 
48.6 (18.2) years], 37 culture 
negative [mean age (SD): 51.7 
(15.5) years], and 46 with non-
mycobacterial, community-
acquired lung diseases [mean age 
(SD): 52.7 (17.3) years]. 
Regional Specialised 
Hospital of 
Tuberculosis and 
Lung Diseases in 
Tuszyn, Poland 
(January 2010 to June 
2011) 
NE Sensitivity (C+): 65.1                                        
Sensitivity (C-): 55.6                                         
Specificity: 87                                                           
Sensitivity (C+): 55.8                                        
Sensitivity (C-): 64.9                                         
Specificity:  71.7                                                            
Threshold: ≥10mm 
Aggarwal 201562 Systematic review and 
meta-analysis of 
IGRAs for diagnosis of 
pleural TB 
20 evaluations of T-SPOT.TB 
including 1,085 subjects; 14 
evaluations of QFT assays 
including 727 subjects (only 1 
high quality study; considerable 
heterogeneity) 
China, Taiwan, 
Egypt, Turkey, 
Korea, Italy, South 
Africa, Norway, 
Italy, Germany and 
Netherlands 
(included studies 
published between 
2007 and 2014)  
Not evaluated separately. 
Results pooled across QFT 
and T.SPOT.TB assays. 
 
Not evaluated separately. NE 
Anwar 201563 Retrospective study of 
QFT-GIT for diagnosis 
of active PTB in 
hospital setting 
142 cases of confirmed TB and 
226 pneumonia cases in Saudi 
Arabia (only patients with QFT-
GIT result included) 
KAMC-R Saudi 
Arabia (January 2009 
to December 2013)  
NE Sensitivity: 74.6 (66.1–81.7)                                                 
Specificity: 76.5 (69.9–82.2) 
Indeterminate rate: 11.4%                                              
NE
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Reference Study design Population   Setting (recruitment 
period) 
T-SPOT.TB QFT-GIT TST 
Bao 201564 Prospective study of 
performance of QFT-
GIT for diagnosis of 
TB in children and 
adults  
60 children and 212 adults with 
suspect active TB. 31 had 
confirmed TB. HIV positive 
patients were excluded. 
Children – Shanghai 
Public Health 
Clinical Center and 
Children’s Hospital 
of Fudan University, 
China (December 
2010 to August 
2011), 
Adults – Huashan 
Hospital of Fudan 
University 
(December 2010 to 
December 2011). 
NE Children 
Sensitivity: 83.9 (66.3–94.6)   
Specificity: 88.5 (70.2–96.8)                                         
Adults 
Sensitivity: 73.7 (57.8–85.2)  
Specificity: 70.4 (62.9–77.0)        
Indeterminate rate: 9.1% 
NE 
Sali 201565 Retrospective study of 
QFT-GIT for diagnosis 
of TB infection or 
disease in children 
621 children with suspected 
active TB, screened for LTBI or 
clinically healthy, nationally or 
internationally adopted children 
evaluated by a national protocol 
for immigrants and 
nationally/internationally adopted 
children, with or without known 
history of contact with adult 
active TB cases; 140 active TB 
suspects; 19 confirmed TB cases. 
Paediatric Infectious 
Disease Unit and 
Catholic University 
of the Sacred Heart–
A. Gemelli Hospital 
in Rome, Italy 
(January 2007 to July 
2010) 
NE Sensitivity: 87.5                                     
Specificity: 93.6    
Indeterminate rate: 4.2%                                    
NE  
(TST was performed in less 
than half of the patients. Hence, 
TST results were not included 
in the analysis.)   
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Reference Study design Population   Setting (recruitment 
period) 
T-SPOT.TB QFT-GIT TST 
Shin 201566 Retrospective review of 
clinical records to 
evaluate use of IGRAs 
for diagnosing EPTB 
amongst suspects 
418 patients with suspected 
EPTB in Korea; 324 with 
confirmed active EPTB. Only 56 
had QFT-GIT results. 
Gangnam Severance 
Hospital in Seoul, 
Korea. (July 2005 to 
June 2012) 
NE  Sensitivity: 70.2 (56.0–81.3)  
Specificity: 66.7 (35.4–87.9) 
Sensitivity: 62.1 (42.3–79.3) 
Specificity: 87.5 (52.9–97.8) 
Sun 201567 Prospective study to 
evaluate utility of 
T-SPOT.TB for 
diagnosis of paediatric 
TB in hospital setting 
117 children with active TB in 
China; 413 children with 
respiratory tract infection. 
Beijing Children’s 
Hospital (March 
2011 to June 2014) 
Sensitivity: 82.9                                     
Specificity: 96.1 
Indeterminate rate: 8.5%                                       
NE Sensitivity: 67.5                                                  
Specificity: 75.3       
Threshold ≥10mm 
 
Results were also available for 
≥5mm and ≥15mm and 
combinations of TST with T-
SPOT.TB 
Wong 201568  Retrospective chart 
analysis for paediatric 
patients who underwent 
QFT-GIT and TST for 
confirmation of active 
TB 
70 paediatric patients in a high 
neonatal BCG vaccination uptake 
population; 8 children had 
confirmed TB. 47 children had 
QFT-GIT.  
 
Intermediate-burden 
region in Taiwan 
(January 2008 to June 
2014) 
NE Sensitivity: 100 (63.1–100)                                            
Specificity: 97.1 (85.1–99.9)  
Indeterminate rate: 6.4%                                           
Sensitivity: 62.5 (24.5–91.5)   
Specificity: 95.2 (76.2–99.9) 
Threshold ≥10mm 
           
Xia 201569 Prospective study of 
QFT-GIT and TST for 
diagnosing PTB 
300 PTB, 41 disease controls and 
59 health community controls 
were enrolled. 
Heilongjiang 
Province and 
southeast Zhejiang 
Province, China  
(May 2010 to April 
2011) 
NE Sensitivity: 80.9 (75.9–85.2)                                      
Specificity: 36.6 (22.1–53.1) 
Indeterminate rate: 0.5%                                          
Sensitivity: 79.5 (74.3–84.4) 
Specificity: 36.6 (22.1–53.1) 
Threshold ≥10mm 
 
Results were also available for 
≥5mm and ≥15mm as well as 
combinations with QFT-GIT  
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Reference Study design Population   Setting (recruitment 
period) 
T-SPOT.TB QFT-GIT TST 
Uzunhan 201570 Prospective comparison 
of QFT-GIT and TST 
for diagnosis of 
childhood TB 
53 children with TB (16 C+); 92 
healthy children with no risk 
factors for TB 
Children referred to 
hospital paediatric 
clinics in Turkey 
(recruitment period 
not reported) 
NE Sensitivity in all TB: 62.3                                       
Specificity: 97.8                                                   
Sensitivity in all TB: 97.8                                               
Specificity: 100                                                                                          
Azghay 201671 Retrospective analysis 
of hospital records to 
analyse contribution of 
QFT-GIT to TB 
diagnosis 
A total of 395 QFT-GIT assays were 
performed for suspected TB patients. 
Jean Verdier Hospital 
in Bondy, Paris 
(June 2008 to June 
2011)  
NE Sensitivity: 85 (73–92)                                                
Specificity: 73.3 (68–78)  
Indeterminate rate: 11.6%   
Sensitivity: 78 (57–91).  
Combined test: 92.6 (74–99). 
Jia 201672 Prospective study to 
evaluate T-SPOT.TB in 
lymph node TB 
405 patients with suspected  
lymph node TB; 83 with 
confirmed TB; 282 with TB 
excluded (21 clinically 
indeterminate and 19 clinical TB 
excluded from analyses) 
Beijing Chest 
Hospital, China, 
(July 2011 to April 
2015) 
Sensitivity: 90.4                                       
Specificity: 70.5      
Indeterminate rate: 3.8%                                                                                                           
NE NE 
C-, culture negative; C+, culture positive; EPTB, extra pulmonary tuberculosis; IQR, interquartile range; NE, not evaluated; PTB, pulmonary 
tuberculosis; SD, standard deviation. 
Studies are listed by year of publication and first author name. Sensitivity and specificity are presented as percentages. If 95% confidence 
intervals were not reported and raw data were available, we calculated 95% CIs using the Wilson method.18, 19
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Appendix 13 Key characteristics of patients with indeterminate QFT-GIT and T-SPOT.TB results 
Table 74 Summary of key characteristics studies of patients with indeterminate QFT-GIT and T-SPOT.TB results 
Characteristic, n (%) 
 
QFT-GIT T-SPOT.TB 
Dosanjh category Total Dosanjh category Total  
Culture 
confirmed 
TB 
Highly 
probable 
TB 
Clinically 
indeterminate 
Active TB 
excluded 
Culture 
confirmed 
TB 
Highly 
probable 
TB 
Clinically 
indeterminate 
Active 
TB 
excluded 
All  21  5  6  47  79  12  5 3  37  57  
HIV status 
     
     
Positive 0 (0) 2 (40) 1 (16.7) 20 (42.6) 23 (29.1) 2 (16.7) 3 (60) 0 (0) 28 (75.7) 33 (57.9) 
Negative 21 (100) 3 (60) 5 (83.3) 27 (57.4) 56 (70.9) 10 (83.3) 2 (40) 3 (100) 9 (24.3) 24 (42.1) 
Diabetes 
     
     
Yes 0 (0) 0 (0) 1 (16.7) 4 (8.5) 5 (6.3) 1 (8.3) 1 (20) 2 (66.7) 0 (0) 4 (7) 
No  21 (100) 5 (100) 5 (83.3) 43 (91.5) 74 (93.7) 11 (91.7) 4 (80) 1 (33.3) 37 (100) 53 (93) 
Immunosuppressive 
therapy 
     
     
Yes 0 (0) 0 (0) 0 (0) 1 (2.1) 1 (1.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
No  21 (100) 5 (100) 6 (100) 46 (97.9) 78 (98.7) 12 (100) 5 (100) 3 (100) 37 (100) 57 (100) 
TST statusa 
     
     
Positive 6 (75) 3 (75) 0 (0) 2 (18.2) 11 (44) 6 (100) 1 (100) 2 (100) 1 (14.3) 10 (62.5) 
Negative 2 (25) 1 (25) 2 (100) 9 (81.8) 14 (56) 0 (0) 0 (0) 0 (0) 6 (85.7) 6 (37.5) 
BCG scar 
     
     
Yes 14 (93.3) 4 (100) 4 (66.7) 29 (80.6) 51 (83.6) 10 (100) 3 (75) 3 (100) 21 (67.7) 37 (77.1) 
No  1 (6.7) 0 (0) 1 (16.7) 2 (5.6) 4 (6.6) 0 (0) 0 (0) 0 (0) 3 (9.7) 3 (6.3) 
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Characteristic, n (%) 
 
QFT-GIT T-SPOT.TB 
Dosanjh category Total Dosanjh category Total  
Culture 
confirmed 
TB 
Highly 
probable 
TB 
Clinically 
indeterminate 
Active TB 
excluded 
Culture 
confirmed 
TB 
Highly 
probable 
TB 
Clinically 
indeterminate 
Active 
TB 
excluded 
Unsure 0 (0) 0 (0) 1 (16.7) 5 (13.9) 6 (9.8) 0 (0) 1 (25) 0 (0) 7 (22.6) 8 (16.7) 
           
BCG vaccinated 
     
     
Yes 15 (71.4) 4 (80) 6 (100) 36 (76.6) 61 (77.2) 10 (83.3) 4 (80) 3 (100) 31 (83.8) 48 (84.2) 
No  6 (28.6) 1 (20) 0 (0) 11 (23.4) 18 (22.8) 2 (16.7) 1 (20) 0 (0) 6 (16.2) 9 (15.8) 
aTest positivity based on the stratified threshold. 
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Appendix 14 Additional results in HIV positive sub study cohort 
 
Table 75 Hospital trusts performing T-SPOT.TB. QFT-GIT and/or TST in the diagnostic 
work up of active TB in HIV positive sub study cohort 
Hospital Trust Tests performed Number 
of patients 
analyseda 
T-SPOT.TB QFT-GIT TST 
Imperial College Healthcare NHS Trust 19 1 4 54 
The Heart of England NHS Foundation Trust  3 0 0 6 
Chelsea and Westminster Hospital NHS Foundation 
Trust  24 0 0 40 
Royal Free Hampstead NHS Trust  6 3 5 53 
St George's Healthcare NHS Trust  0 0 0 5 
Kings College London NHS Trust 0 0 0 2 
University of Leicester Hospitals NHS Trust  0 2 0 23 
Northwest London Hospitals NHS Trust  0 0 3 6 
Oxford University Hospitals NHS Trust  0 0 0 4 
Sandwell and West Birmingham Hospitals NHS Trust  0 0 0 1 
Barts Health NHS Trust 3 0 0 7 
Total 55 6 12 201 
aNumber of patients included from each centre in the analyses of the IDEA study. 
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Table 76 Cross tabulation of T-SPOT.TB and QFT-GIT results in HIV positive sub study 
cohort 
N (%) T-SPOT.TB 
Positive Negative Indeterminate Missing Total 
QFT-
GIT 
Positive 20 (51.3) 4 (3.6) 5 (11.1) 0 29 (14.4) 
Negative 15 (38.5) 82 (73.9) 30 (66.7) 5 (83.3) 132 (65.7) 
Indeterminate 4 (10.3) 24 (21.6) 10 (22.2) 1 (16.7) 39 (19.4)  
Missing 0 1 (0.9) 0 0 1 (0.5)  
Total 39 (100.0) 111 (100.0) 45 (100.0) 6 (100.0) 201 (100.0) 
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 Table 77 Diagnostic accuracy of T-SPOT.TB and QFT-GIT in HIV positive sub study 
cohort: sensitivity analyses with indeterminate IGRA results included 
Test performance T-SPOT.TB QFT-GIT 
n/N Estimate (95% CI) n/N Estimate (95% CI) 
Sensitivity for a diagnosis of active 
TB 
    
All TB 23/31 74.2 (56.8–86.3) 19/32 59.4 (42.3–74.5) 
Culture positive TB 13/18 72.2 (49.1–87.5) 11/18 61.1 (38.6–79.7) 
Culture negative TB 10/13 76.9 (49.7–91.8) 8/13 61.5 (35.5–82.3) 
Smear positive TB 6/9 66.7 (35.4–87.9) 6/9 66.7 (35.4–87.9) 
   Smear negative TB 14/18 77.8 (54.8–91.0) 10/18 55.6 (33.7–75.4) 
Pulmonary TB 10/13 76.9 (49.7–91.8) 9/13 69.2 (42.4–87.3) 
Extra pulmonary TB 11/14 78.6 (52.4–92.4) 7/15 46.7 (24.8–69.9) 
Specificity for a diagnosis of active 
TB 
    
Active TB excluded  101/160 63.1 (55.4–70.2) 117/164 71.3 (64.0–77.7) 
Active TB excluded, TST negative, 
no risk factors for LTBI 
42/66 63.6 (51.6–74.2) 54/67 80.6 (69.6–88.3) 
Predictive value     
Positive predictive value 23/82 28.0 (19.5–38.6) 19/66 28.8 (19.3–40.6) 
Negative predictive value 101/109 92.3 (86.2–96.2) 117/130 90.0 (83.6–94.1) 
Likelihood ratios     
Positive likelihood ratio  2.01 (1.51–2.69)  2.07 (1.42–3.01) 
Negative likelihood ratio  0.41 (0.22–0.75)  0.57 (0.37–0.88) 
LTBI, latent tuberculosis infection; TST, tuberculin skin test. 
Sensitivity, specificity and predictive values are presented as percentages. Indeterminate IGRA 
results were included these analyses as test positives. 
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Table 78 Comparison of T-SPOT.TB and QFT-GIT in HIV positive sub study cohort: 
sensitivity analysis with indeterminate IGRA results included 
Test Na Sensitivity (95% CI) Nb Specificity (95% CI) 
T-SPOT.TB  31 73.4 (55.4–86.0) 160 63.2 (55.4–70.3) 
QFT-GIT  32 59.4 (41.6–75.0) 164 71.4 (64.0–77.8) 
Ratioc (95% CI); P value  1.23 (0.94–1.63); 0.1   0.88 (0.77–1.03); 0.1 
aNumber of test results amongst those with active TB. 
bNumber of test results amongst those without active TB. 
cRatio of the sensitivity (or specificity) of T-SPOT.TB to that of QFT-GIT. The natural outputs 
from generalized estimating equation models are odds ratios. Ratios of sensitivities (relative 
sensitivity) and ratios of specificities (relative specificity) were computed post estimation of the 
models. Confidence intervals were obtained using the delta method. 
Sensitivities and specificities are presented as percentages. 
 
